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Abstract 
If "Diversity is the rule of nature", macrophages, one of the innate immune cells of our body, 
have proven to be a true apostle. At the early stage of infection, they protect the host by exhibiting 
the pro-inflammatory phenotype (M1). Upon clearance of microbial threats, macrophages engage 
themselves in the repair process of the damaged tissue by showing anti-inflammatory or wound 
healing (M2) attributes. While incomplete microbial clearance leads to recurrent infections, defects 
in macrophage-mediated tissue repair mechanism result in immunopathology. The classical (M1) and 
alternatively (M2) polarized macrophages are the two extreme ends of a spectrum of in vivo 
macrophages phenotypes that dictate the nature, duration and severity of inflammation. Murine 
models of chronic inflammatory and autoimmune diseases showed the necessity of an adequate 
balance between macrophage subsets to maintain homeostasis, while imbalance is likely to lead 
exaggerated inflammation. In humans, an association between defective macrophage function and 
disease severity has been reported in many diseases including asthma, cystic fibrosis (CF), COPD, 
and atherosclerosis. Unfortunately, human M1 and M2 macrophages have not been well 
characterized. Firstly, the lack of homologs for certain murine genes in humans makes murine 
markers of limited use in humans. Secondly, there was no consensus method for in vitro 
differentiation of human M1 and M2 macrophages. Therefore, the first part of this thesis aimed to 
develop a novel method to differentiate and characterize human M1 and M2 macrophages. Initial 
studies with THP-1 cell line derived macrophage-like cells demonstrated that they didn’t fully 
represent human monocyte-derived macrophages (MDMs). MDMs were therefore chosen as starting 
materials for the rest of the study. MDMs were considered as uncommitted “M0” macrophages. A 
number of inducers were employed to polarize M0 macrophages into either M1s or M2s. LPS treated 
M1 macrophages showed CD64+CD80+ phenotype, whereas, IFN- induced M1s exhibited 
CD64++CD80- phenotype. These M1s secreted pro-inflammatory cytokines including TNF-, IL-1, 
IL-8 and were highly phagocytic. On the contrary, IL-4/IL-13 induced M2 macrophages were 
identified as CD11b+CD209+ cell population and were endocytic. Once polarized, macrophages then 
were left in cytokine-deficient medium to assess the persistence of polarized phenotype over time. In 
cytokine-free condition, previously polarized macrophages reverted to M0 state by 12 days. 
Treatment with IL-13 on previously polarized M1 macrophages resulted in a switch to CD209+ M2s 
and vice versa indicating the plasticity nature of human macrophages.  
 
Excessive neutrophilic pulmonary inflammation is the hallmark of cystic fibrosis (CF). 
However, factors that trigger such dysregulated neutrophilic inflammation and why this is not 
switched off are not yet clear. Macrophages play crucial roles in initiation and resolution of 
pulmonary inflammation, however, surprisingly little research in CF had been dedicated to 
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macrophages. Defective phagocytosis by macrophages and its association with cystic fibrosis 
transmembrane conductance regulator (CFTR) gene had been reported in CF studies. Nevertheless, 
the influences of the mutated CFTR gene on macrophage polarization and thereby function had not 
previously been studied in CF. The model described above was utilized with blood samples from 
adults and children with CF. M2 polarization was significantly repressed in patients with CF. The 
number of cells expressing the human M2 marker CD209 was significantly low in CF [median (25th-
75th%): healthy (n=9) 59(55-82)%; CF children (n=14) 41(30-52)% (p<0.01); CF adults (n=13) 
46(25-60)% (p<0.01)]. Endocytosis was also decreased in both children and adults with CF 
(P<0.001). Inhibiting CFTR function with CFTRInh-172 and GlyH-101 in healthy cells recreated the 
CF macrophage phenotype, with a decreased number of cells expressing CD209 and decreased 
endocytosis. Following IL-13 treatment, both CF M0 cells and CFTRInh-172 inhibited M0 cells 
showed decreased surface expression of IL-13Rα1 compared to M0s from healthy volunteers 
indicating the inability to respond to IL-13 being associated with CFTR dysfunction. Furthermore, 
during acute pulmonary exacerbation (APE), but not in clinically stable CF, a greater proportion of 
M0 and IL-13 treated macrophages displayed surface expression of M1 marker, CD80 in both adults 
and children indicating both M0 and M2s during APE being prone to M1 polarization. Taken together, 
these data report a CFTR-dependent defective M2, but not M1, polarization of macrophages in CF 
which might be the possible underlying mechanism for exaggerated neutrophilic responses and 
impaired resolution of inflammation in CF. 
 
In summary, two novel models had been developed during this Ph.D. study. The in vitro 
human macrophage polarization and characterization model described the differentiation, 
phenotypic and functional characterization of human M0, M1 and M2 macrophages as well their 
plasticity nature. Knowing the functional states of pathogenic macrophages has a huge impact on 
understanding the disease pathogenesis and developing novel therapeutic targets. The CF 
macrophage model was developed with CFTR inhibitors that recreated CF macrophage phenotypes 
in vitro. Using this model a previously unidentified CFTR-dependent defect of M2 macrophage 
polarization in CF had been reported. 
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1.1 Monocyte/Macrophages Linage: The First Line of Immune Defence 
The mammalian immune system consists of two arms: innate and adaptive immunity. Innate 
immunity is more ancient and constitutes the first line of defense against foreign pathogens (1). The 
mononuclear phagocyte system (MPS) is composed of three major cell types: monocytes, 
macrophages and dendritic cells (DCs). Although they have remarkable heterogeneity related to 
phenotype, functions, tissue localization, proliferative potentials, these features also overlap on all 
these cell types, therefore, no precise boundary had been reported (2). Monocytes and macrophages 
are the central players of innate immune system and are engaged in mounting immune responses to 
invading pathogens by phagocytosis, release of reactive oxygen species (ROS), inflammatory 
cytokines and chemokines. They also play critical roles in the resolution of inflammation and 
reparative functions to the damages tissues. DCs, on the contrary, present antigens to the players of 
adaptive immune system (3). 
 
Monocytes originate from common myeloid progenitor cells in the bone-marrow and 
constitutes around 10% of peripheral white blood cells. After release into the peripheral blood, 
monocytes circulate for several days (3). Following immunological insults, pro-inflammatory or 
metabolic stimuli, circulating monocytes enter into tissue, under the influence of specific growth 
factors, such as, macrophage colony-stimulating factor (M-CSF) or granulocyte macrophage colony-
stimulating factor (GM-CSF) differentiate into either tissue macrophages or specialized cell types, 
such as, dendritic cells (DCs) and osteoclasts and deal with the causative agents to maintain 
homeostasis. However, this traditional concept has been challenged by many recent studies showing 
that alveolar macrophages (AMs) of the lungs, microglia of brain, Langerhans cells of skin were 
seeded during embryonic development and are renewed by local proliferation (4-9).  
 
Peripheral blood monocytes are heterogeneous in terms of size, granularity and nuclear 
morphology. Based on the differential expression of the co-receptor for lipopolysaccharide (LPS), 
CD14, Fc receptor (Fc), CD16 (also known as FcR-III) and unique gene expression profile, human 
blood monocytes were divided into three subtypes: classical monocytes (CD14++CD16-), 
intermediate monocytes (CD14++CD16+) and non-classical monocytes (CD14+CD16++) (10, 11) 
(Figure 1), whereas, two subsets were identified in mice: resident monocytes (CX3CR1
HighCCR2-
Gr1-) and inflammatory monocytes (CX3CR1
LowCCR2+Gr1+) (12). In human, classical monocytes 
comprise the major portion (90%) of peripheral monocyte pool (10). They are able to sense microbial 
stress, perform chemotaxis, phagocytosis and release pro-inflammatory cytokines. They are 
considered as the counterpart of murine Gr1+ inflammatory monocytes (13). Intermediate monocytes 
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were proposed as transitional population bridging between classical and non-classical monocytes 
(10). They have higher ability for antigen presentation and resembled tissue resident macrophages 
(11). Following macrophage colony stimulating factor (M-CSF) treatment, intermediate monocytes 
expanded earlier than non-classical monocytes (10, 11). Non-classical monocytes are involved in 
patrolling and sensing viruses and nucleic acids, however, their responses to LPS were poor (10, 11). 
Cluster analysis of microarray data demonstrated that the intermediate and non-classical monocytes 
were closely clustered, whereas, classical and non-classical monocytes were distally clustered (10). 
Both classical and intermediate monocytes express chemokine receptor 5 (CCR5), whereas, non-
classical monocytes express CCR2 (3).  
 
The physiological roles of human monocytes in healthy and disease conditions have not yet 
been fully revealed. Broadly, both classical and intermediate monocytes are able to exhibit 
inflammatory properties (14, 15). Elevated CD16+ monocytes were observed during bacterial 
infections (14). Murine Gr1- monocytes patrol blood vasculature, enter to the tissue at later stage of 
inflammation and have been suggested to be associated with tissue repair (16, 17). However, clinical 
translation of such murine data was yet not confirmed by human studies (18).  
 
 
 
Figure 1: Phenotypic profile of human monocyte subsets.  Figure was adapted from Cros et al 
(13). Human monocytes were stained with anti-human CD14 and CD16 antibodies.  
 
1.2 Macrophage: A Multi-role Immune Cell 
Macrophages constitute a heterogeneous cell population of innate immune system that 
regulate tissue immunity by orchestrating the initiation and resolution of immune responses against 
environmental or microbial agents and repair of damaged tissue. They were first described by a 
Russian-French biologist, Elie Metchnikoff in late 1884 as phagocytic cells engaging against invader 
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pathogens by elimination. The name “macrophage” came from the Greek words, “makros” large and 
“phagein’ eat (15).  In 1905, Hirsch et al proposed these phagocytic cells as resistant to certain 
bacterial infections and setting the basis for the concept (19). After 60 years of scientific efforts, it 
was gradually evident that antibacterial activity of macrophages is the immunological basis of 
acquired cellular immunity (20). Following infection, dead cells missing MHC-I antigens are first 
targeted by NK cells, then macrophages appear as the second earliest cell type found at the site of 
infection (4). By releasing ROS and pro-inflammatory cytokines, macrophages then exert their anti-
microbial activity, clear invading pathogens and apoptotic polymorphonuclear cells (PMNs) by 
phagocytosis. In addition, macrophages communicate with the adaptive immune system by 
presenting antigens and cytokine storm. At the later stage of inflammation, macrophages play a 
reparative role to repair damaged tissues at the site of inflammation (21, 22).  
 
Macrophage phenotypes and functions vary with their anatomical locations (15). 
Macrophages are found in lymphoid as well as non-lymphoid organs such as liver (Kuppfer cells), 
lung (alveolar macrophages), nervous system (microglia), reproductive organs, and in gut lamina 
propia (23). Kupffer cells, the resident macrophages in the liver, comprise the largest pool of tissue 
macrophages in the body. Based on location in the lungs, two different types of macrophages have 
been described: alveolar macrophages (AMs) and interstitial macrophages (IMs) (24). Both AMs and 
IMs were originated during fetal development, however, during inflammation, circulatory monocytes 
migrate to alveolar spaces and conducting airways. Compared to other tissue macrophages, AMs are 
more phagocytic and express high levels of CD11c and DEC-205 (25). AMs phagocytose potentially 
harmful air-borne pathogens, generate immune response to recruit other inflammatory cells from 
blood (26). Under resting conditions, AMs have a half-life of 1~2 months with a turnover rate of 40% 
in a year in mice (27), however, no studies till date reported about the half-life of human AMs. 
Microglia of brain are unique from tissue macrophages in many aspects. In particular, microglia arise 
from early yolk sac progenitor cells and have their own self-renewal process by local proliferation (7, 
28). Unlike other tissue resident macrophages, tumor-associated macrophages (TAMs) abundantly 
found in tumor exhibit immunosuppressive nature (29).  
  
1.3 Macrophage Polarization and Their Plasticity 
Macrophage function varies with stimuli they received from their surrounding environment. 
Therefore, activation, also known as polarization, of macrophages has evolved as a new fundamental 
area of innate immunology. Over the last decades, the term “activation” or “polarization” of 
macrophages had been used to describe induction of certain sets of genes and proteins of recruited 
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macrophages by cytokines or toll-like receptor (TLR) agonists to display acquired tumoricidal or 
microbicidal activity. The origin of these terms was originated in the early 1990s when interferon-
gamma (IFN-) and IL-4 were described to induce classical and alternative polarization of 
macrophages respectively (30-32). Later classical and alternative polarization were observed to be 
correlated with TH1 and TH2 paradigms, Mills then proposed the “M1-M2” terminologies for CAMs 
and AMMs respectively (32, 33). In this chapter, the words “polarization” and “M1-M2” were mostly 
used.  
 
1.3.1 Classical (or M1) Activation of Macrophages 
Macrophages polarized by IFN- or bacterial products, such as, LPS, are currently referred as 
“classically activated macrophages” or “M1 macrophages”. The understanding of this “classical” 
or “M1 polarization” dated from studies during the 1960s when Mackaness and colleagues described 
enhanced anti-microbial activities of macrophages in mice infected with Mycobacterium bovis 
bacillus Calmette-Guerin (BCG) or Listeria monocytogenes (34). Soon after the discovery of IFN- 
and its cellular activity, it had been shown that IFN- produced by type I T helper (TH-1) cells 
activates antimicrobial, cytotoxic and tumoricidal activities of macrophages (35-38). Later, studies 
with knockout mice and in humans with genetic defects of IFN- or its receptors validated that M1 
polarization is crucial for host defense against microbial infection. Intracellular pathogens, TNF-, 
IFN-, TLR4 ligands were known inducers of M1 polarization (39) though others have shown M1 
polarization with GM-CSF (40, 41). Radiation (42), oxidized low-density lipid molecules (15) and a 
diet containing high salt (43) were able to trigger M1 polarization with enhanced pro-inflammatory 
cytokine secretion.  
 
M1 phenotype is typically considered as being IL-12high and IL-10low (44, 45). M1 
macrophages produce microbicidal enzymes, such as, inducible NO synthase (iNOS) to destroy 
invading pathogens, release pro-inflammatory cytokines, such as, IL-1, IL-6, IL-12, IL-23, TNF-, 
various chemokines to chemoattract other immune cells to the site of infection and matrix 
metalloproteinase (MMPs) and finally promote TH1 immunity (44, 46). The panoply of cytokine and 
antimicrobial genes triggered during M1 polarization are under the regulation of a set of transcription 
factors. These include signal transducer and activator or transcription 1 (STAT1), nuclear factor- B 
(NF-B) and mitogen-activated protein kinases (MAPKs) pathway.  
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Although several studies showed the importance of M1 macrophages in host defense, a few 
concerns about these cells deserve particular attention. Few M1 cytokines, such as, IL-1, IL-6, IL-23 
are able to efficiently trigger TH17 cells. IL-17 from these TH17 cells recruit PMNs that contribute 
autoimmune pathologies (22, 47-49).  
 
1.3.2 Alternative (or M2) Activation of Macrophages 
Inhibition of M1 polarization of macrophages was first reported by Abramson et al (50) who 
demonstrated inhibition of IFN- induced superoxide (O2-) production by IL-4. The term 
“alternatively activated macrophages” was described by Gordon and colleagues in the 1990s 
following their observation that IL-4 induced mannose receptor expression on macrophages (31, 51). 
The term “alternative activation” initially caused confusion in the field since the term “activation” 
was generally associated with host defense which was not in the case here. Later, the concept of 
alternative activation of macrophages by type 2 cytokines, IL-4 and IL-13 gained credence and was 
accepted by many working groups with human cells. These “alternatively-activated macrophages 
were thought to be involved in tissue repair, tumor progression and fibrosis (52-54). M2 macrophages 
were characterized by the cell surface expression of the macrophage mannose receptor (MMR) 
CD206 (31), CD163 (55), CD23 (56) and dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN)/CD209 (57) and the synthesis of soluble factors, such as the CC 
chemokine ligand 17 (CCL17) (58), CCL18 (59), TGF- (60). Other than surface markers and 
cytokines, induction of Arg 1, Ym1 (also known as CHI3L3), Ym2, and FIZZ1 were reported as 
signature genes of M2 polarization (61). The enzyme arginase, Arg 1, is involved in the metabolism 
of arginine into ornithine that leads to the production of proline (62 452). In vitro studies showed 
proline production is directly associated with collagen deposition and production of extracellular 
matrix (ECM), thereby fibrosis (63). Production of other matrix building proteins, such as, chitinase 
and chitinase-like molecules, acidic mammalian chitinase (AMCase) and stabilin-interacting 
chitinase-like protein during M2 polarization support their wound healing property as well (22, 64-
66). In contrast to M1, M2 macrophages demonstrate relatively poor antigen presentation, highly 
phagocytic, release anti-inflammatory cytokines, such as, IL-10, and promote regulatory T cell (Treg) 
development (55, 67, 68). Furthermore, M2 macrophages are key players in tissue remodeling, wound 
healing, chronic inflammation, angiogenesis and fibrogenesis (22, 69, 70).  
 
Based on the stimuli to induce M2 polarization, M2 macrophages were further subdivided 
into three types: M2a induced by IL-4/IL-13, M2b induced by immune complexes (ICs) and TLR 
agonists or IL-1R and M2c by IL-10/TGF- (44). Arginine pathway is induced by M2a and M2c, but 
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not in M2b. Macrophages exposed to IC and LPS (M2b) release high levels of pro-inflammatory 
cytokines with concomitant IL-10high and IL-12low (71). Despite their pro-inflammatory cytokine 
production, M2b macrophages promote TH2 differentiation and humoral antibody production (44, 
68). Interestingly molecular modeling of all these three M2 subsets demonstrated three distinct 
populations with discrete transcriptional profiling (72). It is possible that during the acute phase of 
infection, presence of huge amounts of LPS induces M2b phenotype and IL-10 release by 
macrophages; this secreted IL-10 later suppress the inflammation by polarizing M2c phenotypes. At 
the later stage of inflammation, M2a macrophages predominate and promote wound healing or 
fibrosis. However, this concept needs to be confirmed by systematic investigation approaches and to 
ratify that all these versions of M2 macrophages exist in the immune system and play their own role 
without eliminating others. This concept of diverse versions of M2 macrophages was later supported 
by Mosser et al though with different names: immune complex (IC) or glucocorticoid (GC) induced 
regulatory macrophages, IL-4/ IL-13 mediated pro-fibrotic/wound-healing macrophages, and tumor-
associated macrophages (TAMs) (22, 44, 73). GCs released by adrenal cells at the hypothalamus-
pituitary-adrenal (HPA) axis inhibit macrophage mediated inflammatory responses as well as host 
defense mechanisms, giving rise to regulatory macrophage population that abundantly produce tumor 
growth factor- (TGF-). Regulatory macrophages can also rise during late stages of inflammation 
with the key role of limiting inflammation though the molecular mechanism is yet to be identified 
(71). Tumor-associated macrophages (TAMs) are identified by their secretion of a variety of 
angiogenic factors (22, 73). Although previous literature has equated TAMs to M2s, increasing 
evidences suggest that TAMs are a blend of multiple distinct populations with overlapping features, 
rather than M2s (73).  
 
1.3.3 Plasticity Nature of M1 and M2 Macrophages 
Macrophages are able to exhibit an array of functions through the release of several factors. 
Their diversified pro- and anti-inflammatory roles associated with M1 and M2 polarized states raise 
important questions: 1) whether the polarization of macrophages is stable, reversible or a state of 
terminal differentiation, 2) upon withdrawal of inflammatory stimuli, whether polarized macrophages 
undergo apoptosis and 3) whether reparative macrophages found during the healing phase originate 
from an entirely new emigrated population. Furthermore, the presence of other immune cells 
particularly lymphocytes should be taken into account their cytokine secretions are likely to alter 
macrophage polarization statuses and thereby functions. It is not yet known whether de-differentiation 
of once polarized macrophages is necessary to respond to new stimuli or immigration of new 
macrophages would replenish the once polarized macrophages. In murine models of inflammatory 
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bowel disease and asthma, adoptive transfer of M2 macrophages not only reversed the distribution of 
macrophage subsets but also reduced the disease severity, suggesting a dual role for macrophages in 
orchestrating both the onset and resolution of inflammation (74, 75). The ability of macrophages to 
adapt to changing cytokine environments has been demonstrated in vivo in tumour-bearing mice, 
where changing the microenvironment resulted in a switch of macrophage phenotypes (63, 76, 77).  
 
Several hypotheses have been postulated to explain the mechanism of this plasticity issue (78). 
The first hypothesis considered specific monocyte subsets as precursors of specific macrophage 
phenotypes. For instance, Ly6C+ monocytes become M1 macrophages and Ly6C- monocytes become 
M2s in tissues (16, 17, 78). However, differentiation of Ly6C+ cells to M1, or Ly6C- cells to M2 (16, 
79) and transactivation of Ly6C+ M1 cells to M2 cells (80, 81) does not support this view. The second 
hypothesis proposed sequential recruitment of monocytes into the tissue during the course of 
inflammation. Therefore, monocytes entering at different phases of inflammation come across 
different microenvironments that can activate them into M1s during the acute phase and into M2s at 
the reparative phase (80). However, in vivo transactivation of M2 from M1 macrophages in sterile 
wounds (81) or injured kidney (82) weaken this argument. Based on the later data (81, 82), a third 
hypothesis postulated that macrophages can switch their functional states from one to another in 
response to sequential microenvironment changes, suggesting that the polarized state of macrophages 
is reversible (76, 83). However, apoptosis of M1 cells by its own NO does not fully support this 
hypothesis [Reviewed in (15)](84). Although the mechanism remains unexplored, an adequate 
balance between M1 and M2 subsets is required to maintain homeostatic milieu, and disequilibrium 
is likely to lead to unbalanced inflammation. The perception of adapting functions with changing 
environment has huge implications on understanding the role of macrophages in disease pathogenesis 
and development of therapeutic targets. 
 
1.4 Human and Mouse M1/M2 Macrophage Characterization: Where Do 
Murine Models Diverge From Human? 
Rodents and primates are being frequently used in studying human diseases to identify the 
basic pathophysiological mechanisms and to evaluate therapeutic approaches. Reasons to choose 
animal models include their availability, low housing cost, ease of modification according to interest 
and most importantly, they partly mirror the human immune system. Another advantage of using 
mouse models is that regular confounding factors can easily be controlled with animal housing 
conditions. However, there are no systematic studies that evaluate how well animal models mimic 
human pathological conditions. Absence of animal orthologs in humans is one of the main barriers to 
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translate animal data into humans.  Another problem with animal models is that in vivo experiments 
are hardly able to exclude the effects of pathway redundancy, i.e., knocking out of a single gene may 
confirm its phenotype, but can’t exclude the possibility of another functionally equivalent gene to 
take over to trigger the similar or opposing pathway of interest. For instance, although in vivo 
induction of M2 signature genes, i.e., Ym1, FIZZ1, were drastically halted in IL-4KO mice, a still 
significant expression of these two genes was observed. Such residual though significant induction 
might be as a result of IL-13 signaling (85). In the field of macrophage polarization and function, 
comparative gene expression analysis of mouse and human found Transglutaminase 2 (TGM2) as 
the single gene to be expressed by both species (21). This section, therefore, aimed to point out the 
paradigm and dichotomy of human and murine polarization of macrophages to better understanding 
the knowledge gap associated with species differences.  
 
Macrophage responses are extremely dependent on 1) cell types used, 2) stimuli used to 
induce macrophage polarization. These two issues hugely contribute to the ultimate outcomes of the 
study, such as, gene expression, cytokine and chemokine secretion and phagocytosis of apoptotic 
cells. This section shows how the selection of these two factors determined the polarized macrophage 
attributes and led to discrepancies in earlier studies were discussed. 
 
1.4.1  Starting Material Does Matter 
Genetic background is important while studying host responses to pathogens. Studies using 
mouse macrophages as a model for macrophage polarization have shown that mouse strains or cell 
lines differ in their abilities in cytokine or chemokine production, bacterial killing and time of 
response. C57BL/6 mice were mostly used for macrophage polarization studies (41, 85-87). 
Macrophages of C57BL/6 mice contain a deletion in the promoter region of arginine transporter gene, 
Slc7a2 making them genetically resistant to M2 polarization (88). Following TLR2 and TLR4 agonist 
challenges, macrophages from C57BL/6 mice preferentially produce high IFN-, TNF-, IL-10, IL-
12, IL-17 and low IL-4 and exhibit reduced systemic inflammatory responses (89, 90). These data 
suggest that M1 polarization would more easily achieve in C57BL/6 mice than BALB/c mice (33). 
Conversely, BALB/c showed higher cytokine and chemokine release in the plasma suggesting 
enhanced systemic responses to pathogens (Table 1). Macrophages from BALB/c mice showed 
lowered production of NO and lysosomal enzymes, resulting in lowered bacterial clearance by 
BABL/c mice than C57B/6 (89-92). NO production in BALB/c macrophage was significantly low 
than macrophages from C57BL/6 and was observed at an early stage following LPS challenge than 
at later stage of C57BL/6 mice (89). Phagocytic activity and bactericidal ability of alveolar 
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macrophages from the abovementioned mice strains were different too (93). Hence, C57BL/6 mice 
are regarded as TH1-dominant mouse strains, whereas, BALB/c mice are considered as TH2-biased 
mice strain (90, 91). Conducting macrophage polarization studies with C57BL/6 mouse strain 
inevitably bias the study outcomes toward classical macrophage phenotype, while it is opposite for 
BALB/c mice. Another inbred mouse strain, CBA is used as a model for studying immunobiology of 
cardiovascular and kidney diseases. Macrophages from CBA mice exhibited lowered bactericidal 
responses and failed to activate NFB signaling pathway (94-96).  
 
Cell lines are generally used to test the experimental hypothesis as they offer a homogenous 
population and ease to manipulate them based on the research questions. Macrophage researchers 
frequently use leukemic macrophage-like cell lines, such as J774.1, RAW 264.7 and P388D1 from 
murine sources and THP-1, U937, HL-60 for human. RAW 264.7 is the most commonly used murine 
macrophage cell line which was derived from BALB/c mice infected with Abelson leukemia virus. 
Following treatment with appropriate agents, RAW 264.7 cells express Fc receptors for 
immunoglobulins, release lysozymes and show phagocytic properties to zymogen and latex beads. 
However, RAW 264.7 is extremely sensitive to LPS. The proliferation ability of these cells was found 
to be severely halted by LPS stimulation, and they underwent morphological transformation by 
displaying DC like morphology (97). J774.1, on the other hand, is a murine monocytic cell line, 
mostly used to investigate the host-pathogen interaction studies. Both of these cell lines showed 
similar gene expression to TLR agonists, albeit the time to response to stimuli is shorter in RAW cells 
than JJ774.1 cells. However, the inflammatory responses of either of these two cell lines do not 
correspond the tissue macrophages (98). LPS treatment unable to induce IL-12p70, the bioactive form 
of IL-12, by either RAW 264.7 or J774.1 cells albeit IL-12p40 subunit was minimally induced in 
J774.1 cells, but not in RAW 264.7 cells (Table 1). Surprisingly, none of these two cell lines produced 
IL-12p35 subunit (98). These data suggest that these murine macrophage-like cell lines have distinct 
regulatory systems that differ from tissue macrophages when responding to inflammatory signals. 
Furthermore, continuous in vitro culture of leukemic cell lines may cause gene loss resulting in 
impaired macrophage phenotypes and functions, thereby erroneous interpretation of outcomes. 
Therefore, extensive care should be taken to extrapolate cell line data to tissue macrophages. 
 
To date, the four major primary mouse macrophages, named by their sites that have been 
extensively used are peritoneal macrophages (PMs), bone marrow-derived macrophages (BMDMs), 
splenic macrophages (SMs) and alveolar macrophages (AMs). Although PMs, AMs and SMs 
represent tissue resident macrophages and morphologically and functionally they are very similar, 
they are markedly distinct in many aspects. For example, PMs with their larger size and higher 
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lysosomal content are considered as more matured macrophages than the other three mentioned above 
(99). Elevated expression of MHC II and CD86 ascribed higher antigen presentation ability of PMs. 
In response to microbial pathogens, PMs exhibited enhanced NO and IL-12 production, however, 
they lack proliferative ability, exhibited downgraded phagocytic and antigen presentation and 
scavenger receptor activity (100, 101). Recently Ghosn et al described two physically, functionally 
and developmentally distinct PMs in the peritoneal cavity (102). The first subset was comparatively 
larger in size and was described as resting PMs. These resting PMs were found to express high levels 
of canonical macrophage markers, F4/80 and CD11b. Following LPS challenge, these resting PMs 
exhibited rapid production of NO and thereafter disappeared. The second subset that enters into 
peritoneal cavity following LPS challenge was originated from blood monocytes and was described 
as recruited PMs. Recruited PMs were smaller in size, expressed a basal level of CD11b and F4/80 
and exhibited higher phagocytic activity than resting PMs. This extended heterogeneity of PMs was 
not taken into account during earlier macrophage polarization studies. AMs are lung resident 
macrophages found in bronchoalveolar lavage (BAL) fluid and are critical for maintaining surfactant 
homeostasis in alveolar space. Because of the unique location in the lungs, AMs are the only cells 
among all phagocytes who are continually exposed to noxious materials and infectious pathogens of 
the air (103). AMs express a number of pattern recognition receptors (PRRs) and possess high 
phagocytic activity, which allows them to respond against respiratory pathogens (104). In addition, 
AMs exert anti-inflammatory features by releasing immunosuppressive mediators such as IL-10 
(105) and are able to restrain antigen presenting ability of respiratory DCs (106, 107). During steady 
state, AMs don’t proliferate (108). AMs are mostly CD206+ cells, though AMs found in the airway 
linings are CD169+, whereas, AMs those are found in the airway epithelia are CD169- (109). SMs are 
the most immunogenically active macrophages in the body and able to produce enormous amount of 
pro-inflammatory cytokines and highly cytotoxic (100). However, SMs are less phagocytic and 
require M-CSF for their survival in vitro (99). Nonetheless, AMs, PMs and SMs have a notable 
drawback. The multi-step isolation procedure from tissues is time-consuming and the yield varies 
with isolation approach and skills of the laboratory personnel. Furthermore, the environmental 
conditions of the animal facility severely affect the macrophage biology. On the contrary, M-CSF-
treated BMDMs are fully differentiated macrophages from mouse bone marrow regardless of the 
health condition of the donor mice. BMDMs offer a homogenous population with longer life span. 
These advantages of BMDMs made them more accessible as macrophage model in immunological 
research in last decades. However, BMDMs are highly responsive to M-CSF, highly proliferative and 
phagocytic in nature and produce significantly less TNF- following LPS challenge than PMs (100, 
110). In resting condition, BMDMs produce significant amount of IL-10 and TGF- indicating that 
in vitro grown BMDMs might be less mature and potentially be more likely to have M2 phenotype, 
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giving caution to use in macrophage biology (100). Some studies used BMDMs differentiated in 
conditioning media, for instance, L929, which is a rich source of GM-CSF and GM-CSF 
differentiated bone marrow cells were considered as a model of DCs (111, 112). Such discrepancies 
in the initial materials used in macrophage studies would expect to have a substantial impact on the 
study outcomes (Table 1).  
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Table 1: Issues to consider while choosing models for macrophage polarization studies. 
Starting Materials Remarks 
Mouse Animal 
model 
C57BL/6 Due to deletion in Arg transporter promoter gene (Slc7a2), sensitive to M1 polarization 
BALB/c Low NO and lysosomal enzyme production  
Lowered bacterial clearance 
Enhanced systemic responses 
KO model Pathway redundancy 
Cell lines RAW 
264.7 
Proliferation is halted after LPS stimulation 
Exhibit DCs morphology following LPS stimulation 
No IL-12p70 production 
J774.2 Minimal induction of IL-12p40 
No IL-12p70 production 
Primary cells PM Lack of proliferation ability 
Less phagocytic  
Less Ag presentation ability 
Less scavenger receptor activity 
Two different subsets exist 
Time-consuming and laborious isolation protocol 
AM Low Ag presentation ability 
High IL-10 release 
Lack of proliferation ability 
Expression of surface markers varies with locations 
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Time-consuming and laborious isolation protocol 
SM Highly inflammatory 
Less phagocytic 
Time-consuming and laborious isolation protocol  
BMDM Highly proliferative 
Highly phagocytic 
Less inflammatory 
Require special conditioning medium 
Human Cell lines TDMs Inducer dependent macrophage differentiation  
Resistant to M-CSF and GM-CSF stimulation 
Lose proliferation ability  
No expression of CD206, MHC II DR1 
High expression of CD14 and IL-1 
Attenuated TLR expression 
 U937 Pro-inflammatory profiles following LPS challenge is different than MDM 
Primary cells Monocytes Less inflammatory than MDM 
Transcriptomically different than MDM 
 MDM 
(GM-CSF) 
Enhanced inflammatory cytokine release 
Higher HLA-DQ expression 
 MDM  
(M-CSF) 
Highly phagocytic 
More immunosuppressive (IL-10) 
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Ag: antigen; AM: alveolar macrophages; BMDM: Bone marrow derived macrophages; DC: Dendritic cells; MDM: Monocyte-derived macrophages; 
PM: Peritoneal macrophages; SM: spleen macrophages; TDM: THP-1 derived macrophage-like cells. 
 
 
 
16 
 
Current knowledge on human macrophage polarization is also limited and hampered by the 
lack of consistency in the experimental conditions used to study human macrophages in vitro, 
including the use of cell lines or different cell types for macrophage generation, diverse conditions 
for initial macrophage differentiation and subsequent polarization. THP-1 is the human leukemic 
monocytic cell line frequently used by human macrophage biologists which upon treatment of 
phorbol esters or vitamin D3 (Vit D3) mimic a number of cellular characteristics of peripheral 
monocytes derived macrophages (113, 114). Compared to other human myeloid cell lines, such as 
HL-60, U937, KG-1, or HEL, differentiated THP-1 cells behave more like native monocyte-derived 
macrophages in terms of both morphology and transcriptomically. Following LPS challenge, a 
different inflammatory gene expression signature was observed in U937 compared to MDMs (115). 
However, TDMs do not respond to M-CSF, a potent cytokine for macrophage lineage differentiation, 
but rather internalize and degrade it very quickly (116). Furthermore, disparate data have also been 
observed from THP-1 derived macrophage-like cells (TDMs). For instance, PMA treated TDMs do 
not express mannose receptor (CD206) and MHC class II DR1, while CD14 and IL-1 were 
upregulated compared to monocytes or monocytes-derived macrophages (MDM) (117, 118). 
Furthermore, a subset of PMA treated THP-1 cells do not express scavenger receptors demonstrating 
heterogeneity in this cell line (119). Compared to primary cells, TLR expression and cytokine 
responses of THP-1 to LPS stimulation and to oxidized low-density lipoproteins were severely 
attenuated (120-122). Other significant differences have been recently reviewed by Qin (123). In 
addition, THP-1 expression of CD14 marker and cytokines was found to be very sensitive to culture 
conditions, in particular cell density and duration of stimulation (124). Taken together, TDMs data 
do not fully correspond to macrophage biology of physiological conditions (Table 1).  
 
With the availability of commercial monocyte isolation kits, monocytes or monocytes-derived 
macrophages (MDMs) are now commonly being used in human macrophage studies. Blood 
monocytes were observed not to able to survive in vitro conditions unless they were given GM-CSF 
or M-CSF stimulation (103, 125). In response to LPS, pro-inflammatory cytokine release was found 
significantly higher in MDMs than their precursor monocytes (111). Although being classified as 
mononuclear phagocytic lineage, tissue macrophages and circulating monocytes are functionally 
different cell types and they both have their own independent self-renewal process during steady state 
(8). Comparative transcriptome analysis elegantly demonstrated monocytes, MDMs and dendritic 
cells (DCs) as three distinct cell populations and thereby questioned the interest to use monocytes 
themselves in macrophage studies (72). On the contrary, although both of the hemopoietic growth 
factors induce differentiation of morphologically and functionally distinct macrophages in in vitro 
conditions (126). GM-CSF differentiated macrophages (GM-M) express HLA-DQ and release 
17 
 
substantial amount of pro-inflammatory cytokines, including TNF- and IL-6 (45). Macrophages 
differentiated by M-CSF (M-M) demonstrated higher Fc receptor-mediated phagocytic, 
bactericidal and immunosuppressive (IL-10) activities (125). Induction of IL-1, IL-8, IL-12 and IL-
23 were comparable among GM-M and M-M, however, in response to LPS, release of TNF- was 
higher in GM-M, while, IL-10 was found elevated in M-M (111). Lacy et al elegantly 
demonstrated the comparative gene expression profiles of human GM-M, M-M and M-CSF and 
GM-CSF differentiated BMDMs (111). In human, 13% of genes were differentially expressed 
between GM-M and M-M. These genes were annotated to be involved in immune responses, 
receptor activity, cell adhesion and chemotaxis and endocytosis. Further analysis between human 
GM-M and BMDMs showed 72% homology between species, however, 17% of these genes were 
found under different regulatory mechanisms between human and mouse macrophage systems. Later, 
pathway analysis showed that when cell functions were considered, pathways between human and 
mouse overlaps rather than individual gene expression or regulatory mechanisms (111). Higher yield 
of monocytes from large volume of donor blood and inter-donor heterogeneity are the two major 
pitfalls of using MDM.  
 
1.4.2  Inducers Dictate Macrophage Polarization 
Macrophage responses are extremely dependent on the environmental stimuli and stresses. 
Studies conducted till date on macrophage polarization demonstrated huge discrepancies with regard 
to both the nature of the vitro stimuli used and the duration of the stimulation. These discrepancies 
made it difficult to interpret and compare the outcomes from different studies to draw general 
conclusions on macrophages functions in homeostasis, disease pathogenesis and progression. IFN- 
and IL-4 are two prototypical inducers initially used for M1 and M2 polarizations (31, 35-37, 61). 
Later LPS, TNF- as M1 and IL-13, IL-10, TGF- as M2 inducers were added to the list (38, 39, 44). 
Even so, the study outcomes are still contradictory because of different sources and concentrations of 
cytokines used and the duration of maintaining stimulated conditions in different studies. For 
instance, Arg1 was observed under regulation by IL-4, not by IL-10 (76). LPS at minimal amount is 
sufficient to induce iNOS, however, at high concentration, LPS also led to Arg1 induction (127) 
indicating that the use of an appropriate inducer at an appropriate concentration is crucial while 
studying macrophage biology (Table 2). Furthermore, L-cell conditioned medium used as a source 
of M-CSF for BMDMs additionally contains type I interferons that would definitely have additive 
effects on subsequent polarizations (128). Endotoxin-free recombinant cytokines are therefore the 
best choice in macrophage research. Concentrations of cytokines used are another critical factor. 10 
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to 200nM of PMA were used for differentiation of THP-1 derived macrophage-like cells (TDMs). 
The concentration range of LPS used for M1 polarization varies from 10 to 100 ng/ml without taking 
into account the cytotoxic activity of LPS on the cells (expanded review in Table 5, Chapter 3) (72, 
129, 130). Reporting the cytokine concentrations in different units is another issue to consider. While 
the reporting as “ng/ml” clearly gives an idea of the amount of cytokine(s) added to the culture system, 
the “U/ml” gives researchers no clue about the amount of cytokine used in the experiments. Duration 
of initial macrophage differentiation from monocytes and subsequent polarization varies from 3-8 
days and 2-5 days among studies respectively (45, 72, 111, 129-131).  
 
While GM-CSF and M-CSF are considered as hematopoietic factors for fully differentiation 
of macrophages from monocytes in human (132, 133), in the mouse, M-CSF is required for survival 
and proliferation of BMDMs (100) and GM-CSF treated cells were considered as model of DCs 
(111). In the last decade, some researchers ascribed GM-CSF derived macrophages as M1 (GM-M1) 
and M-CSF derived macrophages as M2 (M-M2) (40, 41, 45, 48, 111, 130, 134), however, there is 
still an ongoing debate on whether GM-CSF or M-CSF stimulated macrophages should be considered 
as fully polarized macrophages or post-differentiation signals with TH1 or TH2 cytokines are 
mandatory for achieving full polarization spectrum (32). In murine models, IL-12High-IL-10Low is 
considered as the hallmark feature of M1 polarization (61). Considering this as a prototypic definition, 
Verreck et al observed IL-12 induction in human GM-M, but not in M-M and described GM-M 
as M1 and M-M as M2 like macrophages (45). Krausgruber et al showed an association of interferon 
regulatory factor 5 (IRF5) with M1 phenotype and impaired M1 cytokine profile in IRF5 KO mice 
(48). Enhanced IRF5 induction was observed in human GM-M, but not in M-M (Table 2). 
Comparable induction of IRF4 was observed in both GM-M and M-M (48). IRF4 was later 
identified as a key regulator of M2 polarization (135). However, higher expression of IRF4 observed 
in human GM-M and both IRF4 and IRF5 expression in M-M not only pointed toward 
experimental inconsistency but also questioned the concept of GM-M as M1 and M-M as M2 
(111). Pro-inflammatory cytokines, for instance, TNF- was upregulated in unstimulated GM-M, 
whereas, M2 associated anti-inflammatory cytokines, such as, IL-10 and CCL2 were induced in M-
M (41, 111). Induction of IL-1, IL-8, IL-12 and IL-23 were comparable among GM-M and M-
M (111). However, release of TNF-, IL-6, IL-12, IL-23 was significantly higher in GM-M than 
M-M following LPS challenge (41, 111). Transcriptome analysis showed significant differences in 
macrophages generated with GM-CSF and M-CSF, however, no conclusive pattern associated with 
M1 and M2 polarization was observed (72, 111). Beyer et al reported M1 and M2 marker expression 
was independent of GM-CSF or M-CSF treatment, but depended on the presence of TLR agonists 
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and TH1 or TH2 cytokines (also reviewed in Table 5, Chapter 3) (136). Taken all together, although 
GM-CSF and M-CSF were able to induce M1 and M2 like phenotypes to some extent, lack of solid 
evidence supporting GM-M as M1 and M-M as M2 made macrophage biologists to conceptually 
abandon these terminologies (32).    
 
1.4.3  Expression of Subset-Specific Markers and Functions in Polarized Mouse 
and Human Macrophages 
Macrophages display polarization specific surface receptor expression, induction of signature 
genes and thereby perform corresponding functions. M1 and M2 polarizations of macrophages had 
been well defined in murine model by list genes, surface markers and soluble mediators. While 
translating the murine data into human, variations were expected due to species variability. This 
section describes differences where murine markers were not applicable to characterize polarized 
human macrophages. IL-12high-IL-10low is the prototypical characterization of murine M1 
macrophages (44, 45). While elevated IL-12 was observed following M1 polarization in human, 
release of IL-10 was not observed following IL-4/IL-13 treatment but rather observed following LPS 
challenge in human macrophages. Therefore, IL-12low-IL-10high axis is not valid for human M2 
polarization (61). Murine M1 condition demonstrated induction of iNOS gene which later induced 
release of NO to destroy invading microorganisms (137). Due to substantial nucleotide sequence 
differences in the promoter regions between human and murine iNOS gene, human iNOS gene 
demonstrated hyporesponsiveness to LPS or IFN-. Additionally, human NF-B induced by IFN- 
binds to the iNOS promoter more weakly than murine NF-B. Consequently, human macrophages 
do not produce substantial NO, therefore analyzing iNOS expression following M1 polarization 
became debatable (138). Different nomenclature for the same gene between human and mouse 
sometimes raise confusion. For instance, human co-stimulatory molecules CD80, CD86 and 
chemotactic cytokine IL-8 are known as B7-1, B7-2 and CXCL1 (KC) in mouse respectively (46).  
 
The disparities between human and mouse were even more significant when comparing M2 
macrophage markers. Induction of Arg 1, Ym1, Ym2, FIZZ1 genes and surface expression of CD206 
and CD163 were associated with murine M2 polarization (31, 55, 61, 66, 85). However, humans do 
not have homologs of murine Ym1 and FIZZ1 genes. Arg 1 assay had been reported as an ineffective 
assay for human MDM-derived M2 macrophages (139). CD206 and CD163 are the two prime murine 
surface markers for M2 macrophages (51). Stein et al first reported expression of mannose receptor  
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Table 2: List of M1/M2 genes differentially expressed in mouse and human macrophages. 
Genes  Mouse (induced by) Human (induced by) 
Arg1 IL-4, LPS, not IL-10 Ineffective assay to assess human M2 
polarization 
Ym1 IL-4 No homolog 
FIZZ1 IL-4 No homolog 
iNOS LPS 
IFN- 
Nucleotide sequence variability in promoter and 
enhanced region  
Hyperresponsive to LPS, IFN- 
IRF5 M-CSF, not by GM-CSF  Variable data in different studies 
GM-CSF, not by M-CSF 
IL-1 GM-CSF 
LPS 
IFN- 
M-CSF 
LPS plus IFN- 
IL-8 
(KC) 
LPS GM-CSF 
LPS 
IL-10 M-CSF 
IL-4/IL-13 
Parasite infection 
M-CSF (Basal)  
Not induced by IL-4/IL-13 
IL-12 GM-CSF 
LPS 
GM-CSF 
CD16 Reported as M1 markers following 
stimulation with nematod Ag 
Reported as M2 marker following stimulation 
with IL-10.  
CD163 
(RM3/1) 
IL-4/IL-13 IL-10, not IL-4/IL-13 
CD206 M-CSF, IL-4, parasitic infection 
IFN- (Basal) 
AMs (Basal) 
GM-CSF 
Not by IL-4/IL-13 
CD209 Not reported  Reported in Chapter 3 
CD226 Not reported  IL-13, LPS 
TGF- IL-4, IL-10 Not induced by IL-4/IL-13 
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(MR), CD206, following stimulation with IL-4 that mediate binding and ingestion of microorganisms 
with surface mannose residues (31). However, expression of CD206 was also observed on resident 
and elicited peritoneal and alveolar macrophages and at low on BCG- or IFN-activated macrophages 
(140). Maximal CD206 expression was observed in mice at an early stage of parasite infection (day 
4) whereas M2 signature genes (Arg1, Ym1, FIZZ1, mMGL1, mMGL2) were substantially induced 
at the very late stage (day 14, 22, 29) (85, 141). Expression of CD206 also varied with in vitro 
experimental conditions. While M-CSF or IL-4 treatment showed significant expression of CD206 in 
mouse (86, 142), enhanced expression was observed on human GM-CSF treated MDMs compared to 
M-CSF treated MDMs (129, 143-146). Similar contradictory observations were found with CD163, 
another hallmark marker of murine M2 macrophages (51, 55, 70). CD163 was found to be highly 
expressed in some fibrotic diseases (147, 148), but not in asthma (143). In vitro differentiated 
macrophages showed CD163 expression following IL-10 treatment, but not following IL-4, in 
humans (129, 146, 149). Extensive transcriptome analysis did not report differential expression of 
CD163 following alternative polarization of human macrophages (72, 136, 150) indicating that 
CD163 expression varies with the experimental conditions (Table 2). These data questioned the 
acceptance of CD206 and CD163 as M2 surface markers for both human and mouse macrophages.  
 
Current experimental protocols for macrophage polarization were inconsistent and imposed 
confusion while characterizing them. Therefore, polarization protocols of macrophages and the 
characterization of polarized subsets necessitated a complete revision as the diversity in experimental 
protocols led to inconsistencies of definition and difficulties in interpretation. Cell lines could be used 
to test hypotheses though cell line data need to be validated in primary cells. The importance of 
murine study in human biology is undeniable, however, extreme care should be undertaken when 
extrapolating conclusions from murine data to humans. Mouse strains should carefully be chosen 
based on the research questions of interest. Fully mature MDMs rather than their precursor monocytes 
should be used by human macrophage biologists. Incomplete reporting of macrophage isolation, 
differentiation and assay protocols hugely impact on the reproducibility across the laboratories. The 
facts elegantly demonstrated by earlier studies that monocytes and macrophages were two distinct 
types cell population and that GM-CSF and M-CSF were not true inducers of human macrophage 
polarization needs to be acknowledged by macrophage community. Researchers entering in this field 
have to keep in mind that the field is still expanding and should not consider that there are only “two 
types of macrophages.   
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1.5 Roles of Polarized Macrophages in Diseases  
Polarized state of macrophages dictates the nature, duration and severity of inflammatory 
responses. M1 and M2 are the two functional states of macrophages which have been proposed to 
play a role in inflammation and fibrosis respectively. The number of macrophages markedly increases 
with the onset and progression of pathological conditions. Selective depletion of macrophages from 
inflamed tissue confirmed their crucial role in diseases pathogenesis. While dysregulated M1 
macrophages elevated the disease score in autoimmune and chronic inflammatory diseases, aberrant 
activity of M2 macrophages can also be detrimental. 
 
Analysis of ex vivo macrophage polarization demonstrated huge plasticity over various 
diseases. For instance, macrophages in the adipose tissues of obese individuals are considered to be 
pro-inflammatory M1 macrophages (151), whereas, important roles of M2 macrophages have been 
reported in many fibrotic diseases (52), insulin resistance (152), cardiac diseases (53) and tumor 
progression (54). A positive association of M2 macrophages with the aggravation of murine allergic 
inflammation and asthma was found (66, 153, 154).  
 
Defective macrophage responses have been reported in patients with respiratory diseases, 
including asthma (155, 156), COPD (157, 158), CF (159-161). In agreement with murine studies, 
higher percentages of macrophages were present in BAL fluid and airway wall tissues from patients 
with asthma and were associated with disease severity (162-165). However, due to lack of appropriate 
M1/M2 subset specific markers, polarized states of these cells in disease condition are still poorly 
elucidated (26, 143). Knowing the functional states of pathogenic macrophages has a huge impact on 
developing novel therapeutic targets.  
 
1.6 Cystic Fibrosis (CF): A Life-threatening Respiratory Disease 
1.6.1 CF, CFTR Function and CF Inflammation 
Cystic fibrosis (CF) is a life-limiting autosomal recessive disease with a high rate of premature 
mortality (166, 167). Mutation in the cystic fibrosis conductance regulator (CFTR) gene is the sole 
origin of CF and affects multiple organs including the lungs, gut, liver, pancreas and reproductive 
tissues, however, the lungs and the gastrointestinal tract are primarily affected. CF lung disease is 
characterized by chronic airway infections, inflammation, bronchiectasis leading to loss of lung 
function, repeated pulmonary exacerbations and eventually complete failure of the respiratory system. 
The highest frequency of CF was observed among the Caucasian population from developed 
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countries, such as, UK, Europe, North America and Australasia (168). However, the prevalence varies 
with genetic background. For instance, the disease occurs in roughly 1 in 3000 whites of Americans 
and Europeans, 1 in 4000–10,000 Latin Americans, 1 in 15,000–20,000 African Americans. 
Interestingly CF is rare or absent in Asians accounting 1 occurrence in 350,000 (169, 170). Several 
different possible mechanisms, including ethnic background, transfer of mutated allele from both 
parents to offspring, heterozygous advantage, multiple loci and reproductive compensation had been 
proposed to explain the high incidence of the disease among Caucasians, but not in the other parts of 
the world (171). In Australia, the frequency of cystic fibrosis is about 1 in 2800 live births, however, 
1 in 25 Australians carry the genetically mutated gene, CFTR. With the advancement of diagnosis 
and treatment, the median survival time of patients with CF increased from 14 years in 1969 to 35 
years in 2001 and to 37 years over the past decade (167, 172-175). Even more, improvement in the 
survival rate to 50 years was realistically predicted among children who born today with CF by a UK 
model (175).  
 
CFTR protein is a cAMP-activated chloride (Cl-) channel expressed at the apical membrane 
of many cell types, including epithelial cells, monocytes, mast cells (160, 176, 177). Following 
synthesis, the CFTR protein is glycosylated in the endoplasmic reticulum (ER). After passing the 
checkpoints for proper folding in ER, CFTR protein migrates to the Golgi apparatus for further 
glycosylation. The fully matured and functional CFTR protein is then transported to the plasma 
membrane to acts as chloride channel (178). In addition, CFTR plays regulatory roles on other 
channel activities, including, regulation of ATP channel, inhibition of sodium (Na+) transport channel 
and calcium (Ca2+)-activated Cl- channel, regulation of intracellular vesicle transportation and 
acidification of intracellular organelles. CFTR is also involved in bicarbonate (HCO3
-)-chloride 
exchange. Deficiency of HCO3
- secretion leads to poor solubility and accumulation of luminal mucin 
(179). Functional CFTR protein is required for fluid secretion in the airways as well as in intestine. 
Mutation in CFTR gene causes reduced transport of Cl- and HCO3
- ions in epithelial cells and blood 
cells (161, 176, 180, 181). In the lung, disturbed airway surface liquid homeostasis produces thick 
and viscous mucus that leads to mucus stasis, airway obstruction, persistence infection, chronic 
inflammation, a gradual decrease in lung function that ultimately results in limited life expectancy 
(168, 182, 183). Culture-independent pioneer studies showed the presence of complex and diverse 
microbiota in the airways of the patients with CF and a substantial shift in the airway microbiota 
composition associated with airway functions (184). 
 
The underlying mechanisms of CFTR-mediated airway inflammation in CF are still under 
investigation. Several hypotheses regarding CFTR dysfunction and CF phenotype have been 
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postulated (185). The major hypotheses are described here. The low-volume hypothesis proposes that 
CFTR dysfunction leads to loss of inhibition of sodium (Na+) ion channel in the epithelial cells, 
causing excessive reabsorption of Na+ and water, resulting in dehydration of airway surfaces and 
reduction of lubricating layer between epithelium and mucus (185, 186). Bacteria, especially 
Pseudomonas aeruginosa harboring in the mucus layer trapped and cause infection (187). According 
to the high-salt hypothesis, due to absence of functional CFTR surplus Na+ and Cl- retained in the 
airway spaces interrupt the regular functions of essential antibacterial peptides (such as, human -
defensin 1, LL-37) and allow bacterial colonization (185, 188). Dysregulated host inflammatory 
response hypothesis was supported by the unabated release of inflammatory mediators in BAL of 
children of 4 weeks of age (189) and uninfected ex-vivo tissue samples (190). Host susceptibility to 
CF associated pathogens, particularly, P. aeruginosa and Staphylococcus aureus, is supported by 
the increased attachment of microbial pathogens to the host cell surface carbohydrate molecules, e.g., 
asialo-GM1, that initiate persistent inflammatory responses which is independent of CFTR (191). It 
would be possible that all four contribute to the pathogenesis of the diseases. 
 
1.6.2  Onset of Inflammation in Cystic Fibrosis 
Inflammation in CF is initiated at early stage of life (189, 192). Repeated and chronic infection 
with bacteria, particularly with S. aureus and P. aeruginosa are common in infancy (193). Other 
pathogens included: H. influenza, RSV, rhinovirus, adenovirus, parainfluenza virus type 3. Episodes 
of infection increase with age and are associated with neutrophilic inflammation leading to lung 
damage, bronchiectasis that leads to fibrosis during adulthood (193). This common pattern of disease 
inception and progression suggests intrinsic defects in host innate defense mechanism (194). The 
innate arm of host pulmonary defense comprises of three components: a) mucous layer as physical 
barrier that contributes to antioxidant defense, mucociliary transport and tight junctions, b) humoral 
immunity provided by surfactants and antimicrobial proteins, e.g., defensins, c) cell-mediated 
immunity provided by macrophages, neutrophils, epithelial cells, natural killer cells. Escape of 
pathogens from all these three innate arms activate the adaptive immune responses. (195). However, 
airways of infants with CF are susceptible to infection by P. aeruginosa, Haemophilus influenza or 
S. aureus which leads to inflammatory cytokine storm causing chemotaxis of neutrophils and PMNs 
(185, 196). Other pathogens associated with CF include Burkholderia cepacia (a complex of at least 
9 different species), Stenotrophomonas maltophilia, meticillin-resistant S. aureus (MRSA), and 
atypical mycobacteria (172, 197).  
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Inflammatory responses in the CF airways are compartment-dependent. Inflammation in 
airway lumen is mostly mediated by macrophages, neutrophils, airway epithelial cells (AECs), NK 
cells whereas, recruitment and accumulation of lymphocytes was observed in the bronchial mucosa 
(194, 198). Neutrophils were hardly seen in CF and non-CF airways during fetal development (195). 
However, excessive neutrophil counts were observed in BAL of infected CF patients, but not in that 
of uninfected CF patients, compared to control (192, 196). Increased neutrophilic elastase and matrix 
metalloproteinase (MMP) activity, reduced antimicrobial activity and dysregulated cytokine 
production were reported in CF neutrophils (199, 200). Mouse models of CF showed an inverse 
relationship between dysfunctional CFTR protein and cellular redox state, ER stress and mucin 
overproduction by AECs (201). Pediatric studies in CF demonstrated increased oxidative stress in the 
airways of young children with CF (202).  Reduced oxidative stress of AECs has been thought to be 
associated with defective bacterial clearance. Furthermore, many studies reported mitochondrial 
abnormalities, including oxidative phosphorylation, calcium homeostasis, oxidative stress associated 
with mutated CFTR (203). 
 
Although macrophages are the professional phagocytes in the respiratory linings, the role of 
macrophages has largely been overlooked in CF. During fetal development, macrophages are the 
most abundant cells in respiratory linings of both CF and non-CF. However, the number of 
macrophages was significantly increased in CF airways with increasing fetal age while in non-CF 
macrophage count decreased (195). In accordance with the earlier study, significantly higher levels 
of CCL20, a chemokine involved in macrophage recruitment, were detected in BAL of CF infants 
(204). However, defective clearance of apoptotic cells (205) and blunted phagocytosis (160, 161) of 
macrophages were reported. Failure of bacterial clearance in the respiratory epithelia results in 
chronic infections that later lead to remodeling and thickening of airway lining and eventually failure 
of pulmonary function (206). Taken together it seems that macrophages in CF patients contain 
intrinsic defect (s). Furthermore, earlier studies demonstrated that AMs control inflammation in 
respiratory sites (207). Chronic inflammation in CF indicates that AMs failed to dampen pro-
inflammation in CF lungs.  
  
1.6.3 Types of Mutations in CFTR Gene 
More than 1900 mutations have been so far reported in human CFTR gene which are broadly 
categorized into six different classes based on the mechanism of the degradation or absence of CFTR 
protein (Table 3). Mutations that introduce signals for premature termination of nascent CFTR 
polypeptide are known as class I mutations. Types of mutations include insertion of a stop codon, 
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frameshift due to insertion or deletion or nonsense mutations. Class I mutations leads to truncated or 
aberrant protein. Class II mutations are associated with impaired post-translational modification, such 
as, glycosylation. Despite the presence of full-length CFTR protein, class III mutations contribute to 
dysregulated CFTR channel activity resulting in lowered Cl- transport, whereas, class IV mutations 
cause reduced Cl- permeability. Class V mutations lead to defective RNA splicing generating minimal 
copies of normal CFTR. Finally, class VI mutations negatively affect the protein stability causing 
accelerated turnover of CFTR protein at cell surfaces thereby reduce the quantity. In all cases, the 
abnormal CFTR protein rapidly undergoes proteolytic degradation in the ER (208).  
 
Deletion of phenylalanine at position 508 in the CFTR protein, known as F508 or 
Phe508Del, was the first identified mutation in CFTR gene (171, 209, 210) and the most common 
mutation among the patients with CF. Over 75% of patients carry at least one allele of F508 (211, 
212). Due to F508 mutation CFTR protein is defectively folded and trapped in the endoplasmic 
reticulum (ER) and targeted for degradation, resulting in minimal amounts of CFTR at the cell surface 
(213-218). The small fraction of CFTR protein that was able to be delivered to the cell surface exhibits 
defective channel gating and increased turnover (219, 220). Loss of CFTR-mediated Cl-ion transport 
cause an imbalance between fluid secretion and absorption, resulting in dehydration of airway 
epithelial spaces of CF lungs (186).  
 
G551D, also known as S549N, is the second most common mutation, carried by around 5% 
of patients with CF (211). Despite the synthesis trafficking of full-length CFTR protein to the cells 
membrane, due to G551D mutation, the protein fails to open the channel, resulting in little or no ion 
transport (221).   
 
Other than these two mutations, S549R and Trp1282X mutations are common in the United 
Arab Emirates (61.5%) and Israel respectively (211). Sharma et al recently reported 11 new rare 
CFTR mutations among patients of the Indian subcontinent that increased the spectrum of CFTR 
mutations worldwide (222).  
 
1.6.4 Small Molecules That Modulates CFTR Functions 
One of the major difficulties in CF research is lack of proper animal model of the disease. CFTR-
knockout murine models experience low survival rate (223) and do not spontaneously develop 
chronic infection and demonstrate little or no airway inflammation making them a less appropriate 
surrogate model for conducting mechanistic studies for CF. However, they showed significant 
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inflammatory responses following P. aeruginosa infection. Recently ferret (224) and pig models 
(225) of CF were developed, albeit expression of CFTR mRNA showed variability with tissue 
distribution and the pathological phenotype of these CFTR-null animals have not been 
comprehensively studied. Hence, there was considerable interest in developing CFTR inhibitors to 
investigate CFTR-mediated Cl- transport in vivo and to generate animal models of CF. Several high-
affinity CFTR inhibitors have been introduced which have shown clinical potentials as therapy in 
secretory diarrhea, polycystic kidney disease and in inhibiting male fertility (226, 227). However, 
some of them block or inhibit all ion channels showing lack of CFTR specificity. For instance, 
diphenylamine-2-carboxylate (DPC) and 5-nitro-2(3-phenylpropyl-amino) benzoate (NPPB) inhibit 
CFTR in a nonspecific manner (228). Glibenclamide inhibits all Cl- transporters as well as K+ 
channels (226, 229). 
 
Table 3: Class of CFTR Mutations  
Class Defects Mutation 
Example 
Cellular phenotype 
I Presence of nonsense 
mutations (i.e., stop 
codon), frameshift 
mutations, or abnormal 
mRNA splicing 
W1282X Synthesis of no or minimal functional CFTR 
protein.  
II Defect in protein 
processing and 
trafficking 
F508 Delivery of reduced copies of CFTR protein 
to the cell surface.  
III Defect in regulation of 
channel gating  
G551D Presence of CFTR protein at the cell surface 
with no channel activity 
IV Defect in ion selectivity 
and conductance 
R117H Surface CFTR protein unable to conduct ion 
transportation  
V Defect in RNA splicing 3849+ 
10Kbc>T 
Reduced copies of CFTR mRNA leads to 
minimal synthesis of CFTR protein 
VI Defect in protein stability Q1412X Accelerated turnover of CFTR protein at cell 
surfaces thereby reduce the quantity.  
 
At 2002, Ma et al reported six high-affinity small molecule CFTR inhibitors that directly 
interact with CFTR expressed on epithelial cells: CFTRInh-020, CFTRInh-029, CFTRInh-172, CFTRInh-
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185, CFTRInh-214 and CFTRInh-234 (226). Of them, CFTRInh-172 was the most potent 2-thioxo-4-
thiazolidinone chemical class CFTR inhibitor that is rapidly absorbed and selectively and efficiently 
blocked the Cl- channel gate from the cytoplasmic side in a voltage-independent manner. CFTRInh-
172 has also been shown to inhibit mitochondrial respiration and increases reactive oxygen species 
(ROS) production (230). N-(2-naphthalenyl) and 3,5-dibromo-2,4-dihydroxyphenyl glycine 
hydrazide, known as GlyH-101, is an open-channel blocker, i.e., it binds at the external side of the 
CFTR channel, thereby, inhibits inward rectification of CFTR function in respiratory and intestinal 
epithelial cells in both human and mice, i.e., Cl- influx from the intra- to the extracellular side of the 
cells is more rigorously attenuated than that in the opposite direction (227). Like CFTRInh-172, GlyH-
101 is able to inhibit cholera toxin-induced fluid secretion in mouse model of diarrhea (227). MalH-
2 is another water soluble and non-absorbable glycine hydrazide type CFTR inhibitor (231). MalH2 
rapidly, fully and reversibly blocked CFTR-mediated Cl- current in mouse intestine (cholera toxin-
induced model).  
 
All these abovementioned CFTR blockers have advantages as well as pitfalls. CFTRInh-172 
has a number of fascinating properties. In terms of potency, CFTRInh-172 readily inhibits CFTR-
mediated Cl- channel in less than 2 minutes (226). Secondly, CFTRInh-172 has no effect on other ion 
channels and transporters found in epithelial cells, including Ca2+-activated and volume-regulated Cl- 
channels and the ATP-binding cassette transporter P-glycoprotein showing specificity to CFTR-
dependent Cl- channels (226). GlyH-101, on the contrary, inhibits Ca2+-dependent CL- channels. 
Thirdly, CFTRInh-172 showed longer mean channel closure time than GlyH-101 (231). Fourthly, by 
effectively inhibiting cholera toxin-induced fluid secretion in mouse diarrhea model CFTRInh-172 
showed its therapeutic potential (226). Nevertheless, CFTRInh-172 suffers at least three drawbacks. It 
has limited solubility in water and intact cells and tissues reducing potency (227). Stahl et al reported 
a marked species difference in sensitivity to CFTRInh-172 and recommended using 20M 
concentration to achieve 50% inhibition of CFTR in human oocytes (232). GlyH-101 has been 
considered as better CFTR inhibitor than CFTRInh-172 for three reasons (233). GlyH-101 is highly 
water soluble and remains as a monovalent anion between pH 6.0 and 8.0 (227). Submaximal 
concentration of GlyH-101 is enough to rapidly attenuate Cl- influx in a voltage-dependent manner 
(227). In animal models, CFTRInh-172 must be administered through the intraperitoneal route to 
inhibit CFTR activity, whereas GlyH-101 can be administered directly into the lumen of the small 
intestine (227). MalH-2 has even greater water solubility than GlyH-101 (231).  
 
CFTRInh-172 and GlyH-101 have been widely used to inhibit CFTR activity and to study 
cellular mechanisms in CF inflammation. From 1 to 20M concentrations of CFTRInh-172 and GlyH-
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101 had no effect on cellular viability albeit higher concentrations, such as, 50M, cause cell death 
(234, 235). 10M was recommended for both CFTRInh-172 & GlyH-101 for in vitro cellular studies 
(159, 226, 234, 236). Studies mostly were conducted with epithelial cells to model CF and to evaluate 
the ability of CFTR inhibitors to mimic CF inflammation (234, 236). Both inhibitors induced a rapid 
increase in ROS level. Activation of nuclear translocation of nuclear factor-κB (NF-κB) was observed 
by CFTRInh-172, but not by GlyH-101. Spontaneous IL-8 release was slightly reduced by CFTRInh-
172 though increased by GlyH-101 (235). IL-6 and GM-CSF release were not affected by CFTRInh-
172 (236). Such varying data suggest that induction of ROS and NF-B signaling cascade and IL-8 
release are independent of CFTR function or regulation (234, 236). Effect of CFTR inhibition by 
CFTRInh-172 on Cl
- and phagocytosis in alveolar macrophages was first studied by Di et al (161). 
Later similar Cl- channel attenuation and impaired bactericidal activity were demonstrated in 
monocyte-derived macrophages (MDM) from patients with CF (159, 160). Viability, IL-1β release 
and surface marker expression of CD14, CD16, CD64, TLR-2, TLR-4, TLR-5 on MDM were mostly 
unaffected following CFTR inhibition by CFTRInh-172 (159).  
 
1.6.5 Current Treatment Options and Mutation Specific Therapies 
1.6.5.1 Current Therapeutic Options 
Inhaled dornase- (recombinant human deoxyribonuclease, given daily) and inhaled 
tobramycin (300mg twice daily) are recommended by the US Cystic Fibrosis Foundation as treatment 
options for patients with moderate to severe CF. Hypertonic saline, macrolide antibiotics (e.g., 
azithromycin), ibuprofen, and inhaled β-agonists are recommended for patients over 6 years of age 
(174).  Corticosteroids did not robust benefits to the patients rather impose adverse effects (174).  
 
Tobramycin is an aminoglycoside that is used for gram negative infections. It is especially 
effective against Pseudomonas species. It binds on bacterial 30S and 50S RNA thereby prevent 
formation of 70S complex. As a result, mRNA can’t be translated into protein ensuing cell death. 
However, tobramycin can’t pass through the gastrointestinal (GIT) and is therefore administered 
intravenously (IV), intramuscularly (IM) or via inhalation. Tobramycin is approved antibiotic in the 
United States and highly recommended for patients with CF to delay colonization of P. aeruginosa 
in the lungs (237). Six different independent studies showed significant improvement of lung 
functions in patients with moderate to severe CF and decreased chronic P. aeruginosa count and 
weight gain following tobramycin treatment compared to placebo or standard treatment (174, 238-
242). Tobramycin delayed biofilm formation of P. aeruginosa as well as disruption of already formed 
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biofilms thereby limits the growth of P. aeruginosa (243). P. aeruginosa count dropped in the 
infected lungs following intratracheal instillation of tobramycin (300g/kg body weight) suggesting 
decreased pulmonary bacterial load in the infected animals (239). In addition, tobramycin limits LPS 
induced inflammation in human bronchial epithelial cells (244). On the contrary, chronic use of 
tobramycin has been shown to promote resistance and biofilm formation by surviving bacteria (239). 
However, modulatory effects of tobramycin on host immune surveillance cells, such as, macrophages 
had not been comprehensively studied.  
 
1.6.5.2 Introduction of Small Molecules as Mutation-specific Therapeutics 
Currently available therapeutic options are unable to repair or modulate the basic genetic 
defect of CF, i.e., the mutation(s) in CFTR gene. Therefore, researchers are seeking for mutation-
specific drug that can specifically target mutant CFTR and restore normal CFTR function. Agents 
that increase the delivery of functional CFTR to the cell surface are called CFTR correctors, whereas, 
agents that increase Cl- channel gating are called CFTR potentiators. Ivacaftor, previously known as 
VX-770, is an FDA approved CFTR potentiator for the patients carrying G551D allele (245). 
Ivacaftor had been shown to enhance channel activity, improve lung function, lowers sweat chloride 
level thereby improve the clinical outcomes in patients carrying class III mutation (246-250). 
Lumacaftor, formally known as VX-809, is a promising investigational CFTR corrector that has been 
shown to correct F508 mutation selectively, thereby improve CFTR processing, maturation in the 
ER and trafficking to the cell surface, finally enhance Cl- secretion (249). Lumacaftor (VX-809) 
corrected F508-CFTR protein was presented on the cell surface for longer period suggesting that 
F508-CFTR protein was no longer recognized as defectively folded protein by the peripheral protein 
quality control machinery. The maximal effect has been observed after 24hr of treatment. Following 
washout of Lumacaftor, Cl- transportation returned to an uncorrected level within 48hr (249). 
 
Unfortunately, monotherapy with either of these drugs failed to improve lung functions in 
patients who are homozygous for F508 mutation (251, 252). In a double-blinded RCT with CF 
patients who carry homozygous mutation of F508, Lumacaftor did not show any improvement in 
CFTR function in nasal epithelial cells or significant changes in lung functions (251). Furthermore, 
patients with heterozygous mutation for F508/G551D mutations require treatment with both 
Ivacaftor and Lumacaftor to achieve clinical benefit (253). In vitro studies showed that combined 
treatment of Ivacaftor and Lumacaftor showed enhanced channel gating compared to corrector or 
potentiator alone (249). Likewise, in phase 2 clinical trial Ivacaftor-Lumacaftor combination therapy 
demonstrated improvement in lung function with a modest effect on sweat chloride concentration 
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among F508 homozygous patients (254). Later phase 3 trials in two different multicenter studies 
demonstrated significant improvement in lung function with lowered rate of hospitalization and 
intravenous antibiotic administration in patients who received such combined treatment over 6 
months compared to the placebo group (255). However, the study was conducted only in patients 
who had moderate to severe clinical symptoms. The effect of Lumacaftor-Ivacaftor treatment in 
patients with even poor pulmonary function has not been investigated yet.  
 
Affordability of such Ivacaftor-Lumacaftor treatment is another key issue. Lumacaftor-
Ivacaftor therapy is almost $300,000 per year which delays its introduction to the patients carrying 
G551D mutation. Other CFTR correctors, such as, SAHA, 4-phenylbutyrate, VRT-325, corr-4a have 
been reported in many studies, though they are less selective and insufficiently restore CFTR function 
(249). VX-325 is a promising small molecule capable of correcting F508 mutation. VX-325 treated 
monocytes from patients carrying F508 mutation showed higher expression of CFTR along with 
significant recovery of normal CFTR function (256). Patients who carry mutations other than F508 
mutation still had no choice other than conventional therapies.  
 
1.7 Macrophages: The Missing Link in CF Inflammation? 
Macrophages play critical roles in inception and resolution of pulmonary inflammation. 
Studies showed spontaneous infiltration of monocytes and macrophages in alveolar spaces as well as 
local tissues, such as, peritoneum (257). Depending on the post translational processing, three 
isoforms of CFTR proteins have been shown in earlier studies (176): isoform A of MW 130-140KD 
corresponds to an immature, incompletely-glycosylated form of CFTR. Isoform B represents the 
incompletely glycosylated form of CFTR protein expressed by CFTR-KO human bronchial epithelial 
cells. The fully glycosylated form of CFTR is known as isoform C. Monocytes from healthy 
individuals express all three isoforms. Presence of functional CFTR protein was demonstrated on the 
surface of human and murine AMs, peritoneal macrophages (161) as well as in vitro differentiated 
human macrophages (160). Conversely, the presence of isoform B was detected in monocytes from 
patients with CF (176, 180). Truncated forms of the protein appear to be loosely localized on the 
membrane. Macrophages from CF patients homozygous for F508 mutation showed cytoplasmic 
localization of CFTR protein indicating trafficking defect due to class II CFTR mutation (160). 
Similar mislocalization of F508 CFTR in cytoplasm had previously been reported primary airway 
and nasal epithelial cells (258, 259).  
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A recent study showed increased CFTR expression over AMs following LPS stimulation (260). 
Upon administration of CFTR inhibitor, MalH-2, wild-type mice showed a substantial increase in 
cytokine production following LPS challenge compared to corresponding controls suggesting 
regulation of CFTR on pro-inflammatory cytokine production during bacterial infection and how the 
lack of functional CFTR during bacterial infection worsen lung inflammation (260). Cellular 
phagocytosis activity encompasses the uptake and engulfment of foreign particles to a 
phagolysosomal compartment, also called phagosome and then destruction or killing of the foreign 
particles by phagolysosomal acidification – a combination of oxidative mechanisms including 
superoxide (O2-), hypochlorous acid (HOCl), acidic pH and lysosomal enzymes (261). Using CFTR-
KO mice Di and colleagues elegantly showed that uptake and phagosome formation were not 
defective in CFTR-KO mice, rather phagosomes from CFTR-KO AMs were less acidic, pH of 6.5 
than their wild-type counterparts, pH of 4.5, to kill the invaded bacteria suggesting the role of CFTR 
in the acidification of phagolysosomal compartments (161). Monocyte-derived macrophages from 
patients with CF showed the similar altered bactericidal activity to P. aeruginosa indicating impaired 
clearance of pathogens by CF macrophages which later led to persistence infection and chronic 
exacerbated pro-inflammatory responses.(159, 160). 
 
F508 mutation bearing CF mice demonstrated M1 polarization with substantial induction of 
IL-1 in compared to wild-type mice even in the absence of M1 stimulation suggesting an association 
of M1 polarization and intrinsic CFTR defect (257). LPS challenge led to substantial induction of M1 
signature genes in CF mice than in wild-type mice indicating that bacterial infection on a background 
of intrinsic CFTR mutation worsen the pulmonary inflammation. On the contrary, polarization of M2 
signature genes as well as IL-10, hallmark M2 soluble marker in mouse, were not remarkably induced 
in AMs and PMs of CF mice (257). Taken together, this data suggests exaggerated pro-inflammatory 
responses in CF with basal or no induction of anti-inflammatory M2 macrophages. In human, 
increased expression of IL-13, but not IL-4, was observed in patients with CF (262). Nevertheless, 
subset specific macrophage responses have never been studied among patients. 
 
Patients with CF are treated with antibiotics to prevent and eradicate respiratory infections 
(241). Aminoglycoside antibiotics such as tobramycin, gentamicin has been shown to restore 
expression of full-length functional CFTR and significant increase of cAMP-activated chloride 
channel (180, 263). In a mouse model Meyer et al analyzed the immunoregulatory effects of 
azithromycin on macrophage polarization (257). In wild-type mice, in the absence of M1 stimulation, 
NO production was not induced by azithromycin alone, however, azithromycin administration 
following M1 polarization led to substantial down-regulation of NO production. In the absence of 
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M2 stimulation, Arg 1 activity was enhanced by azithromycin alone in a dose-dependent manner in 
wild-type mice, whereas, a combination of both M2 stimulation and azithromycin treatment 
considerably promoted M2 polarization in AMs and PMs. These data suggest that antibiotics 
downregulate pro-inflammatory macrophages and activate anti-inflammatory macrophages. 
Unfortunately, the authors did not analyze the effects of azithromycin on macrophage polarization in 
CF mice. In addition, the precise mechanism of action of azithromycin on macrophage polarization 
still remained unclear. A similar study was not carried out with human macrophages.  
 
All these data reflect that CFTR dysfunction due to intrinsic defect is linked to macrophage 
polarization and function in CF. However, understanding of the contributions of macrophages in CF 
pathophysiology is lacking. Furthermore, the mechanism of actions of administered antibiotics on 
macrophage functions needs to be explored.  
 
1.8 Hypothesis and Specific Aims 
1.8.1 Hypothesis 
Macrophage function is dependent on its polarization state. Both mouse and human studies 
showed a positive association of defective between CFTR function and impaired macrophage 
responses. Therefore, the hypothesis of this Ph.D. study was that dysfunctional CFTR leads to 
defective polarization of macrophages and thereby contribute to the chronic airway infections, and 
inflammation leading to loss of lung function in CF. Therefore, the general aim of this study is to 
investigate subset specific macrophage phenotype and function in young and adult patients with CF 
during their acute pulmonary exacerbation (APE) and clinically stable conditions.   
 
1.8.2 Specific Aims 
1.8.2.1  Development of in vitro Model to Characterize Human Classical and Alternatively 
Activated Macrophages  
The first aim of this Ph.D. project was to develop a novel approach to characterize human M1 
and M2 macrophages by surface markers, signature genes, inflammatory mediators and functional 
aspects. Additional interest was to analyze the persistence of polarized macrophages over time and to 
assess their reprogramming ability upon appropriate stimulation.  
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1.8.2.2  Study Subset-Specific Macrophage Responses in CF and Identify the Defective 
Macrophage Subset(s) in Cystic Fibrosis  
Defective macrophage function has already been reported in murine CF models and human 
studies. Nevertheless, the dynamic changes of macrophage subsets during acute exacerbation and 
stable conditions of CF had never been studied among CF patients. A comprehensive analysis aimed 
to be conducted with the model mentioned in Aim 1 to identify defective macrophage subsets in CF. 
The hypothesis here was that M2 polarization of macrophages might be defective which leads to 
incomplete resolution of inflammation in patients with CF. Since phagocytosis is under CFTR 
regulation, it was postulated that aberrant M2 polarization of macrophages might also be associated 
with a lack of CFTR function.  
 
1.8.2.3 Effects of Tobramycin on Macrophage Polarization 
Effects of tobramycin on macrophage polarization in CF was aimed to investigate in this Ph.D. 
study with the aim that how antibiotics modulate the host immune system. 
Chapter 2 Methodology 
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2.1 Ethics Approval 
The study protocols, consent forms and advertising materials related to healthy individuals 
considered as controls of this study had been approved by the human research ethics committee 
(HREC) of the Royal Children’s Hospital (RCH), Brisbane and the University of Queensland (UQ), 
Australia. Permissions from the relevant Institutional Review Boards, i.e., Prince Charles Hospital 
and Children Health Queensland (Royal Children Hospital/Lady Cilento Children’s Hospital), 
Brisbane, were obtained for collecting blood samples from patients with CF. Written consents from 
all adult patients or the parents of young patients were obtained.  
 
2.2 Study Sites 
 The entire Ph.D. project was conducted as a research study at Queensland Children’s 
Medical Research Institute (QCMRI), Royal Children’s Hospital, Brisbane, and later at Children’s 
Health Research Centre, UQ (CHRC-UQ). All patients’ samples were collected from the CF clinics 
at the Prince Charles Hospital and Children Health Queensland (Royal Children Hospital/Lady 
Cilento Children’s Hospital), Brisbane, Australia.  
 
2.3 Study Populations 
2.3.1 Patients Samples 
Adult (n=13) and children (n=27) patients with verified CF carrying at least one F508 allele 
were recruited from the CF clinics at the Prince Charles Hospital and Children Health Queensland 
(Royal Children Hospital/Lady Cilento Children’s Hospital), Brisbane, Australia respectively. Paired 
blood samples from adult patients were collected by venepuncture during admission to hospital due 
to acute pulmonary exacerbation (APE) and prior to discharge from the hospitals. Blood from children 
were collected on admission to hospital (n=16) and/or at a clinic visit (n=14) when they are clinically 
stable. Paired blood samples were collected only from 2 children. Smoking habit of the enrolled adult 
patients or parents of young patients with CF was not taken into account this study.  
 
2.3.2 Healthy Controls 
A total of 29 buffy coats from healthy donors, aged from 18 to 40 years, were obtained from 
the Australian Red Cross blood services (ARCBS) (Brisbane, Australia). Buffy coats were processed 
within 18 hrs of collection. Buffy coats were initially used for optimizing and developing methods 
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for macrophage subset characterization. Later data from buffy coats were used as controls to compare 
with data from CF patients. Unfortunately, no demographic other than sex and age were inaccessible.   
 
To validate the buffy data, similar experiments were conducted with freshly collected blood 
from volunteers. Volunteers at QCMRI or later at CHRC agreed and signed informed consent forms 
to be enrolled in the study. All volunteers were enrolled based on following selection criteria.  
Inclusion criteria: 
1. Individuals of either sex 18 years and older.  
2. Individuals who were healthy at the time of enrolment. 
3. Individuals who were not taking any medication in the last 24 hours.  
Exclusion criteria: 
1. Individuals who were suffering from any acute or chronic medical condition at the 
time of enrolment.  
2. Individuals who were taking any medication for current cold and/or allergies.  
3. Individuals who experienced any episode of allergy or asthma in the last three months. 
 
Peripheral blood was collected from volunteers by experienced phlebotomists following 
WHO guideline (264). Following venous puncture, blood was collected in preservative free heparin 
containing tubes (20units/ml). To avoid clotting, blood containing tubes were inverted and kept 
standing at room temperature for 10-15min.  
 
2.3.3 THP-1: Human Monocytic Cell Line 
Due to lack of continuous supply or unavailability of human cells and less viability over longer 
periods, biologists tend to use continuous cell lines which mimic many characteristics of primary 
cells as a model system for investigating disease pathogenesis. At the very early time of this study, 
human monocytic cell line, THP-1, was used to establish macrophage culture. THP-1 cell line has 
been using for studying human macrophages and their involvement in diseases (115). Treatment with 
phorbol esters or vitamin D3 (Vit D3) enable THP-1 cells to differentiate into macrophage-like cells 
which mimic native monocyte-derived macrophages (MDM) in several respects, such as, morphology 
(e.g. adherent to the culture plate), secretory products, expression of membrane antigens (e.g., CD68, 
CD14) and the involvement of genes involved in lipid metabolism (113, 114). THP-1 cell line was 
brought from American Type Culture Collection (ATCC).  
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2.4  General Laboratory Methods  
2.4.1 Differentiation of THP-1 derived Macrophages  
Differentiation of THP-1 cells to macrophage-like cells was induced by overnight stimulation 
with 20nM of phorbol 12-myristate 13-acetate (PMA) (Sigma, USA) or 6-days stimulation with M-
CSF (50ng/ml) (Invitrogen, USA). THP-1 derived macrophage-like cells were referred as TDMs all 
through this thesis.  
 
2.4.2 Isolation of Peripheral Blood Mononuclear Cells (PMBCs) and Purification 
of Monocytes  
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats or peripheral 
blood from patients or healthy volunteers by density gradient centrifugation using Lymphoprep 
(Axis-Shield, UK). PBMCs were washed twice with PBS to get rid of any serum, platelets or residual 
Lymphoprep. All the steps were performed in a biosafety cabinet to maintain sterility. Monocytes 
were purified from PBMCs using CD14+ magnetic microbeads following manufacturer’s instructions 
(Miltenyi Biotech, Germany). Briefly, cells were incubated with CD14+ microbeads for 15 min at 4C. 
Cells were then washed and spun down at 300g for 10min. Cells were resuspended in MACS buffer 
(0.5mg BSA/ 2mM EDTA/ 100ml PBS) and passed through the MACS column (Miltenyi, Germany). 
After washing, cells magnetically retained in the column were recovered by flushing with a plunger. 
Purified monocytes were then counted by hemocytometer.  
 
2.4.3 Analysis of Monocyte Subsets 
CD14+ monocytes isolated from buffy coats or from blood samples of patients with CF were 
subjected to monocyte subset analysis. Classical, intermediate and non-classical monocytes were 
analyzed by their surface expression of CD14 and CD16. Briefly, monocytes were incubated with Fc 
blocking solution or FACS buffer (FBS, 2%-BSA,0.1%-PBS, 100ml) for 20min at 4C. Cells were 
then spun down and resuspended in FACS buffer and stained with anti-human CD14-PE Cy 7 (BD, 
USA), CD16-PerCP Cy5.5 (BD, USA) and CD45-V450 (BD, USA). This analysis also demonstrated 
the purity of monocytes isolated by MACS separation. Data were acquired on BD LSR-Fortessa using 
BD FACS Diva software. All flow cytometric analysis were performed on Flowjo platform (Tree 
Star, USA). 
 
39 
 
 2.4.4 In vitro Differentiation of Monocyte-derived Macrophages  
Both M-CSF and GM-CSF are potent hematopoietic growth factors for macrophage 
differentiation from monocytes. M-CSF is abundant in the circulation, while the respiratory lining is 
rich in GM-CSF. GM-CSF, therefore, was mostly used in this study to define respiratory 
macrophages. M-CSF was used to confirm that M-CSF differentiated macrophages exhibited similar 
phenotypes and functions to GM-CSF differentiated macrophages.  
 
For macrophage differentiation, monocytes were cultured in RPMI-1640 (Lonza, USA), 
supplemented with 10% heat inactivated FBS (Life Tech, USA), 1% Penicillin-streptomycin-
fungizone (Lonza, USA) and rhGM-CSF (50ng/ml) (BioLegend, USA) or rhM-CSF (50ng/ml) 
(Invitrogen, USA) for 6 days. Medium was refreshed on day 3 with appropriate amount of cytokines. 
These 6-day differentiated macrophages were considered as uncommitted macrophages and referred 
as M0 throughout this thesis.  
 
2.4.5 Phenotypic Characterization of M1-M2 Macrophages 
Flow cytometry has been widely used as a powerful tool to quantify any cell population by 
size, granularity and the presence of specific markers. In this study, this technique has been 
extensively used to characterize human macrophages and their subsets. For phenotypic 
characterization of polarized macrophages, cells were incubated with Fc blocking solution or FACS 
buffer (FBS, 2%-BSA,0.1%-PBS, 100ml) for 20min at 4C. Cells were then spun down and 
resuspended in FACS buffer and stained with appropriate antibodies. 7-AAD (BD, USA) staining 
was performed to exclude dead cells for further analysis. Differentiation of macrophages was assessed 
by their intra-cellular expression of CD68 antigen using anti-human CD68-AF647 antibody (BD, 
USA). For intracellular staining, cells were fixed and permeabilized with CytoFix solution (BD, 
USA) following manufacturer’s instructions. Characterization of M1 and M2 macrophages 
performed by staining with a panel of surface markers: CD1a, CD1b, CD11b, CD14, CD23, CD64, 
CD68, CD80, CD163, CD200R, CD206, CD209, CD226 (Suppl Table 1 and Suppl Table 2). Data 
were acquired on BD LSR-Fortessa using BD FACS Diva software. All flow cytometric analysis 
were performed on CD68 positive cells on Flowjo (Tree Star, USA). 
 
Unfortunately, phenotypic characterization of macrophages is complicated by their inherent 
autofluorescence (AF) property (265-267). AF is associated with cellular complexity (268). 
Macrophages are granulated and contain substantial amounts of NAD and FAB. These molecules can 
be excited by distinct wavelengths, especially 488nm in flow cytometry (269). This signal obscures 
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fluorescent signals generated by standard fluorescent dyes, such as, fluoresceine isothiocyanate 
(FITC) or phycoerythrine (PE) (265, 270). Irregular shapes of macrophages is another contributing 
factor for AF (270). Cigarette smoking was reported as an external factor that is also involved in AF 
of macrophages though the underlying mechanism is not known (271). Therefore, antibodies with 
fluorochromes at far blue, red and violet dyes were chosen for this study. Quality control of the flow 
cytometer including fluorescence standardization, linearity assessment, and spectral compensation 
were performed on daily basis to ensure identical operation from day to day.  
 
2.4.6  Quantification of Inflammatory Cytokines and Chemokines 
To quantify cytokines present in the culture supernatant, supernatants were collected and spun 
down to get rid of any residual cells. Cell-free supernatants were immediately stored at -200C. IL-1, 
TNF-, IFN-, IL-8, RANTES, IP-10, IL-10 and IL-13 in cell-free culture supernatants were 
quantified in duplicate wells by alphaLISA (Perkin Elmer, USA). TGF-, CCL17 (BioLegend, USA), 
CCL18, CCL22 (R&D Systems, USA) in the culture supernatant were quantified using conventional 
ELISA. IL-13R2 was measured using sandwich ELISA (Ray Biotech, USA).  
 
2.4.7 Total RNA Extraction and Gene Expression Analysis by Quantitative PCR 
(qPCR) 
RNA was extracted using RNeasy Kit, reverse transcribed to cDNA using Quantitect RT kit 
(Qiagen, USA). qPCR was performed using pre-designed TaqMan primer/probe combinations for 
human IRF4, IRF5, APOL3, TNF-, CXCL11, CCL18, FN1, COX-2, and -actin genes in at least 
duplicate wells (LifeTech, USA) on ABI 7900HT (Applied-Biosystem, USA). Primer sequences are 
available on the manufacturer’s website. After normalizing the data with -actin, relative gene 
expression was calculated by considering M0 as control (272). CT was calculated by the formula 
below:  
 
2^(-ΔΔCT)=[CT(target,untreated)−CT(ref,untreated)]−[CT(target,treated)−CT(ref,treated)] 
 
2.4.8 Networking Analysis of M2 Macrophages by Microarray 
Microarray analysis requires genomic DNA (gDNA) free high-quality RNA. To get gDNA free 
RNA, RNA for microarray experiments were extracted using RNeasy Plus Kit (Qiagen, USA). RNA 
integrity number (RIN) were analyzed with Agilent Bioanalyzer 2100 in the sequencing facility of 
41 
 
the Institute for Molecular Bioscience (IMB), University of Queensland. RIN numbers for all samples 
were above 8.0. Microarray was conducted using U219 array plate (Affymetrix, USA) containing 
more than 36,000 gene probes at the Ramaciotti Centre for Genomics, University of New South Wales 
(UNSW), Australia. To identify biological processes whether upregulated or downregulated in CF 
macrophages compared to macrophages from healthy individuals, network analysis was performed 
using Ingenuity Pathway Analysis (IPA) software by Professor Anthony Bosco, Telethon Kids 
Institute, University of Western Australia. 
 
2.5  Novel Methods Developed During This Ph.D. Study 
2.5.1 In vitro Model for Human M1 and M2 Macrophages Polarization and 
Characterization 
Initial experiments at the early stages of this Ph.D. study were commenced with non-adherent 
monocytic cell line THP-1. To get adherent macrophage-like cells, THP-1 cells were treated them 
with 20nM of PMA (Sigma, USA) or M-CSF (50ng/ml, Invitrogen, USA), or GM-CSF (50ng/ml, 
BioLegend, USA). Differentiation to macrophage-like cells was analyzed by cell adherence to the 
tissue culture plate. Overnight PMA treatment showed full adherence of THP-1 derived macrophage-
like cells (TDMs). However, M-CSF treated cells did not adhere at all (117), while GM-CSF 
treatment exhibited partial adherence. PMA treated TDMs were then treated with LPS (20ng/ml, 
Sigma, USA) plus rhIFN- (20ng/ml, Life Technologies, USA) for M1 polarization and with IL-13 
(20ng/ml, Life Technologies, USA) for M2 polarization. Whether TDM data can truly reflect MDM 
data, monocytes from healthy donors were differentiated with either M-CSF (50ng/ml, Invitrogen, 
USA) or GM-CSF (50ng/ml, BioLegend, USA) and polarized with abovementioned protocol and 
compared with TDM data. Expression of CD80 as M1 marker and CD163 and CD206 as M2 markers 
were analyzed by flow cytometry. 
 
TDMs showed partial induction of CD80 following LPS treatment compared to LPS treated 
MDMs (Suppl Figure 1). In the case of M2, no or basal induction of CD206 (Suppl Figure 2) and 
CD163 (Suppl Figure 3) were observed on IL-13 treated TDMs. Induction of these two murine M2 
markers were not substantial on IL-13 conditioned MDMs compared to medium control. Taken 
together, firstly, TDMs demonstrated disparate data than MDMs, therefore did not mimic the 
phenotypes of MDMs. Secondly, murine M2 markers CD163 and CD206 failed to distinguish IL-13 
treated M2s from medium controls and therefore were off use in human indicating the necessity of 
new markers for human macrophage study. No further experiment was conducted with TDMs.  
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Available human data on M1/M2 polarization were inconsistent in the experimental 
conditions used to generate in vitro human macrophages and stimuli those were used for macrophage 
polarization (reviewed in Chapter 1). Based on earlier studies (72, 136) 6-day GM-CSF or M-CSF 
stimulated and fully differentiated MDMs were chosen for experiments onwards. 6-day fully 
differentiated macrophages were termed as uncommitted (M0) macrophages in this entire thesis. All 
possible combinations for M1 and M2 inducers were employed and later compared the phenotype 
and functions to define the best in vitro inducers for corresponding polarized states. Following 6-day 
stimulation with GM-CSF or M-CSF, fully differentiated macrophages were washed with sterile PBS 
to get rid of any residual GM-CSF or M-CSF. Medium containing either E. coli LPS alone (20ng/ml) 
(Sigma, USA), recombinant IFN- alone (20ng/ml) (Invitrogen, USA) or LPS plus IFN- were added 
to M0 cells for next 2 days for M1 polarization. M2 polarization was induced by using recombinant 
IL-4 alone (20ng/ml) (Invitrogen, USA), IL-13 alone (20ng/ml) (BioLegend, USA) or IL-4 plus IL-
13 for 2 days (Figure 2).  
 
Although earlier studies mostly focused on gene expression profiles of M1 and M2 
macrophages, differential expression of a few number surface markers for human M1 and M2 
macrophages had also been reported (72, 130, 136). Since those markers were shared by both subsets, 
a single population for each subset was hard to identify. Therefore I was looking for markers those 
were not shared and would clearly differentiate M1 or M2 macrophages as a single population. That’s 
why a panel of surface markers including CD1a, CD1b, CD11b, CD14, CD23, CD64, CD80, CD163, 
CD200R, CD206, CD209, CD226 were tested by flow cytometry (Suppl Table 1 and Suppl Table 
2).  
 
To validate this model, expression of subset-specific genes reported by previous studies were 
analyzed by qPCR. For instances, genes associated with M1 polarization included Cox-2, APOL3, 
CXCL11, TNF- and IRF5 (48, 72, 130, 136), whereas IRF4, FN1 and CCL18 were found to be 
associated with M2 polarization (111, 130, 135, 273). These genes were chosen based on their highest 
expression reported in the abovementioned studies. Release of inflammatory mediators and functional 
attributes of M0, M1 and M2 macrophages were also studied. This method ultimately allowed to 
characterize M0, M1 and M2 macrophages based on their surface markers, signature genes, secreted 
inflammatory mediators and functions.  
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Figure 2: In vitro model for human macrophage polarization. Human CD14+ monocytes were 
differentiated into macrophages (M0) by either GM-CSF (A) or M-CSF (B) and further polarized into 
M1 or M2 macrophages using either LPS/IFN- or IL-4/IL-13 for two days respectively. To study 
the stability of the phenotype, after polarization to M1 or M2, the cells were left in cytokine-free 
medium and analyzed after 6, 9 or 12 days. To test reprogramming into the opposite functional state, 
after 6 or 12 days in cytokine-free medium, M1 cells were exposed to M2 stimulus, and M2 cells 
were exposed to M1 stimulus for 2 days and analyzed. (B) Similar differentiation and polarization 
were performed with M-CSF derived macrophages. * denotes the time of cell harvest and phenotypic 
analysis by flow cytometry.   
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2.5.3 Phagocytosis and Endocytosis: Functional Properties of M1 and M2 
Macrophages 
Phagocytosis and endocytosis represent mechanisms by which M1 and M2 macrophages, 
respectively engulf and eliminate foreign particles (31). These functional properties have not been 
fully studied in human macrophage subsets. Commercially available kits for phagocytosis and 
endocytosis were used to demonstrate the subset-specific functional attributes of human M0, M1 and 
M2 macrophages. Internalization of AF-647 labeled dextran (10KD) (LifeTech, USA) and pHrodo 
green E. coli bioparticles (LifeTech, USA) were used to assess endocytic and phagocytic abilities of 
human M0, M1 and M2 macrophages. Phagocytosis process involves detection and attachment of the 
foreign microorganisms, engulfment of microbes and formation of phagosomes, fusion of 
phagosomes with lysosomes and finally killing of engulfed microbes by lysosomal acidic enzymes. 
pHrodo® green conjugates are sensitive to pH. They are non-fluorescent outside the cell at neutral 
pH, but fluoresce brightly green at acidic pH such as in phagosomes.  
 
Macrophages were incubated with either 5g/ml of dextran for endocytosis or recommended 
numbers of pHrodo green E. coli bioparticles for phagocytosis. Earlier studies recommended 90min 
incubation at 370C for these assays (274). A washing step after 90-min incubation with pHrodo 
conjugates had been reported to result in a decrease in fluorescence signals. Therefore any wash step 
was avoided in phagocytosis assay (274). However, cells subjected to the endocytosis assay were 
washed after incubation as recommended by the supplier. Uptake and internalization were measured 
by mean fluorescence intensities (MFIs) of corresponding fluorochromes by flow cytometry. Cells 
without bacteria or dextran were set as negative control (NC), M0 macrophages were set as a baseline 
control.  
 
Phagocytosis or endocytosis index (%) = (MFI, experimental well - MFI, NC) / (MFI, baseline 
control well - MFI, NC) ×100%. 
 
2.5.4 In vitro CF Macrophage Model 
This study developed an in vitro model for CF macrophages using two CFTR inhibitors, 
CFTRInh-172 and GlyH-101. Using CFTRInh-172, earlier study had shown that the inhibition of 
normal CFTR function alter phagocytosis ability of human macrophages (159), however, the 
macrophage differentiation protocol was different. In the study described here, monocytes from buffy 
coats were exposed to CFTR inhibitors CFTRInh-172 (10M) (Sigma, USA) or GlyH-101 (10M) 
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(Santa-Cruz, USA) during macrophage differentiation or polarization or both (Suppl Figure 8). These 
inhibitors work by different mechanisms, with CFTRInh-172 binding CFTR intracellularly, while 
GlyH-101 blocks the channel on the cell surface (226, 227). The rationale was to study whether 
blocking CFTR function in two different mechanisms would provide same or similar macrophage 
phenotypes and to choose an in vitro CF macrophage model that mostly mimic physiological 
functions and phenotypes of CF macrophages. 
   
2.5.5 Effects of Tobramycin on Macrophage Polarization and Functions  
Peak concentration of tobramycin in the BAL and sputum samples of CF patients was reported 
as 1mg/ml/ (243, 275, 276). No cytotoxic effect was observed in human bronchial epithelial cells 
with this concentration of tobramycin. Therefore, this concentration of tobramycin was chosen for in 
vitro macrophage differentiation and polarization to maintain clinical relevance. Tobramycin was 
added every 3rd day in the culture media. 
 
2.6 Data Handling and Storage 
All patients and volunteers information were collected at the time of the enrolment and were 
entered into a database in a non-identifiable way and stored on a secure system at The University of 
Queensland. All data from laboratory analyses were stored in the same location. 
 
2.7 Statistical Analysis 
All statistical analysis were performed using GraphPad-Prism (version 6.07) software (San 
Diego, CA). Statistical tests were chosen based on the research questions to be addressed and the 
experimental designs. In the Chapter 3, one-way nonparametric ANOVA was performed among M0, 
M1 and M2 groups. Data in Chapter 4 were shown as group mean±SD for flow cytometry and median 
and IQR unless stated otherwise. Wilcoxon paired signed ranked test was performed to determine the 
differences of inflammatory parameters amongst adult patients between hospital admission and 
discharge. Mann-Whitney test was performed to assess statistical significance of inflammatory 
parameters between control and CF groups. Two-way ANOVA was used in time-course studies, with 
group (CF/control) and time entered as main effects. Statistical significance was considered with 
p<0.05. 
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2.8 Supplementary Data 
 
 
Suppl Figure 1: Partial induction of CD80 in PMA treated THP-1 macrophages (TDMs) 
following LPS stimulation.  TDMs and GM-CSF treated MDMs were given LPS (20ng/ml) 
stimulation for 2 days. Cells were harvested washed and stained with CD64 PE Cy7 (X-axis) and 
CD80 AF 700 (Y-axis). At least 5000 events were acquired on BD LSR Fortessa. Data were shown 
from at least 2 experiments. 
 
 
Suppl Figure 2: Expression of CD206 is not induced by IL-13 in PMA treated THP-1 derived 
macrophages (TDMs). TDMs and M-CSF or GM-CSF treated MDMs were given IL-13 (20ng/ml) 
stimulation for 2 days. Cells were harvested washed and stained with CD64 PE Cy7 (Y-axis) and 
CD206 PE-Cy 5 (X-axis). At least 5000 events were acquired on BD LSR Fortessa. Data were shown 
from at least 2 experiments.  
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Suppl Figure 3: Expression of CD163 is not induced by IL-13 in PMA treated THP-1 derived 
macrophages (TDMs). TDMs and M-CSF or GM-CSF treated MDMs were given IL-13 (20ng/ml) 
stimulation for 2 days. Cells were harvested washed and stained with CD64 PE Cy7 (Y-axis) and 
CD163 PE CF594 (X-axis). At least 5000 events were acquired on BD LSR Fortessa. Data were 
shown from at least 2 experiments. 
 
Chapter 3 Phenotypic, Functional and Plasticity Features of Classical 
and Alternatively Activated Human Macrophages 
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3.1 Summary 
Identification of the polarized state of macrophages is the cornerstone in understanding 
disease pathogenesis. Therefore, the first aim of this chapter was to develop an in vitro model for 
human M1 and M2 polarization and their characterization. Macrophages were differentiated from 
monocytes isolated from buffy coats by 6-day stimulation with GM-CSF and M-CSF. These 
uncommitted macrophages were termed as M0. A number of stimuli were employed to polarize M0 
macrophages to M1 and M2 macrophages to find out the best in vitro stimulus for the corresponding 
polarized state. A panel of surface markers was tested to get single population for M0, M1 and M2 
macrophages. The model was verified by subset-specific genes reported by earlier studies. Subset-
specific cytokine and chemokine secretion and functional characteristics were analyzed.  
 
The second aim of this chapter was to assess the persistence of polarized phenotypes over 
time. Once polarized M1 and M2 macrophages were left in the cytokine-free medium for next 12 
days and subset-specific surface marker expression was monitored every 3rd day by flow cytometry.  
 
Plasticity is another hallmark feature of macrophages. Murine model showed that upon 
appropriate stimuli, once polarized M1 macrophages were able to switch to M2 and vice versa. 
Unfortunately, this concept had not been clearly shown in human. Therefore the final aim of this 
chapter was to assess the reprogramming ability of once polarized macrophages into another.  
 
This chapter was accepted and published in the American Journal of Respiratory Cellular and 
Molecular Biology, Vol 53, No. 5, Nov. 2015.  
DOI: 10.1165/rcmb.2015-0012OC 
PMID: 25870903 
URL: http://www.ncbi.nlm.nih.gov/pubmed/25870903   
 
Authorship: Abdullah A Tarique, Jayden Logan, Emma Thomas, Patrick G Holt, Peter D Sly, 
Emmanuelle Fantino. 
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3.2 Abstract  
Macrophages are dynamic cells that mature under the influence of signals from the local 
microenvironment into either classically (M1) or alternatively (M2) activated macrophages with 
specific functional and phenotypic properties. While the phenotypic identification of M1 and M2 
macrophages is well established in mice, this is less clear for human macrophages. In addition, the 
persistence and reversibility of polarized human phenotypes is not well established. Human peripheral 
blood monocytes were differentiated into macrophages (M0) and then polarized to M1 and M2 
phenotypes using LPS/IFN- and IL-4/IL-13, respectively. M1 and M2 were identified respectively 
as CD64+CD80+ and CD11b+CD209+ by flow-cytometry. Polarized M1 secreted IP-10, IFN-, IL-8, 
TNF-, IL-1 and RANTES while M2 secreted IL-13, CCL17 and CCL18.  Functionally, M2 were 
highly endocytic. In cytokine deficient medium the polarized macrophages reverted back to the 
uncommitted M0 state within 12 days. If previously polarized macrophages were given the alternative 
polarizing stimulus after 6 day resting in cytokine deficient medium, a switch in polarization was 
seen, i.e., M1 macrophages switched to M2 and expressed  CD11b+CD209+ and vice versa. In 
summary, we report phenotypic identification of human M1 and M2 macrophages, their functional 
characteristics and their ability to be re-programmed given the appropriate stimuli.  
 
Keywords: Macrophage, classically activated macrophages (CAM/M1), alternatively activated 
macrophages (AAM/M2), phagocytosis/endocytosis, phenotypic stability, reprogramming of 
polarization. 
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3.3 Introduction  
Macrophages are widely distributed innate immune cells that play central roles in host defense 
against invading pathogens and in maintaining immunological homeostasis. Heterogeneity and 
plasticity are hallmarks of macrophages (61). Macrophages have broadly been characterized as either 
classical activated (M1) or alternatively activated (M2) based on surface receptors, gene signatures 
and secretion of inflammatory mediators (61, 277). Studies with knock-out mice made it possible to 
identify a number of signature genes (iNOS, Arg 1, Ym1, FIZZ1) along with chemokines that 
discriminate between different polarization pathways (141, 278, 279). However, due to the substantial 
physiological and immunological disparities between mouse and human, murine models poorly 
mimic human inflammatory biology (150, 280, 281)  and murine markers are of limited use in human 
studies. For instance, murine studies are usually performed using either bone-marrow derived 
macrophages or peritoneal macrophages, whereas human studies are carried out using monocytes or 
monocytes derived macrophages (MDMs). Additionally, murine M1 or M2 signature genes iNOS, 
Ym1, FIZZ1 have no homologs in humans. The expression of the surface markers that define mouse 
M1 and M2 macrophages is different in human. The mannose receptor, CD206, a prototypic mouse 
M2 marker, is highly expressed in M-CSF treated macrophages in mouse, while in human monocytes 
CD206 is substantially induced by GM-CSF (86, 146). CD163, scavenger-R type A, another mouse 
M2 marker is highly expressed after IL-10 treatment in human, but not in IL-4 condition (146). 
Transaminoglutamase 2 (TGM2) had been found as the sole gene induced in both murine and human 
M2 macrophages (150). These data cast doubt on whether murine M1/M2 definition really mimics 
human macrophage biology.  
 
Available human data on M1/M2 polarization are limited and hampered by the lack of 
consistency in the experimental conditions used to study human macrophages in vitro, including the 
use of different cell types or cell lines for macrophage generation, different culture conditions and 
different stimuli for macrophage differentiation and polarization. Monocytic cell lines, such as THP-
1 are commonly used by human macrophage biologists. However, while THP-1 is recognized as a 
good model, some significant differences have been identified when comparing to primary cells. For 
instance, PMA treated THP-1 macrophage-like cells do not express mannose receptor (CD206) MHC 
class II DR1, while CD14 and IL-1 were upregulated compared to monocytes or monocytes-
derived macrophages (MDM) (117). Furthermore, a subset of PMA treated THP-1 cells do not 
express scavenger receptors demonstrating heterogeneity in this cell line (119).  Compared to primary 
cells, the responses of THP-1 to LPS stimulation (121) and oxidized low-density lipoproteins (120) 
were attenuated and finally TLR3 and TLR5 mRNA expression were lower (122). Other significant 
differences have been recently reviewed by Qin (123). In addition, THP-1 expression of CD14 marker 
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and cytokines was found to be very sensitive to culture conditions, in particular cell density and 
duration of stimulation (124). Therefore monocytes or monocytes-derived macrophages (MDM) are 
now more frequently being used in human macrophage studies. Transcriptome-based network 
analysis revealed that macrophages are clearly distinct cell types from their progenitor monocytes 
(72). While using monocytes, some investigators induce M1 and M2 polarization with GM-CSF and 
M-CSF, respectively (48), whereas others used type II interferon and/or TLR agonists for M1 and 
TH2 cytokines, e.g., IL-4, IL-13 for M2 polarization, showing no consensus protocol for human 
macrophages polarization. Beyer et al reported a few surface markers for human M1 and M2 
macrophages; the expression level of these markers was independent of GM-CSF or M-CSF 
treatment, but depended on the presence of TH1 or TH2 cytokines (136). This study not only 
demonstrated the necessity of using MDM for human macrophage research as well as the importance 
of cytokines or TLR agonists for macrophage polarization, but also challenged the concept of GM-
CSF and M-CSF mediated M1 and M2 polarization in human studies. However, the differentially 
expressed markers reported by Beyer et al were not adequate to distinguish between uncommitted 
(M0), M1 and M2 macrophage subsets.   
 
The current literature is not definitive on whether the polarized subsets of macrophages are 
stable, whether the shift from pro- to anti-inflammatory conditions or vice versa required removal of 
one subset and replacement by a new subset or whether depolarization followed by repolarization 
could occur in situ. An adequate balance between M1 and M2 subsets maintains the homeostatic 
milieu, whereas disequilibrium is likely to lead to unbalanced inflammation. In murine models of 
inflammatory bowel disease and asthma, adoptive transfer of M2 macrophages not only reversed the 
distribution of macrophage subsets but also reduced the disease severity, suggesting a dual role for 
macrophages in orchestrating both the onset and dissolution of inflammation (74, 75). The ability of 
macrophages to adapt to changing cytokine environments has been demonstrated in vivo in tumor-
bearing mice, where changing the microenvironment resulted in switch of macrophage phenotypes 
(63, 76, 77). Such shifts between macrophage subsets have not been studied using human macrophage 
models.   
 
Both M-CSF and GM-CSF are potent hematopoetic growth factors for macrophage 
differentiation from monocytes. M-CSF is abundant in the circulation, while the respiratory lining is 
rich in GM-CSF. We utilized GM-CSF in most parts of our study to define respiratory M1 and M2 
macrophages. However, we also used M-CSF to confirm that, in humans, M-CSF derived 
macrophages exhibited similar functional phenotypes following M1 and M2 polarization. Therefore 
our findings would not be limited only to respiratory macrophages exposed to a GM-CSF-rich 
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environment. In the present study, we used MDMs to determine combinations of surface markers that 
distinguished between populations of M0, M1 and M2 macrophages and described their functional 
signatures. We also analyzed the phenotypic stability of each polarized state over time, and 
demonstrated the reprogramming ability of one polarized state into another.  
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3.4 Materials and Methods  
3.4.1 In vitro Polarization of M1 and M2 Macrophages 
Buffy coats from eight healthy blood donors were obtained from the Australian Red Cross 
blood services (Brisbane, Australia) and PBMCs isolated by density gradient centrifugation using 
Lymphoprep (Axis-Shield, UK). Monocytes were purified using CD14+ magnetic microbeads 
(Milteny Biotech, Germany). For macrophage differentiation, monocytes were cultured in RPMI-
1640 (Lonza, USA), supplemented with 10% heat-inactivated FBS (Life Tech, USA), 1% Penicillin-
streptomycin-fungizone (Lonza, USA) and rhGM-CSF (50ng/ml) (BioLegend, USA) or rhM-CSF 
(50ng/ml) (Invitrogen, USA) for 6 days. Uncommitted macrophages (M0) were polarized into M1 
using E. coli LPS alone (20ng/ml) (Sigma, USA), rhIFN- alone (20ng/ml) (Invitrogen, USA) or LPS 
plus IFN- and into M2 using rhIL-4 alone (20ng/ml) (Invitrogen, USA), rhIL-13 alone (20ng/ml) 
(BioLegend, USA) or IL-4 plus IL-13 for 2 days (Figure 3). To assess the persistence of polarized 
phenotype, M1 and M2 cells were washed with PBS and left in medium without any cytokine for up 
to 12 days. Cells that previously received M1 stimuli were then given M2 stimuli (IL-13) and vice 
versa. Less than 2% cell death was observed in all conditions.  
 
3.4.2  Phenotypic Characterization of M1/M2 macrophages 
Cells were harvested by TrypLE (Invitrogen, USA), washed with PBS and incubated with Fc 
blocking solution (FBS, 2%-BSA,0.1%-PBS, 100ml). Cells were stained with a panel of surface 
markers: CD1a, CD1b, CD11b, CD14, CD23, CD64, CD68, CD80, CD163, CD200R, CD206, 
CD209, CD226 (Suppl Table 1 and Suppl Table 2). 7-AAD (BD, USA) staining was performed to 
gate out dead cells. Data were acquired on BD LSR-Fortessa using BD FACS Diva software. Cell 
populations were identified on CD68 positive cells on Flowjo (Tree Star, USA). 
 
3.4.3 Gene Expression Analysis by Real-Time PCR 
RNA was extracted using RNeasy Kit, reverse transcribed using Quantitect RT kit (Qiagen, 
USA). qPCR was performed using TaqMan primer/probe combinations for human IRF4, IRF5, 
APOL3, TNF-, CXCL11, CCL18, FN1, COX-2 and -actin genes in at least duplicate wells 
(LifeTech, USA) on ABI 7900HT (Applied-Biosystem, USA). After normalizing the data with -
actin, relative gene expression was calculated by considering M0 as control (272).  
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3.4.4 Quantification of Cytokines and Chemokines 
IL-1, TNF-, IFN-, IL-8, RANTES, IP-10, IL-10, IL-13 in culture supernatant were 
quantified in duplicate wells by alphaLISA (Perkin Elmer, USA). TGF-, CCL17 (BioLegend, USA), 
CCL18, CCL22 (R&D Systems, USA) were quantified using conventional ELISA.  
 
3.4.5 Functional Assays: Phagocytosis and Endocytosis 
Internalization of AF-647 labeled dextran (10KD) (LifeTech, USA) and pHrodo green E. coli 
bioparticles (LifeTech, USA) were used to assess endocytic and phagocytic abilities of macrophages. 
Briefly, macrophages were incubated with either dextran (5g/ml) or green E. coli for 90min at 37C. 
Uptake and internalization were measured by mean fluorescence intensities (MFIs) by flow 
cytometry. Cells without bacteria or dextran were set as negative control (NC), M0 macrophages 
were set as baseline control.  
 
Phagocytosis or endocytosis (%) = (MFI, experimental well − MFI, NC) / (MFI, baseline 
control well − MFI, NC) × 100%.  
 
3.4.6 Statistical Analyses 
Statistical analysis was performed using GraphPad-Prism software. One-way nonparametric 
ANOVA was performed among M0, M1 and M2 groups. Statistical significance was considered with 
p<0.05 and data presented as means  SEM.   
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Figure 3: In vitro model for human macrophage polarization. Human CD14+ monocytes were 
differentiated into macrophages (M0) by either GM-CSF (A) or M-CSF (B) and further polarized into 
M1 or M2 macrophages using either LPS/IFN- or IL-4/IL-13 for two days respectively. To study 
the stability of the phenotype, after polarization to M1 or M2, the cells were left in cytokine-free 
medium and analyzed after 6, 9 or 12 days. To test reprogramming into the opposite functional state, 
after 6 or 12 days in cytokine-free medium, M1 cells were exposed to M2 stimulus, and M2 cells 
were exposed to M1 stimulus for 2 days and analyzed. (B) Similar differentiation and polarization 
were performed with M-CSF derived macrophages. * denotes time of cell harvest and phenotypic 
analysis by flow cytometry.  
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3.5 Results  
3.5.1 M1s are CD64HiCD80- or CD64+CD80+ while M2s are CD11b+CD209+  
Macrophages differentiated in the presence of GM-CSF for 6 days maintained the regular 
morphology while macrophages differentiated in the presence of M-CSF were elongated with 
numerous vacuoles (Suppl Figure 4A). We did not find any substantial difference in CD68 expression 
between GM-CSF and M-CSF derived macrophages (Suppl Figure 4B). Following 2-day 
polarization of mature M0 macrophages with M1 and M2 stimuli, we investigated the expression of 
a broad panel of surface markers by flow cytometry (Suppl Table 1). The markers that best 
characterized M1 macrophages were CD64 (the high-affinity Fc receptor I) and CD80 (T-
lymphocyte activation antigen). However, the levels of induction of these two markers were different 
depending on the nature of the M1 stimulus: M1-IFN- cells exhibited a robust upregulation of CD64 
(CD64hi) in 6 out of 8 donors (Figure 4A). Co-stimulatory molecule, CD80 was expressed mainly 
when cells received LPS. A distinct CD64+CD80+ population was detected when M1 polarization 
derived from LPS (72%) or LPS plus IFN- (63%) stimulation (Table 4). Both M0 and M2 cells were 
CD64+CD80-.   
 
M2 macrophages were identified based on the expression of CD209, [dendritic cell-specific 
ICAM-3-grabbing non-integrin (DC-SIGN)] a C-type lectin. M2 macrophages polarized with IL-4, 
IL-13 or both all expressed CD11b+CD209+ (Table 4, Figure 4B). In addition, 50% of these CD209+ 
M2 cells expressed the inhibitory receptor CD200R. M2 cells also expressed either T-cell surface 
glycoproteins CD1a or CD1b both (Table 4, Suppl Figure 4C), with 50% of the M2 cells in a 
CD1a+CD1b+ population. CD23 was solely expressed in M2 macrophages, though the magnitude 
varied among donors. 
 
M-CSF differentiated macrophages showed a similar pattern of expression of CD64+CD80+ 
for M1 cells and CD11b+CD209+ for M2 cells (Suppl Figure 5). In contrast to GM-CSF derived 
macrophages, M-CSF derived IFN- polarized M1 cells contained a subpopulation that expressed the 
CD64hiCD80+ surface phenotype. 
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Figure 4: Phenotypic characterization of human M1 and M2 macrophages. Monocytes from 
healthy donors were cultured with GM-CSF containing medium for 6 days to differentiate into 
uncommitted macrophages (M0). M1 macrophages were then generated by stimulating with LPS 
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alone, IFN- alone and LPS plus IFN-. M2 polarization was performed with IL-4 alone, IL-13 alone 
and IL-4+IL-13 for 2-days. Population frequencies of M0, M1 an M2 conditioned cells were assessed 
with two marker sets; A: CD64 and CD80, and B: CD11b and CD209. A & B were representative 
flow cytometric plots of 1 donor out of 8 donors. Bar graphs (C & D) represent the mean and SD of 
population frequencies of CD64+CD80+ and CD11b+CD209+ respectively for at least 8 different 
individual subjects. Statistical significance was calculated using nonparametric one-way ANOVA. 
 
Table 4: Population frequencies of human M0, M1 and M2 macrophages 
 M0 M1 M2 
 Medium LPS IFN- LPS+IFN- IL-4 IL-13 IL-4+ 
IL13 
CD64+CD80+ 4.5  
5.7 
71.6  
23.7 
25.4  
36.8 
63.4  40.2 3.4  
1.2 
3.1  
1.8 
5.5  3.7 
CD11b+CD209+ 3.6  
3.1 
4.6  
3.2 
4.7  
4.8 
3.8  3.4 68.4  
18 
68.5  
17 
65.5  
15.9 
CD209+CD200R+ 1.4  
2.6 
0.6  
1.0 
0.8  
1.5 
0.7  1.5 35.7  
13.2 
34  
15.6 
25.4  
18.8 
CD1a+CD1b+ 6.7  
4.4 
7.7  
4.1 
8.5  
2.7 
7.2  2.6 54  
9.6 
39.8  
17.2 
43.8  
18.6 
Data were representative of at least 5 individual donors. Mean  SD were shown. 
 
3.5.2 Transcriptional Profiles of M1 and M2 Macrophages 
 Considering the M0 as controls, we observed upregulation of Cox-2, APOL3, CXCL11, IRF5 
and TNF- in all M1 cells (Figure 5), however, the magnitude varied with the polarizing stimulus. 
Polarization with LPS plus IFN- demonstrated the maximal induction of these genes compared to 
individual treatments. These genes were suppressed in M2 macrophages. Conversely, IRF4, FN1 and 
CCL18 were significantly induced in M2 cells and suppressed in M1 cells.  
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Figure 5: Gene expression profile of human M0, M1 and M2 macrophages. M1 and M2 
macrophages harvested after polarization with either LPS alone, IFN- alone, LPS plus IFN- or IL-
4 alone, IL-13 alone and IL-4 plus IL-13 for qPCR analysis. Each symbol represents results from an 
independent subject (n=8). Group mean and SEM are shown. Statistical significance was calculated 
using nonparametric one-way ANOVA. 
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Figure 6: Unique inflammatory profile of M1 and M2 macrophages. GM-CSF derived 
uncommitted macrophages (M0) were induced with LPS alone, IFN- alone or LPS+ IFN-. M2 
polarization was performed with IL-4 alone, IL-13 alone and IL-4+IL-13 for 2-days. Each symbol 
represents an independent experiment. Error bars represent the SEM for n=8. Statistical significance 
was calculated using non-parametric one-way ANOVA.   
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3.5.3 Unique Inflammatory Profiles of M1 and M2 Macrophages 
Similar to the phenotypic data, we observed two different cytokine and chemokine patterns 
among M1 cells. IP-10 and IFN- were produced at much higher levels by M1-IFN- macrophages 
indicating an autocrine feedback induction of these cytokines by IFN- itself (Figure 6). LPS induced 
IL-8, TNF-, RANTES and IL-1 secretion. IL-8 was the most abundantly secreted M1 cytokine 
measured at microgram (g/ml) level, whereas, others were within the nanogram (ng/ml) range. 
These cytokine data support the presence of two sub-types of M1 macrophages. Conversely, CCL17 
and CCL18 were induced in M2 macrophages. Induction of CCL17 was observed in LPS treated M1 
cells although not statistically differently than in M2 cells. We observed significantly elevated IL-13 
production by IL-13 treated M2 macrophages, but not by M0, M1 and IL-4 treated M2 macrophages. 
IL-10 was only induced by LPS. LPS treated and LPS+IFN- treated M1 cells showed higher IL-10 
production than M0 and M2 macrophages (P 0.0009, 0.0002). All macrophage subtypes secreted 
similar amounts of TGF- and CCL22 (data not shown). Comparable cytokine and chemokine 
profiles were observed in M-CSF derived M1 and M2 macrophages (Suppl Figure 6A).  
 
 
 
Figure 7: Phagocytosis and endocytosis of polarized M1 and M2 macrophages. M0, M1 and M2 
polarized macrophages were treated with either (A) pHrodo green E. coli bioparticle for phagocytosis 
or (B) AF-647 labeled dextran (10KD) for endocytosis (B) for 90 mins at 37°C. Percentages of 
phagocytosis and endocytosis were calculated by normalizing the data to M0. Data reflect 7 
independent experiments from 7 independent donors. Error bars represent the SEM. Significance was 
determined using nonparametric one-way ANOVA among M0, M1 and M2 groups.  
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3.5.4 M2 Macrophages Are Highly Endocytic and Partially Phagocytic  
LPS treated M1 cells exhibited the highest level of phagocytic activity (Figure 7A). Enhanced 
phagocytic activity was observed in M0 and M2 macrophages (M0 vs M1, p<0.0001; M1 vs M2, 
p=0.02; M0 vs M2, p=0.5) (Figure 5A). Conversely, robust endocytic activity was observed by M2 
macrophages when compared to M1s (p<0.001) (Figure 7B). M2 macrophages exhibited enhanced 
dextran uptake compared to M0 cells, although this failed to reach statistical significance (p=0.07). 
M1s showed less dextran uptake suggesting lower endocytic ability than uncommitted M0 cells. 
Similar phagocytic and endocytic indices were observed with M-CSF derived M1 and M2 
macrophages (Suppl Figure 6B). 
 
3.5.5 Stability and Reversibility of the Polarized M1 and M2 Phenotypes 
In cytokine deficient medium, both M1 and M2 cells lost their polarized phenotype over time. 
After 6-day resting in cytokine-free medium, the percentages of CD64+CD80+ M1 cells or 
CD11b+CD209+ M2 cells were reduced by at least 50% with concomitant increases in CD64+CD80- 
or CD11b+CD209- M0 cells. These cells fully reverted to uncommitted M0 state by day 12 (Figure 
8). As expected, the corresponding genes and cytokines declined accordingly (Figure 9A & B).  
 
Upon exposure to IL-13, previously polarized M1 cells showed the distinctive 
CD11b+CD209+ M2 phenotype (Figure 6A). However, we did not observe CD1a, CD1b and CD200R 
expression in these switched (previously M1) M2 cells. Similarly, following LPS plus IFN- 
treatment, previously M2 cells exhibited the M1 phenotype of CD64+CD80+ (Figure 8B). When 
rested in cytokine-free medium for 6-days prior to being exposed to the alternative stimulus, 
previously polarized M1 and M2 cells showed the similar switch in phenotypes, i.e., following IL-13 
treatment previously M1-IFN- cells switched to the characteristic CD11b+CD209+ M2 phenotype 
and following IFN- treatment previously M2 cells switched to M1 phenotype demonstrating the 
representative M1-IFN- population, CD64HiCD80- (Suppl Figure 7A).  
 
Induction of M1 signature genes, IRF5, APOL3, CXCL11, TNF-, was observed in switched 
M1 (previously M2) cells (Figure 9A, Suppl Figure 7B). IFN-, IP-10, TNF-, RANTES, IL-8, the 
hallmark cytokines and chemokines for M1 cells were also induced in switched M1 cells. Similarly, 
M2 signature genes, i.e., IRF4 and FN1 and cytokines, such as, IL-13, CCL17 and CCL18 were 
substantially induced in switched M2 (previously M1) cells, at similar levels to 2-day polarized M2s 
(Figure 9B). However, we did not see any switch in the functional features within the time frame of 
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the experiments. Switched M2 (previously M1) cells gained phagocytic activity similar or slightly 
higher than the original M2 cells, however, their endocytic ability stayed at original M1 levels (Figure 
9C). Switched M1 (previously M2) cells lost their endocytic but not their phagocytic activity.    
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Figure 8: Phenotypic stability and reversibility of polarized macrophages. Previously LPS plus 
IFN- treated M1 and IL-13 treated M2 cells were left in cytokine-free medium till 12 days after 
initial polarization. IL-13 stimulus was then given to M1 cells and LPS plus IFN- was given to M2 
cells for next 2 days. Population frequencies of switched M1 (M2M1) and switched M2 (M1M2) 
cells were assessed using two previously described markers; A: CD64 and CD80, and B: CD11b and 
CD209. Data were representative of at least 5 different individual donors. 
 
 
 
Figure 9: Gene expression, inflammatory and functional profiles of reprogrammed M1 and M2 
macrophages. Previously M1 and M2 cells were left in cytokine-free medium for 12 days after initial 
polarization. M2 stimulus was then given to M1 cells (M2M1) and M1 stimulus was given to M2 
cells (M1M2) for next 2 days. Gene expression (A), cytokine/chemokine secretion (B) and 
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phagocytic/endocytic ability (C) of reprogrammed M1 (M2M1) and reprogrammed M2 (M1M2) 
macrophages were analyzed. Results are mean± SEM (A and B) or SD (C) from at least 5 independent 
experiments. 
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3.6 Discussion 
Previous human macrophage studies particularly focused on the differential gene expression 
profiles of M1 and M2 macrophages as well as identification of functional surface markers (51, 130, 
136, 146, 282). However, a clear phenotypic characterization of human M1 and M2 subsets is 
important for better understanding their biological functions and their roles in diseases. Here, we 
present the results of a systematic study analyzing definitive separation of human macrophages into 
M1 and M2 phenotypes using surface markers, specific gene expression, secreted inflammatory 
profiles and functional activity. Furthermore, we demonstrated that these polarized subsets exhibit 
plasticity in that they can depolarize to uncommitted (M0) macrophages or repolarize into the 
opposite phenotypes (M1 to M2 and vice versa) depending on the cytokines present in their local 
environment. We highlighted the major findings of our studies along with three other macrophage 
studies to provide an overview on the recent progresses of human M1 and M2 macrophage 
characterization (Table 5). Xue et al (72) demonstrated monocytes-derived macrophages (MDM) as 
a distinct cell type than monocytes or DCs in regard to surface marker expression and cytokine 
secretion. Beyer et al (136) demonstrated that induction of macrophage functional states relies on 
TH1 and TH2 cytokines, not on the growth factors like GM-CSF or M-CSF. Finally, extensive 
differential gene expression profiles by Martinez et al (130) facilitated the understanding of two 
functional states of macrophages.  
 
Macrophage responses to stimuli are variable across species and are highly sensitive to culture 
conditions. For instance, the mannose receptor (CD206) and the scavenger receptor type A (CD163) 
are considered as prototypic murine M2 markers (31, 142). CD206 expression in murine macrophages 
is upregulated by M-CSF (86) or IL-4 and inhibited by LPS, IFN-  and GM-CSF (142). The scenario 
for these two receptors is opposite in human macrophages, i.e., GM-CSF treated human monocytes 
are reported to show higher CD206 expression than  M-CSF treated monocytes (146). CD163 is 
induced in murine macrophages by IL-6, IL-10 and by immunosuppressants (146, 149), but not by 
IL-4 (143). These data raised two essential questions: firstly, whether GM-CSF and M-CSF are true 
inducers of M1 and M2 polarization of human macrophages, and secondly, whether CD163 and 
CD206 are useful human M2 markers. 
 
To date, there is no widely agreed upon in vitro culture conditions for human M1 and M2 
polarization. Previous human studies mostly used M-CSF, the most abundant circulating growth 
factor, for macrophage differentiation, and then polarized to  M1 and M2 by TH1 and TH2 cytokines 
respectively (130, 136)  The respiratory lining is rich in GM-CSF and GM-CSF derived macrophages 
phenotypically and functionally resembled lung macrophages (126). Therefore, in this study, we 
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primarily used GM-CSF to define M1 and M2 macrophages. We then employed a number of stimuli 
(such as IL-13, bacterial product lipopolysaccharide LPS and inflammatory cytokine IFN-) to model 
M1 and M2 polarization of respiratory macrophages. IL-13 is associated with wound repair and 
fibrosis (52). Enhanced IL-13 had been reported in patients with asthma and cystic fibrosis (66, 283). 
M-CSF was used to confirm that following M1 and M2 polarization human M-CSF derived 
macrophages exhibited similar functional phenotypes than GM-CSF derived macrophages. 
 
M1 macrophages polarized by LPS or IFN- alone or in combination could be best described 
by surface expression of CD64 and CD80. Upregulation of these receptors was previously reported 
following M-CSF and IFN- treatments, but not with GM-CSF in humans (146). The differential 
expression of CD64 and CD80 we observed was related to the M1-polarizing stimuli rather than to 
GM-CSF or M-CSF. Interestingly, we observed two distinct phenotypic patterns for M1 
macrophages: CD64hiCD80- population for IFN- treated M1s and CD64+CD80+ population when 
LPS was employed, either alone or in conjunction with IFN-. Such differential expression of CD64 
and CD80 would permit the separation of IFN treated M1 cells from LPS treated M1 cells. In 
contrast, M2 macrophages polarized by IL-4 or IL-13, alone or in combination showed analogous 
phenotypes in all three conditions, suggesting a single M2 phenotype in these conditions. M2 cells 
expressed CD209, CD200R, CD1a and CD1b. CD209 (DC-SIGN), a human C-type lectin, has 
previously been reported to be expressed on both immature DC (284) as well as M-CSF, IL-4 or IL-
13 treated monocytes, but not on GM-CSF treated monocytes (285). IFN- has been reported as a 
negative regulator of CD209 (284, 285). In agreement with previous studies, we observed a distinctive 
population of CD11b+CD209+ amongst IL-4/IL-13 polarized M2 macrophages, demonstrating that 
IL-4/IL-13 was able to dominate over the GM-CSF effect and induce the M2 pathway. Since DCs 
express CD83, M2 macrophages, therefore, can be discerned from DCs as a CD83-CD209+ 
population. Expression of CD1a and CD1b was significantly induced in our M2 conditions (57, 136, 
284). In agreement with previous reports, we did not observe induction of these two markers on GM-
CSF or M-CSF differentiated uncommitted M0 macrophages. Similar to the previous study, we 
observed enhanced CD226 expression following IL-4/IL-13 treatment, (136); however, because of 
its shared expression over all M0, M1 and M2 cells, it was not a useful marker for phenotypic 
discrimination between subsets. CD226 could rather be a differentiation marker of GM-CSF versus 
M-CSF macrophage differentiation (111). 
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Table 5: Major Findings of three recent human M1/M2 macrophage studies.  
 Chapter 3 (286) Martinez et al. (130) Beyer et al. (136) Xue et al. (72) 
Cell types used Human MDM Human MDM Human MDM Human MDM 
In vitro  
macrophage  
differentiation  
GM-CSF (50ng/ml) or M-
CSF (50ng/ml) (6 days) (M0) 
M-CSF (100ng/ml)  
(7 days) (M0) 
GM-CSF (500 U/ml) or M-
CSF (100 U/ml) (3days) (M0) 
GM-CSF or M-CSF (3days) 
(M0) 
M1/M2 
polarization 
M1: LPS (20ng/ml), IFN- 
(20ng/ml) 
M2: IL-4 (20ng/ml), IL-13 
(20ng/ml) 
M1: LPS (100ng/ml) + 
IFN- (20ng/ml) 
M2: IL-4 (20ng/ml) 
M1: LPS (10g/l), IFN- (200 
U/ml), TNF- (800 U/ml) 
M2: IL-4 (1000 U/ml), IL-13 
(100 U/ml) 
29 different stimuli. 
  
Methodology C, FC, GE, functional assays C, GE, TP, WB FC, GE, NA, TP, WB C, FC, GE, NA, TP, WB 
Differential 
surface markers  
expression 
M0: CD64 
M1: CD64Hi, CD80 
M2: CD1a, CD1b, CD200R, 
CD209 
M0: Not described. 
List of differentially 
expressed M1/M2 
markers at mRNA level.  
M0: Not described. 
M1: CD14, CD64, CD89, 
CD120B, TLR2, SLAMF7,  
M2: CD1a, CD1b, CD11b, 
CD23, CD93, CD200R, 
CD226 
M0: Not described. 
M1: CD14, CD86 
M2: CD23, CXCR7 
CD14, CD23, CD25, CD86, 
CD197 
Signature 
population  
M0: CD64+CD80-CD209- 
M1: CD64+CD80+CD209-  
M2: CD64+CD80-CD209+ 
Not studied Not studied Not studied 
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Genes M0: Basal induction  
M1: Cox-2, TNF-, APOL3, 
CXCL11, IRF5 
M2: FN1, IRF4, CCL18 
List of differentially 
expressed M1/M2 genes.  
List of differentially expressed 
M1/M2 genes. 
A list of differentially 
expressed M1/M2 genes. 
Soluble factors 
release 
M0: Basal secretion  
M1: IFN-, IP-10, TNF-, 
IL-1, IL-8, RANTES 
M2: IL-13, CCL17. CCL18 
M0: Not described. 
M1: IP-10, CXCL13,  
CXCL15, CXCL19, 
CXCL20 
M2: CCL13, CCL14,  
CCL17, CCL18, CCL23 
Cytokines mRNA expression 
only.  
M0: Not described. 
M1: CXCL5, IL-1 . 
 
Functional 
Features 
M0: Phagocytic  
M1-LPS: Phagocytic  
M2: Phagocytic; Highly 
endocytic  
Not studied Not studied Not studied 
Stability of 
polarized 
phenotypes over 
time 
Yes Not studied Not studied Not studied 
Reprogramming 
to opposite 
polarizing states 
Yes Not studied Not studied Not studied 
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C: Cytokine/chemokine secretion, FC: Flow cytometry; GE: subset-specific gene expression validation by real-time PCR; MDM: Monocyte-
derived macrophages; NA: Network analysis; TP: Transcriptional profiling; WB: Western blot. 
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Since earlier studies have extensively studied the transcriptional regulation of macrophage 
polarization, we chose a several subset-specific, differentially-expressed genes to validate our M1/M2 
model (72, 130, 136). Genes associated with lipid metabolism were induced in M1 macrophages, 
such as, Cox-2, APOL3. APOL3 is the one of the gate keepers for eliminating tissue cholesterol, 
while Cox-2 has long been associated with arachidonic acid metabolism (287). Biological functions 
of M2 signature genes, i.e., fibronectin (FN1) and IRF4, reported in this study are involved in wound 
repair mechanism. FN1 is involved in an extracellular matrix formation, whereas IRF4 is pivotal to 
negatively regulating TLR signaling thereby downregulating inflammation (111, 130, 273).  
 
M1 signature cytokines and chemokines represent an immuno-stimulatory state. Similar to 
the phenotypic data, we observed two distinct inflammatory patterns in M1 macrophages: IFN- 
polarization predominantly induced IFN- and IP-10 suggesting an autocrine feedback loop where 
IFN- induces further IFN- secretion. LPS polarized M1 macrophages produced the minimal or basal 
level of IFN- or IP-10 but secreted TNF-, RANTES, IL-1 and IL-8. In agreement with previous 
reports (130, 282), we observed high levels of CCL17 and CCL18 in all M2-polarizing conditions. 
To our knowledge, no distinct cytokine profile has previously been reported for human M2s (32). In 
the present study only human M2 macrophages secreted IL-13. Although IL-10 is a hallmark M2 
cytokine in mouse (71), as we and others have shown that, in human, IL-10 is induced in LPS treated 
M1 cells (273, 282). Such distinct cytokine/chemokine profiles of M1 and M2 macrophages may 
contribute to pathophysiology.  
 
Phagocytosis and endocytosis represent mechanisms by which M1 and M2 macrophages, 
respectively, engulf and eliminate foreign particles (31). Binding and ingestion of microorganisms 
during non-opsonic phagocytosis had been reported via mannose receptor (CD206) (31). IFN- is 
reported to downregulate CD206 expression, and thereby suppress phagocytic activity (288), whilst, 
LPS enhanced the engulfing of phagocytic cells (289). In line with these reports, we observed 
suppressed phagocytic activity by IFN- induced M1 cells compared with M0 and M2 cells and 
enhanced phagocytic activity by LPS induced M1 cells. In the present study, we used non-opsonized 
bacteria to calculate a phagocytic index in unpolarized (M0) macrophages. M0 macrophages have 
previously demonstrated the comparable phagocytic ability for either IgG-opsonized or non-
opsonized bacteria (290), suggesting that our experimental conditions are unlikely to have adversely 
influenced our results. In addition, the demonstration of suppressed endocytic ability of M1 cells is 
consistent with previous reports that LPS and other pro-inflammatory cytokines inhibit 
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macropinosome formation, thereby modulating antigen uptake and downregulating endocytosis both 
in human and mouse macrophages (291, 292).  
 
We observed antagonistic effects of M1 and M2 inducers on polarized macrophages i.e., M1 
conditions were able to downregulate M2 phenotype, gene expression, inflammatory mediator 
secretion and functional features and vice versa. Furthermore, our observation of two distinct M1 
phenotypes induced by either LPS or IFN- fully corresponded with a previously reported network 
analysis (72) suggesting heterogeneity within the M1 phenotype. A similar transformation of 
functional phenotypes of macrophages has been reported for murine macrophages (76, 77) although 
these studies did not analyze the fate of polarized macrophages when stimulatory cytokines were 
removed. The present study provides an in-depth analysis of stability and reversibility of macrophage 
phenotypes and confirms that polarization does not represent terminal differentiation. Such a shift 
from M1 to M2 state or vice versa may indicate how the innate immune balance is maintained by 
macrophage subsets during inflammatory and homeostatic conditions. Taken together, this model of 
macrophage subset characterization can be used to investigate macrophage-related disease 
pathogenesis and facilitate developing therapeutic interventions where restoring the subtle balance of 
macrophage subsets would become beneficial for patients. 
 
We observed qualitatively similar phenotypic, signature gene expression, inflammatory and 
functional profiles of M1 and M2 macrophages when differentiated by either GM-CSF or M-CSF. 
Our data thereby questions the validity of inducing M1 and M2 polarization by GM-CSF and M-CSF 
in humans. We recognized one limitation in our study. We assume that our donors were healthy and 
this is supported by the relative consistency in results obtained between donors, however, we do 
acknowledge that direct information concerning the clinical status of the donors was very limited.  
 
In summary, we have defined in vitro conditions for differentiating human monocytes into 
macrophages and then polarizing them into M1 and M2 subsets. Our data provides a way to 
characterize human M1 and M2 macrophages which will aid the study of human macrophage biology 
as well as the analysis of macrophage profile in clinical samples.  
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3.7  Supplementary Data 
Suppl Table 1: List of monoclonal antibodies, clones and manufacturers.  
CD antigen Clone Fluorochrome IgG class Source 
CD1a HI149 BV421 M IgG1, k BioLegend 
CD1b SN13 PE M IgG1, k BioLegend 
CD11b ICRF44 APC M IgG1, k BD 
CD14 HCD14 PE Cy 7 M IgG1, k BioLegend 
CD16 3G8 PerCP Cy5.5 M IgG1, k BD 
CD23 EBVCS-5 PerCP Cy5.5 M IgG1, k BioLegend 
CD64 10.1 PE Cy7  M IgG1, k BD 
CD68 Y1/82A AF488 M IgG2b, k BioLegend 
CD68 Y1/82A AF647 M IgG2b, k BD 
CD80 2D10 BV421 M IgG1, k BioLegend 
CD80 2D10 PE M IgG1, k BioLegend 
CD163 GHI/61 PE-CF594 M IgG1, k BD 
CD200R OX108 FITC M IgG, k AbDSerotec 
CD206 19.2 PE Cy 5 M IgG1, k BD 
CD209 DCN46 BV450 M IgG2b, k BD 
CD2131 (IL-13R1) SS12B APC M IgG1, k BioLegend 
CD226 11A8 APC M IgG2b, k BioLegend 
7-AAD    BD 
 
 
Suppl Table 2: Antibody panels for macrophage phenotyping. 
Panel 1 Panel 2 Panel 3 
CD68 AF488 
CD64 PE Cy7 
CD80 V421 
CD206 PE Cy5 
CD68 AF488 
CD1a V421 
CD1b PE 
CD163 PE-CF594 
CD226 APC 
CD11b APC 
CD209 V450 
CD200R FITC 
CD23 PerCP Cy5.5 
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Suppl Figure 4: Morphology and CD68 expression of GM-CSF and M-CSF derived 
macrophages. CD14+ Monocytes from healthy donors were cultured with GM-CSF or M-CSF 
containing medium for 6 days to differentiate into uncommitted macrophages (M0). (A) Morphology 
was observed under microscope. (B) Intracellular expression of CD68, a macrophage marker in 
human, was analyzed by flow cytometry. M1 macrophages were then generated by stimulating with 
LPS alone, IFN- alone and LPS plus IFN-. M2 polarization was performed with IL-4 alone, IL-13 
alone and IL-4+IL-13 for 2-days. Population frequencies of M0, M1 an M2 conditioned cells were 
assessed by CD1a and CD1b marker combination (C). Bar graph represents the mean and SD of 
population frequencies of CD64/CD80 and CD11b/CD209 respectively. Data were representative of 
at least 5 different individual subjects. Statistical significance was calculated using nonparametric 
one-way ANOVA. 
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Suppl Figure 5: Phenotypic characterization of M-CSF derived human M1 and M2 
macrophages. Monocytes from healthy donors were cultured with M-CSF containing medium for 6 
days to obtain uncommitted macrophages (M0). M1 macrophages were then generated by stimulating 
with LPS alone, IFN- alone and LPS plus IFN-. M2 polarization was performed with IL-4 alone, 
IL-13 alone and IL-4+IL-13 for 2-days. Population frequencies of M0, M1 an M2 conditioned cells 
were assessed for two different panels; A: CD64 and CD80, and B: CD11b and CD209.  Bar graphs 
(C & D) represent the mean and SD of population frequencies of CD64/CD80 and CD11b/CD209 
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population respectively. Data were representative of 3 different individual donors. Statistical 
significance was calculated using nonparametric one-way ANOVA.  
 
 
 
Suppl Figure 6: Inflammatory and functional profile of M-CSF derived human M1 and M2 
macrophages. M-CSF derived uncommitted macrophages (M0) were induced with LPS alone, IFN-
 alone or LPS+IFN-. M2 polarization was performed with IL-4 alone, IL-13 alone and IL-4+IL-13 
for 2-days. (A) A panel of cytokines and chemokines were analysed in the supernatants of M0, M1 
and M2 macrophages. Each symbol represents an independent experiment. Error bars represent the 
SEM for n=3. Statistical significance was calculated using non-parametric one-way ANOVA. (B) 
M0, M1 and M2 polarized macrophages were treated with either pHrodo green E. coli bioparticle for 
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phagocytosis or AF-647 labeled dextran (10KD) for endocytosis for 90 mins at 37C. Data reflect 3 
independent experiments from 3 independent donors. Error bars represent the SEM. Significance was 
determined using nonparametric one-way ANOVA among M0, M1 and M2 groups. 
 
Suppl Figure 7: Phenotypic and gene expression reversibility of reprogrammed M1 and M2 
macrophages. Previously IFN- treated M1 and IL-13 treated M2 cells were left in cytokine-free 
medium till 12 days after initial polarization. IL-13 stimulus was then given to M1 cells and IFN- 
was given to M2 cells for next 2 days. (A) Population frequencies of switched M1 (M2M1) and 
switched M2 (M1M2) cells were assessed using two previously described markers; A: CD64 and 
CD80, and B: CD11b and CD209. (B) Gene expression profile of switched M1 (M2M1) and 
switched M2 (M1M2) cells were analyzed by qPCR. Data were representative of 5 individual 
donors. Mean and SEM are shown. Statistical significance was calculated using nonparametric one-
way ANOVA. 
Chapter 4 CFTR-Dependent Deficiency in Alternatively-Activated 
Macrophages in Cystic Fibrosis  
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4.1 Summary 
Roles of macrophages in CF inflammation had largely been overlooked. However, a few studies 
demonstrated that impaired macrophage functions in CF were associated with dysregulated function 
exhibited by mutated CFTR. Since there was no valid marker for human M1/M2 macrophages, no 
comprehensive studies have been conducted to analyze subset specific macrophage responses in CF. 
Using the model described in Chapter 3, this chapter aimed to study the subset-specific macrophage 
responses in CF, to identify defective macrophage subset(s) in CF and finally to investigate the 
underlying mechanism. 
 
The manuscript was submitted to the New England Journal of Medicine.  
 
Authorship: Abdullah Al Tarique, Peter D Sly, Patrick G Holt, Robert S Ware, Anthony Bosco, 
Jayden Logan, Scott Bell, Claire E Wainwright, Emmanuelle Fantino. 
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4.2 Abstract 
Background: Exaggerated neutrophil-dominated inflammation is an integral component of cystic 
fibrosis (CF) lung disease. Why this occurs and is not switched-off normally is unclear. Macrophages 
play important roles in initiation and resolution of pulmonary inflammation but have not been 
extensively studied in CF. 
Methods: Using an ex vivo model we developed for differentiating and polarizing monocytes into 
uncommitted (M0), classically-activated (M1) and alternatively-activated (M2) macrophages, we 
determined macrophage phenotype and function in patients with CF and compared them with healthy 
adults. The effect of inhibiting CFTR function in healthy monocytes was also determined. 
Results: Macrophages deficient in CFTR function, naturally or experimentally-induced, showed an 
reduced ability to respond to IL-13 with a significant reduction in the expression of the M2 marker 
CD209 [median(25th-75th%): healthy (n=9) 59(55-82)%; CF children (n=14) 41(30-52)% (p<0.01); 
CF adults (n=13) 46(25-60)% (p<0.01)].  Endocytosis was also decreased in both children and adults 
with CF compared with healthy adults (both p<0.001). CF M2s showed a marked reduction in 
expression of the archetypal M2 gene IRF4, decreased surface expression of IL-13Rα1 but increased 
secretion of IL-13. M1 phenotype and pro-inflammatory cytokine secretion was normal or increased 
in children and adults with CF, especially during an acute pulmonary exacerbation. However, CF 
M1s were resistant to repolarization to M2 by IL-13 and inhibition of CFTR function in healthy 
macrophages markedly reduced phagocytosis.   
Conclusions: We have demonstrated a CFTR-dependant deficiency in the ability of macrophages to 
respond to IL-13, limiting the development and function of alternatively-activated macrophages in 
CF.  
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4.3 Introduction 
Progressive destructive inflammation is the hallmark of lung disease in cystic fibrosis (CF); 
with most studies reporting an exaggerated neutrophilic response to infective or inflammatory stimuli 
(189, 192, 293). The extent of that response is a major risk factor for the onset and progression of 
structural lung disease (294, 295). However, the factors initiating an exaggerated inflammatory 
response in the lungs of young children with CF or why this is not switched off normally are not clear. 
While most research into CF inflammation has concentrated on neutrophils, we have previously 
shown that the number of macrophages, together with the levels of CC macrophage attractant 
chemokines, present in the bronchoalveolar lavage (BAL) of young children with CF were higher 
than in non-CF disease controls (296). As macrophages play important roles in initiation and 
resolution of pulmonary inflammation, these earlier data raise the possibility that some macrophage 
functions may be abnormal in CF.  
 
Elegant studies in murine models of acute lung injury have given insight into the roles 
macrophages play (297, 298). The resident pulmonary macrophage population, alveolar macrophages 
(AM), are thought to populate the lung during fetal development, replicate locally and not repopulate 
from the bone marrow. Macrophages recruited to the lungs by inflammatory stimuli are of bone 
marrow origin, differentiate from monocytes (monocyte-derived macrophages (MDM), M0) and 
polarize into pro-inflammatory (classically-activated or M1) or inflammation-resolving 
(alternatively-activated or M2) phenotypes in both mice (297) and humans (286). M1s secrete pro-
inflammatory cytokines (TNF-α, IFN-, IL1β) and have anti-microbial and phagocytic function while 
M2s secrete cytokines (IL-4, IL-13) that inhibit M1 function and are endocytic (51). The initial 
murine response to acute lung injury is an influx of neutrophils, peaking on day 2-3, followed by 
recruitment of M1 macrophages, peaking on day 6-12.  Resolution of inflammation is facilitated by 
M2 macrophages over the next 10+ days (297, 298), including clearance of apoptotic cells by 
efferocytosis to remove inflammatory stimuli from the lungs (299).  
 
Given the importance of macrophages in pulmonary inflammation, there has been surprisingly 
little research in patients with CF dedicated to these cells. Major differences between mouse and 
human macrophages (286) made interpretation of murine study outcomes difficult, necessitating 
human studies. Abnormal function of human macrophages in CF has been reported with: increased 
secretion of IL-1β and TNF-α; decreased surface expression of CD11b, and TLR-5; decreased 
phagocytosis (159) and decreased killing power against P. aeruginosa related to defective chloride 
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channel function resulting in a failure to acidify the phagolysosome (160). Data on macrophages 
apoptosis and efferocytosis in CF are conflicting (300). 
 
We have recently described a technique for differentiating and polarizing human monocytes 
into MDMs and characterizing their phenotypes and function (286), allowing us to examine M0, M1 
and M2s and their response to external stimuli. The present study was undertaken to test the 
hypothesis that alternatively-activated M2 macrophages are abnormal in CF, especially when 
collected during an acute pulmonary exacerbation requiring admission to hospital (APE). We also 
aimed to determine whether any deficiencies in macrophage function were related to defective CFTR 
function, i.e. intrinsic to CF or secondary to acute inflammation during an exacerbation. 
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4.4 Methods 
4.4.1 Study Participants 
Thirteen adults and 27 children with verified CF carrying at least one F508 allele were 
recruited from the CF clinics at the Prince Charles Hospital and Children Health Queensland (Royal 
Children Hospital/Lady Cilento Children’s Hospital), Brisbane, Australia. Demographic and clinical 
characteristics are shown in the Table 6. Paired blood samples were collected by venepuncture from 
adult patients on admission to hospital with an acute pulmonary exacerbation and prior to discharge 
after ceasing treatment. Blood was collected from children on admission to hospital (n=16) and/or at 
a clinic visit (n=14) when clinically stable, with paired bloods only available from 2 children. 
Permission was obtained for the study from the relevant Institutional Review Boards and written 
consent obtained from patients and/or their parents, as appropriate. As the study reported in Chapter 
3 buffy coats (n=9) from healthy donors, aged 18 to 40 years, obtained from the Australian Red Cross 
Blood Services, Brisbane were used as controls (286). No demographic data apart from age were 
available for the controls. These cells adequately represent peripheral blood monocytes obtained from 
healthy adult volunteers (Suppl Figure 11).  
 
Table 6: Demographic and clinical characteristics of the patients with CF. 
 Adults (n=13) Children (n=27) 
Age, years (range) 23-46 9 -15 
Sex, male (%) 11 (84.6%) 17 (62.9%) 
Genotype 
F508 homozygous 
F508 heterozygous 
 
5 (38.5%) 
8 (76.5%) 
 
11 (40.8%) 
16 (59.2%) 
Lung function 
FVC (L) (mean±SD) 
FEV1 (L) (mean±SD) 
 
2.62±0.9 
1.78±0.93 
 
2.9±0.75 
2.4±0.72 
P. aeruginosa infection status 
Chronic 
Intermittent 
Once 
 
13 (100%) 
- 
- 
 
2 (7%) 
16 (59%) 
4 (34%) 
 
85 
 
4.4.2 Flow Cytometric Analysis of Monocyte Subsets in CF 
Monocytes were isolated by CD14+ magnetic microbeads (Miltenyi, Germany) from blood 
samples of patients with CF, as previously described (Chapter 3) (286).  Classical, intermediate and 
non-classical monocytes were analyzed by their surface expression of CD14 and CD16 as described 
in Chapter 2.  
 
4.4.3 In vitro Macrophage Differentiation and Polarization 
Macrophages were differentiated (M0) and polarized into M1 and M2 subsets, as previously 
described (286) (Figure 10). M1/M2 surface markers were analyzed using antibodies to CD64, 
CD80, CD209 (286). Following M2 polarization by IL-13, CD209+ cells sorted by CD209 magnetic 
microbeads following manufacturer’s instruction (Miltenyi, Germany). Kinetic expression of IL-13 
receptor α1 (IL-13Rα1) was analyzed following IL-13 stimulation on M0 macrophages. Data were 
acquired on BD LSR-Fortessa using BD FACS Diva software. Subsequent analysis was performed 
on CD68+ macrophages using Flowjo (Tree Star Inc. USA).  
 
4.4.4 Cytokines and Chemokines Quantification  
IL-1, IL-8, IL-13, IP-10, TNF-, IFN-, RANTES were quantified in the culture supernatant 
by alphaLISA (Perkin Elmer, USA). Soluble IL-13R2 in the culture supernatants was measured by 
sandwich ELISA (RayBiotech, US).  
 
 
 
 
Figure 10: Schematic representation of monocyte-derived macrophage differentiation (M0) and 
subsequent M1 and M2 polarization.  
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4.4.5 Phagocytosis and Endocytosis  
pHrodo green E. coli bioparticles (LifeTech, USA) and internalization of AF-647 labeled 
dextran (10KD, LifeTech, USA) were used to assess phagocytic and endocytic abilities of M1 and 
M2 macrophages, respectively. Briefly, macrophages were incubated with either dextran (5g/ml) or 
green E. coli at 37C for 90min. pHrodo dye fluoresces only in acidic environments which mimic 
physiological phagolysosomal compartments. Specific mean fluorescence intensities (MFIs) were 
recorded by flow cytometry. MFI of cells without bacteria or dextran were subtracted from 
experimental samples.  
 
4.4.6 M1-M2 Subset-Specific Gene Expression 
RNA was extracted using RNeasy Kit (Qiagen, USA), reverse transcribed using Quantitect 
RT kit (Qiagen, USA). qPCR was performed using TaqMan primer/probe combinations for human 
Cox-2 (M1 specific), IRF4 (M2 specific) and -actin genes (LifeTech, USA) on ABI 7900HT 
(Applied Biosystem, USA). After normalizing the data with -actin, relative gene expression was 
calculated by considering M0 as control (272). 
 
4.4.7 CFTR Inhibition During Macrophage Differentiation/ Polarization 
Monocytes obtained from healthy controls (buffy coat) were exposed to the CFTR inhibitors 
CFTRInh-172 (10M, Sigma, USA) or GlyH-101 (10M, Santa-Cruz, USA) during macrophage 
differentiation and/or polarization (Suppl Figure 8). These inhibitors work by different mechanisms, 
with CFTRInh-172 binding CFTR intracellularly and while GlyH-101 blocks the channel on the cell 
surface (226, 227). 
  
4.4.8 Networking Analysis of M2 Macrophages by Microarray 
Microarray analysis requires genomic DNA (gDNA) free high-quality RNA. To get gDNA free 
RNA, RNA for microarray experiments were extracted using RNeasy Plus Kit (Qiagen, USA). RNA 
integrity number (RIN) were analyzed with Agilent Bioanalyzer 2100 in the sequencing facility of 
the Institute for Molecular Bioscience (IMB), University of Queensland. RIN numbers for all samples 
were above 8.0. Microarray was conducted using U219 array plate (Affymetrix, USA) containing 
more than 36,000 gene probes at the Ramaciotti Centre for Genomics, University of New South Wales 
(UNSW), Australia. To identify biological processes whether upregulated or downregulated in CF 
macrophages compared to macrophages from healthy individuals, network analysis was performed 
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using Ingenuity Pathway Analysis (IPA) software by Professor Anthony Bosco, Telethon Kids 
Institute, University of Western Australia. 
 
4.4.10 Effects of Cox-2 Inhibition on Macrophage Polarization 
Monocytes obtained from healthy controls (buffy coat) were exposed to indomethacin alone 
(inhibitor of Cox-1 & Cox-2) (100M) (Cayman, USA) or NS-398, a Cox-2 specific inhibitor alone 
(50M) (Cayman, USA) or in combination with CFTR inhibitor, CFTRInh-172 (Cayman, USA) 
during their differentiation to macrophages and polarization to M1 and M2 macrophages. 
 
4.4.11 Statistical Analysis 
Data are shown as median and interquartile range (IQR) unless stated otherwise. Wilcoxon 
paired signed ranked test was performed to determine the differences of inflammatory parameters 
amongst adult patients between hospital admission and discharge. Mann-Whitney test was performed 
to assess differences in inflammatory parameters between control and CF groups. Two-way ANOVA 
was used in time-course studies with group (CF/control) and time entered as the main effects. 
Statistical analysis was performed using GraphPad Prism 6.7 (San Diego, CA). Statistical 
significance was set at p<0.01 to allow for multiple comparisons.  
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4.5 Results 
4.5.1 Monocyte Subsets in CF is Similar to Healthy Controls 
No difference in the frequencies of classical and intermediate monocyte subsets was observed 
between CF patients and healthy controls (Figure 11). The percentages of non-classical monocytes 
were very minimal in both controls and CF patients. Therefore data were not shown.  
 
 
Figure 11: Monocyte subsets in CF. Isolated CD14+ monocytes from buffy coats and patients with 
CF were Fc blocked and stained with anti-human CD14 PE-Cy 7 and CD16 PerCP Cy5.5 antibodies. 
Data were shown as median and IQR.   
 
4.5.2 Deficient M2 Polarization in CF  
Following M2 polarization with IL-13, the proportion of cells expressing CD209 was 
significantly reduced in children [median (25th-75th%) healthy (n=9) 59(55-82)%; CF children (n=14) 
41(30-52)%; CF adults (n=13) 46(25-60)%; all comparisons p<0.01]. Data from representative 
individuals (flow cytometry plots) and from the group are shown in (Figure 12). Endocytosis by M2s 
was decreased in all CF groups (Figure 12). The group median (25th-75th%) MFI for controls was 
22,711(10,639-34,253) compared to 3,769(2,350-8,101) and 10,104(1,922-2,685) for adults with CF 
on admission (p<0.001) and discharge (p<0.001) from hospital, respectively and to 9,031(2,003-
16,667) and 5,896(3,818-7,376) for children with CF on admission to hospital (p=0.01) and when 
clinically-stable (p<0.001), respectively. Secretion of IL-13 was higher in all CF groups (p<0.001), 
than in controls (Figure 12).  
 
To determine whether the decreased M2 function seen in CF was due to a reduced number of 
normally-functioning M2 or to a failure of CF M0 to respond to IL-13, we sorted CF and control cells 
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by CD209 expression following exposure to IL-13. Expression of M2-associated gene IRF4 was 
essentially absent in CF M2 macrophages, regardless of surface expression of CD209 (Figure 13).  
 
 
 
 
Figure 12: Deficient M2 polarization in CF. A representative flow cytometry plot from an adult 
with CF showing surface expression of the M2 marker CD209 following differentiation by GM-CSF 
and polarization to M2 by IL-13 of monocytes obtained on admission to hospital for an acute 
pulmonary exacerbation and when clinically stable.  Group data are shown as median and interquartile 
range as well as individual data. Groups sizes are as follows: Control (n=10); Adult CF on admission 
(n=11) and on discharge (n=12); children with CF on admission (n=14) and at clinic (n=13). 
 
4.5.3 CF M0 and M1 Macrophages Exhibit Comparable Phenotypes to Controls 
Following differentiation but prior to polarization a similar proportion of M0s from all groups 
showed expression of the M1 marker CD80 (Suppl Table 3). The surface expression of CD80 was 
more variable in both children and adults with CF, especially during APE (Suppl Figure 9).  
 
Following M1 polarization with LPS the proportion of cells expressing CD80 was not 
significantly different between healthy controls and children and adults with CF, both during periods 
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of clinical stability and with an APE (Suppl Table 3). Surface expression of CD80 was more variable 
in patients with CF (Suppl Figure 9).  
 
 
Figure 13: Expression of the archetypal M2 gene IRF4 in CF and Control macrophages 
following stimulation with M2-polarizing cytokine IL-13. Cells are stratified by surface expression 
of the M2-marker CD209. RNA was extracted from sorted cells and induction of M2 signature gene, 
IRF4 was analysed with real-time PCR. After normalization by β-actin, gene expression is shown as 
fold-change compared to the relevant M0 gene expression (median and IQR). 
 
Phagocytic activity of M1 macrophages was similar in children and adults with CF both when 
clinically stable and on admission to hospital, to that seen in heathy controls (Suppl Figure 10). There 
was no obvious difference in the pattern of secretion of pro-inflammatory cytokines from M1 
macrophages in patients with CF (Suppl Figure 10). Secretion of RANTES was higher is all CF 
groups than in controls (p<0.01 for all comparisons) but no consistent pattern was seen for IL-1β. 
Secretion of IFN- was also higher in all CF groups (p<0.01 for all comparisons).  
 
Unexpectedly, surface expression of the M1 marker CD80 was higher following polarization 
with IL-13 (Figure 14) in children (p=0.006) on admission to hospital than healthy controls (Suppl 
Table 3).  A similar trend was seen in adults with APE that was not statistically significant (p=0.08). 
The proportion of “M2” cells expressing CD80 was not different when clinically stable in children or 
adults (Suppl Table 3) (acute vs stable p=0.60, p=0.50, respectively). 
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Figure 14: Expression of CD80 on M2 following polarization with IL-13. A representative flow-
cytometry plot from an adult with CF showing surface expression of the M1 marker CD80 following 
differentiation by GM-CSF and polarization to M2 by IL-13 of monocytes obtained on admission to 
hospital for an acute pulmonary exacerbation and when clinically stable. Group data are shown as 
median and interquartile range as well as individual data. Groups sizes are as follows: Control (n=10); 
Adult CF on admission (Acute n=11) and on discharge (n=12); children with CF on admission (Acute 
n=14) and at clinic (n=13). 
 
4.5.4 CF Macrophage Model: Inhibition of CFTR Function in Healthy 
Macrophages Mimics CF Phenotypes 
When control MDMs were differentiated and polarized in the presence of CFTR inhibitors 
they adopted a phenotype seen in CF. Following polarization with IL-13 the expression of the M2 
marker CD209 was markedly reduced (p=0.002) but the expression of CD80 on M1s was not affected 
(p=0.80) (Figure 15). This effect was seen with both inhibitors. CFTR-inhibition reduced 
phagocytosis by M1s (p=0.03) and endocytosis by M2s (p=0.006) (Figure 15). Using IL-4 to polarize 
M2 did not result in an increase in CD209 expression in the presence of CFTRInh-172 (Suppl Figure 
13). 
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Figure 15: Effect of CFTR inhibition on macrophage phenotype and function. Group median 
(IQR) expression of the M1 marker CD80 and the M2 marker CD209 following differentiation and 
polarization in the presence of the CFTR inhibitors (CFTRInh-172 or GlyH-101). The effects of CFTR 
inhibition on phagocytosis and endocytosis are also shown as group median and interquartile range. 
 
 
 
Figure 16: Effect of CFTR inhibition on macrophage surface expression of IL-13Rα1 and 
secretion of IL-13. MDMs from healthy donors were stimulated with IL-13 (20ng/ml) in the presence 
(n=5) or absence (n=4) of CFTRInh-172. CF monocytes (n=5) were differentiated to MDMs. Kinetic 
expression of surface IL-13R1 (A) and secretion of IL-13 (B) following IL-13 stimulation were 
measured by flow cytometry and alphaLISA respectively. Data showed median and IQR.  
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Surface expression of IL-13Rα1 was reduced in CF M2 and when CFTR function was 
inhibited in control cells by CFTRInh-172 (Figure 16). When control M0s were incubated with IL-13 
to induce M2 polarization there was a time-dependent reduction in surface expression of IL-13Rα1 
(Figure 16). The surface expression of IL-13Rα1 also decreased over time in cells with lacking CFTR 
function, either naturally or experimentally-induced with incubation with IL-13 (p=0.001) (Figure 
16). There was no reduction in surface expression of IL-4Rα in CF or with CFTRInh-172. Despite no 
reduction in the ability of either control or CFTR-inhibited cells to secrete IL-13, neither CF M1s nor 
experimentally-induced “CF” M1s were responsive to IL-13 and did not re-polarize into the M2 
phenotype (Suppl Figure 12). No soluble IL-13R2 was detected in the supernatants of IL-13 treated 
CF, CFTR inhibited and control cells.  
 
4.5.5 Cox-2 Inhibition Downregulates M1 and M2 Polarizations 
Preliminary analysis of microarray data showed significant upregulation of prostaglandin E 
receptor 2 (PGE2) signaling pathway. M1 signature gene, Cox-2, had been reported as a regulator of 
PGE2 pathway while functional CFTR negatively regulates the COX-2-PGE2 positive feedback loop 
(301). That’s why, we hypothesized that inhibition of Cox-2 would restore M2 polarization in CF or 
CFTR inhibited condition. Cox-2 inhibition did not have any effect on M1 or M2 polarization in 
control cells. However, a marked reduction of CD80 expression was observed on NS-398 plus 
CFTRInh-172 treated M1 cells compared to control (p = 0.02) and CFTRInh-172 treated cells (p = 
0.02) (Figure 17A). No effect of Cox-2 inhibition was observed on CD209 expression in control and 
CFTRInh-172 treated cells (Figure 17B). Interestingly, inhibition of Cox-1/2 by indomethacin showed 
downregulation of both CD80 (M1) and CD209 (M2) expression compared to controls.  
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Figure 17: Effects of Cox-2 inhibition of macrophage polarization.  CD14+ monocytes from buffy 
coats (n=4) were differentiated and polarized into M1 and M2 macrophages in presence or absence 
of indomethacin (Cox-1/2 inhibitor) and NS-398 (Cox-2 inhibitor). Percentage of CD80+ and CD209+ 
cells were analyzed for M1 and M2 polarization respectively.   
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4.6 Discussion 
Exaggerated neutrophil-dominated inflammation is a hallmark of CF lung disease, especially 
in early life and is associated with an increased risk of developing structural lung disease (293, 295). 
However, the precise mechanism underlying this phenomenon is not known. Similar to earlier studies 
(302, 303), no difference in monocyte compartments was observed between CF and healthy controls. 
However, MDMs showed impaired functions (159-161). The results of the present study demonstrate 
a CFTR-dependent defect in MDMs to respond to IL-13 that results in reduced ability of M0s to 
polarize into the M2 phenotype and of M1s to repolarize to M2s. However, inhibition of CFTR 
function resulted in a marked reduction of the ability of M1s to acidify the phagolysosome, as 
previously reported (161). This potentially means that macrophages in CF can initiate inflammatory 
responses to infective or inflammatory stimuli but may not contribute normally to bacterial killing or 
inflammation resolution.  
 
The data from the present study point to defective macrophage function in the resolution phase 
of inflammation. Macrophages act to limit neutrophil-dominated inflammation in numbers of ways 
including: directly engulfing neutrophil granular molecules and enzymes such as myeloperoxidase 
(304); efferocytosis of apoptotic neutrophils and those expressing surface “eat-me” markers (304); 
and participating in the killing of bacteria contained within efferocytosed neutrophils (304). Using 
the ex-vivo model we developed (286), we have previously shown that the phenotype of polarized 
macrophages is not “fixed” and they can be induced to re-polarize to the opposite phenotype. If re-
polarization occurs in vivo this provides an advantage for resolving inflammation as the pro-
inflammatory M1 cells can be reprogrammed into M2s in situ by locally-secreted IL-13 or IL-4. The 
data from the present study suggest that this is unlikely to happen in CF, where incubation with IL-
13 fails to induce the M2 phenotype (Figure 13), especially during an APE where cells that should 
be M2 express the M1 surface marker CD80 (Figure 14). In addition, experimentally-induced “CF” 
M1s were not able to re-polarise to the M2 phenotype. 
 
The lack of CFTR function, both in patient cells and in our experimentally-induced “CF” 
macrophages has several important consequences on macrophage phenotype and function. Pro-
inflammatory CF M1s readily produce inflammatory cytokines but do not have the normal ability to 
acidify the phagolysosome, which will inhibit bacterial killing. M0s lacking CFTR function, either 
naturally or experimentally, have a markedly lower surface expression of IL-13Rα1 and fail to 
respond to IL-13 despite more than adequate IL-13 production. Lack of CFTR function also results 
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in marked reduction of expression of the archetypal M2 gene, IRF4, irrespective of surface expression 
of CD209. Why CF CD209+ M2s do not express IRF4 is unclear, but the relative kinetics of 
expression may be involved. Why lack of CFTR function should decrease expression of IRF4, surface 
expression of IL-13Rα1 and how this contributes to the failure to response to IL-13 is not clear but 
warrants further investigation. 
 
Cox-2 had been shown to be upregulated following LPS stimulation and suppressed following 
IL-13 stimulation in MDMs (72, 130, 136, 286). Induction of Cox-2 was shown to be associated with 
upregulation of NF-B signaling cascade, thereby promoting inflammation. Drugs for instance 
ibuprofen that non-specifically inhibit Cox-1/2 had been beneficial for patients with CF (305). Chen 
et al have reported functional CFTR as a negative regulator of Cox-2 in AECs (301). However, how 
inhibition of Cox-1 or -2 modifies macrophage function and polarization still remained unexplored. 
It was assumed that inhibition of Cox-2 might suppress M1 and restore M2 polarization. Similar to 
AECs study (301), simultaneous inhibition of Cox-2 and CFTR exhibited a reduction in CD80 
expression (M1 polarization). Such reduction in CD80 was not observed in control Cox-2 inhibited 
cells which indicates an associated with inhibition or dysregulation of CFTR function and 
exaggerated CF inflammation. Increased expression of CD80 in CF M0 is consistent with this. 
However, inhibition of Cox-2 in CFTR inhibited cells does not restore CD209 expression (M2 
polarization) suggesting a link between normal CFTR function and the molecular machinery involved 
in M2 polarization. In accordance with earlier study (305), inhibition of both Cox-1/2 resulted in 
decreased expression of CD80 (M1) and CD209 (M2). Taken together, this study indicates that 
inhibition of Cox-2 might suppress inflammation in CF but would not be able to trigger anti-
inflammatory mechanism.  
 
There are several limitations with the present study that need to be acknowledged. We have 
collected peripheral blood monocytes to differentiate and polarize into MDMs ex vivo. Studies on 
acute lung injury in mice suggest that these are the cells that are attracted to the lungs to respond to 
inflammatory or infective stimuli (297, 298). Certainly, such monocyte-lineage cells are important 
components of the acute inflammatory response seen in acute asthma (306, 307). However, whether 
these are the cells responsible for resolution of pulmonary inflammation in CF remains to be proven. 
In addition, while we have paired samples from adults with CF collected during APE and when 
clinically stable, we do not have paired samples from the children with CF. Clearly using paired 
samples from individual patients would have allowed us to determine with more certainty how 
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macrophage function changed with an APE. While trends were seen for uncommitted M0 
macrophages to be pre-primed towards the M1 phenotype this response was variable and the study 
did not have sufficient power to address this question.  
 
Despite the limitations, the results of the present study have some clear clinical implications 
and give direction for future study. If, as indicated by the present data, CFTR function is essential for 
the development of the inflammation-resolution M2 phenotype then this poses a major problem for 
patients with CF. Studies from the AREST CF group in Australia have demonstrated the 
predominance of neutrophil-dominated inflammation, even in the absence of clinical symptoms and 
detectable infection, that increases the risk for bronchiectasis in infants as young as 3 months of age 
(293, 295). A CFTR-dependant deficiency in M2 macrophages could be the underlying reason for 
these findings. An understanding of the links between deficient CFTR function and M2 polarization 
may lead to novel therapeutic targets aimed at delaying the onset and progression of structural lung 
disease in CF. If macrophage function can be restored by correcting CFTR dysfunction it will become 
imperative to study the effects of CFTR potentiators and correctors on the inflammatory airway 
milieu and structural and functional disease outcomes in early life as by 5 years of age 50-70% already 
have bronchiectasis (255, 295, 308). 
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4.7 Supplementary Data 
 
 
 
Suppl Figure 8: In vitro model for CF macrophage differentiation and polarization. Schematic 
representation of developing CF macrophage model with CFTR-inhibitors (n=3). A: CFTR inhibitor, 
CFTRInh-172 or GlyH-101 was added either during polarization only or during differentiation and 
polarization. B: Frequency of CD209+ cells were analyzed as M2 macrophages by flow cytometry.  
Data were from at least three individuals and shown as mean±SD. 
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Suppl Table 3: Surface expression of CD80 in macrophages subtypes. Data are shown as median and 25th – 75th percentile; comparisons are 
CF group against control.  
CD80+ (%) Controls Adults with CF Children with CF 
APE Discharge APE Clinic 
M0 2.5 (1.3-3.9)% 1.0 (0.0-19.3)% 
p=0.6 
1.0 (0.0-9.5) % 
p=0.6 
2.0 (0.8-30.5)% 
p=0.6 
2.0 (2.0-16.0)% 
p=0.2 
M1 76.9 (64.4-87.9)% 62.0(20.5 -77.5)% 
p=0.19 
48(22.5-77.0)% 
p=0.07 
63.0(49.5-85.5)% 
p=0.42 
66.0(50.5-75.5)% 
p=0.17 
M2 2.2 (2.0-3.15)% 7.8 (0.0-28.0)% 
p=0.36 
5.0 (2.0-13.0)% 
p=0.08 
8.0 (4.0-25.7)% 
p=0.006 
3.0(1.0-15.5)% 
p=0.62 
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Suppl Figure 9: Function of M1 and M2 macrophages from children and adults with CF, on 
admission to hospital and when clinically stable) compared to healthy controls. Individual data 
as well as group median and IQR are shown. 
  
101 
 
 
Suppl Figure 10: Surface expression of M1 marker, CD80, following M1 polarization. 
Monocytes from buffy coats from healthy donors, clinically stable patients with CF and hospital 
admitted patients with CF for acute pulmonary exacerbation were differentiated to macrophages by 
6-day stimulation with GM-CSF. M1 polarization was induced with LPS (20ng/ml). % of CD80+ 
cells was analyzed by flow cytometry. Group data are shown as mean and standard deviation as well 
as individual data. 
  
102 
 
 
 
 
Suppl Figure 11: Comparison of phenotype and functions of polarized macrophages derived 
from buffy coat and freshly isolated monocytes. CD14+ monocytes were isolated from either buffy 
coats provided by ARCBS or freshly isolated donor blood samples (n=5). 6-day GM-CSF (50ng/ml) 
was given to get fully mature macrophages. M1 and M2 polarization was induced by LPS (20ng/ml) 
and IL-13 (20ng/ml) respectively. Percentage of CD80+ and CD209+ cells were assessed for M1 and 
M2 polarization (A). Phagocytic ability of M1 cells and endocytic ability of M2 cells were analyzed 
by flow cytometry (B). Data represents mean±SD.  
 
 
 
Suppl Figure 12: Reprograming ability of CFTR inhibited macrophages.  M1 and M2 
polarizations were performed with monocytes from buffy coats (n=4) in absence or presence of 
CFTRInh-172 (See method section). M1 and M2 cells were then left in cytokine-free medium for 6 
days. M1 cells were then given to IL-13 for next 2 days. Expression of CD209 (left Y axis) and CD80 
(right Y axis) were analyzed at d2, d6 and 2-day after IL-13 stimulation given to M1 cells. Ability of 
M1 cells to respond to IL-13 was analyzed by CD209 expression. Mean and IQR were shown. On 
each testing occasion the surface expression of CD209 was significantly lower in cell that had been 
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incubated with the CFTRInh-172 than in control cells; after 2 days incubation (D2) p=0.004, after 6 
days in cytokine-free medium (D6) p=0.01 and after previously polarized M1s were incubated with 
IL-13 (M1M2), p=0.01.  
 
 
 
Suppl Figure 13: IL-4 mediated M2 polarization and surface expression of IL-4Rα in CFTR 
inhibited cells.  MDMs were differentiated using monocytes from buffy coats (n=3) in presence or 
absence of CFTR inhibitor, CFTRInh-172. (A) CFTR inhibitor, CFTRInh-172 treated or control M0 
cells were exposed to IL-4 for M2 polarization. CD209 expression was analyzed. (B) Surface 
expression of IL-4R on M0 cells from clinically stable patients with CF (n=4), CFTRInh-172 treated 
(n=4) and controls (n=4) were analyzed at time 0 and after 4 hours stimulation with IL-13. Data were 
shown as median and IQR.  
  
Chapter 5 Effects of Tobramycin on Macrophage Polarization  
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5.1 Introduction 
Antibiotic treatment for patients with CF is directed to prevent and eradicate respiratory 
infections. Aminoglycosides, such as, tobramycin, gentamicin has been shown to restore 
expression of full CFTR and cAMP-activated chloride channel in HeLa cells transfected with 
mutated CFTR gene (263). A recent article reported restoration of functional CFTR with a 
significant increase in CFTR-dependent chloride efflux in monocytes following azithromycin, 
ciprofloxacin (180). Azithromycin treatment demonstrated suppressed M1 polarization and 
enhanced M2 polarization in murine alveolar and peritoneal macrophages (257). However, the 
mechanism of action of antibiotics on the restoration of CFTR function and macrophage 
polarization were yet to be explored.  
 
 
Figure 18: Chemical structure of tobramycin. 
Tobramycin is a water-soluble aminoglycoside antibiotic produced by Streptomyces 
tenebrarius (Figure 18).  It is an approved bactericidal drug and highly recommended for 
patients with CF to suppress of P. aeruginosa infection in the lungs that result in improved 
lung function and prevention of pulmonary exacerbations (237). Since intravenous tobramycin 
poorly penetrates into the bronchoalveolar spaces, a frequent and high dose of tobramycin is 
required to achieve the optimal therapeutic concentration at the site of infection (237, 309). To 
exclude the possibility of systemic toxicity due to its high dose, tobramycin inhaled solution or 
dry powder inhaler is of the choice of clinicians for treating patients with CF. Inhaled 
tobramycin has a longer half-life in the lung tissues and remained detectable for at least 4 weeks 
after exposure ceased. After administration of aerosolized tobramycin, the mean peak 
concentration of tobramycin measured was 1,237g/g in sputum and 0.95g/ml in serum (276). 
Similar concentration (1mg/ml) of tobramycin had been shown to prevent biofilm formation of 
P. aeruginosa as well as disrupt already formed biofilms (243, 275, 310, 311). Neither group 
reported any cytotoxicity of such higher concentration of tobramycin on cells.  
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Although studies demonstrated significant improvement in lung function in patients with 
moderate to severe CF, immunomodulatory effects of tobramycin at cellular level is scarce. A 
very recent study demonstrated that tobramycin treatment on THP-1 derived macrophage-like 
cells was shown to suppress LPS induced TNF-, IL-1, CXCL1, but produced significant IL-
8 (312). Lack of an appropriate CF macrophage model was an obstacle to study the mechanism 
by which tobramycin modulate host immune responses. Using the CF macrophage model 
reported in Chapter 4, I aimed to study the effect of tobramycin on macrophages in CF.  
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5.2 Methods 
5.2.1 In vitro Differentiation and Polarization of Macrophages 
Monocytes from buffy coats or patients from CF were differentiated into monocyte-
derived macrophages (MDMs) and then polarized into M1 and M2 macrophages as previously 
described in Chapter 3. Tobramycin (Sigma, USA) dissolved in water was added to the 
medium at day 0, 3 and 6 (Figure 19). To optimize the dose of tobramycin for macrophage 
differentiation and polarization, initially 0.1, 1.0 and 10mg/ml of tobramycin were used.  
 
 
 
Figure 19: In vitro differentiation and polarization of human macrophages in the presence 
of tobramycin.  Human CD14+ monocytes were differentiated into macrophages (M0) by GM-
CSF (50ng/ml) and further polarized into M1 and M2 macrophages using LPS (20ng/ml) and 
IL-13 (20ng/ml) respectively. Tobramycin was added to the culture media at day 0, 3 and 6. 
Phenotype was assessed by flow cytometry.  
 
5.2.2 Cell Viability Assay of Tobramycin Treated Macrophages 
To assess the cytotoxicity of different tobramycin doses used, the viability of 
macrophages was tested using 7-aminoactinomycin D (7-AAD) staining on M0 macrophages 
(BD, USA). 7-AAD is a fluorescent derivative of actinomycin D that selectively binds to GC 
regions of the DNA (313). 7-AAD is unable to pass through the intact cell membranes of live 
cells. Rather, it can easily enter through the disrupted membrane of dead cells and stain the 
DNA. Fully differentiated macrophages (M0) were harvested at day 6 by TrypLE (Invitrogen, 
USA), washed with PBS and incubated with Fc blocking solution (FBS,2%-BSA,0.1%-PBS, 
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100ml) for 20min at 40C. Cells were then spun down and resuspended in FACS buffer and 
stained with 7-AAD (5g/ml) 20min at 40C (313). After a second washing step, cells were 
analyzed on BD LSR-Fortessa using BD FACS Diva software. Subsequent analysis was 
performed using Flowjo (Tree Star Inc. USA). 
 
5.2.3 Effect of Tobramycin on CF Macrophages 
To study how tobramycin modulates macrophage polarization and thereby function in 
CF, tobramycin (1mg/ml) was added in the CF macrophage model described in Chapter 4. 
Briefly, monocytes obtained from buffy coats or patients from CF were exposed to the CFTR 
inhibitor CFTRInh-172 (10M) (Sigma, USA) alone, tobramycin alone (1mg/ml) or in 
combination during macrophage differentiation and/or polarization.  
 
5.2.4 Phenotypic Characterization of Tobramycin Treated M1/M2 
Macrophages 
For assessing M1/M2 marker expression on tobramycin-treated M0, M1 and M2 
macrophages, cells were harvested and stained with anti-human CD64, CD80, CD209, as 
previously described (Chapter 3) (286). Surface expression of IL-13 receptor α1 (IL-13Rα1) 
was examined on M2 macrophages using flow cytometry. Data were acquired on BD LSR-
Fortessa using BD FACS Diva software. Subsequent analysis was performed on CD68+ 
macrophages using Flowjo (Tree Star Inc. USA).  
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5.3 Results 
5.3.1 Dose Selection 
1- and 10mg/ml of tobramycin resulted in an immediate increase in pH of the culture 
medium from 7.0 to 6.2. Therefore tobramycin-containing medium was left in the CO2 (5%) 
incubator for 60-90min to bring the pH to 7.0. At 0.1mg/ml conc. no change in medium pH 
was observed. The percentages of live cells with 0.1 and 1mg/ml of tobramycin were similar 
to the untreated macrophages. However, viability significantly declined at the higher dose of 
tobramycin, with only 16.7% of cells surviving (Figure 20). Since 1mg/ml concentration of 
tobramycin was found in the BAL of CF patients, this concentration was chosen for 
experiments afterward (276).  
 
 
   
Figure 20: Cytotoxicity assay of tobramycin-treated macrophages. 6-day GM-CSF 
differentiated macrophages (M0) were harvested, Fc blocked and then stained with 7-AAD 
(5g/ml) for 20min at 40C. Forward scatter (FSC) versus 7-AAD plot shows the distribution 
of the live and dead cells.   
 
5.3.2 Tobramycin Downregulates Macrophage Polarization  
Tobramycin alone showed downregulation of both M1 (p = 0.009) and M2 (p = 0.002) 
polarizations assessed by CD80+ and CD209+ cells respectively when compared to untreated 
controls (Figure 21). As previously reported in Chapter 4, CFTRInh-172 treated cells showed 
comparable frequency of CD80+ cells with medium control cells. Combined effect of CFTR 
inhibitor, CFTRInh-172 and tobramycin showed synergistic inhibitory effect on M1 polarization 
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assessed by the percentage of CD80+ cells compared to untreated control (p = 0.002) or 
CFTRInh-172 treated cells (p = 0.009).  
 
 
Figure 21: Expression of M1/M2 markers on tobramycin-treated M1 and M2 
macrophages. CD14+ monocytes were isolated from buffy coats (A & B) or patients with CF 
(n=4) (C). Monocyte-derived macrophages (MDMs) were differentiated by 6-day stimulation 
with GM-CSF in presence or absence of CFTRInh-172 alone, tobramycin (Tob) (1mg/ml) alone 
or in combination. M1 (A) and M2 (B & C) polarizations were induced by E. coli LPS and IL-
13 respectively. Error bars represent the SD. Statistical significance was calculated using non-
parametric t-test. 
 
M2 polarization assessed by CD209+ cells was significantly lower in CFTRInh-172 and 
tobramycin-treated cells compared to controls. Interestingly combining tobramycin with 
CFTRInh-172 significantly upregulated the percentage of CD209
+ cells compared to CFTRInh-
172 (p = 0.002). However after stimulation with IL-13, monocytes derived macrophages from 
CF patients did not show similar restoration of CD209+ cells following tobramycin treatment. 
The difference in M2 polarization between CFTRInh-172 inhibited cells and cells from patients 
with CF following tobramycin treatment raised a possibility of competitive binding between 
tobramycin and CFTRInh-172 which remained unexplored. Due to insufficient patient material, 
it was not possible to analyze the effect of tobramycin on M1 polarization.  
 
5.3.3 Tobramycin Induces IL-13R1 Expression 
Kinetic expression of IL-13R1 following IL-13 stimulation was analyzed to investigate 
the mechanism of observed M2 restoration in CFTRInh-172 inhibited plus tobramycin-treated 
111 
 
cells. Initially kinetic expression of surface IL-13R1 was analyzed on M0 cells following IL-
13 stimulation. Tobramycin treated M0 cells displayed comparable receptor expression with 
untreated M0 cells (Figure 22). Significant reduction of IL-13R1 expression was observed 
on CFTRInh-172 inhibited cells compared to controls (p = 0.0005) and tobramycin-treated cells 
(p = 0.001). Enhanced IL-13R1 expression was observed following synergistic effect of 
tobramycin and CFTRInh-172 that was not significant. IL-13R1 expression was then analyzed 
on differentiated M0 cells from CF monocytes (n=4) and 4h after IL-13 stimulation (Figure 
22B). Differentiated M0 cells from CF monocytes exhibited similar IL-13R1 expression to 
CFTRInh-172 treated cells. Due to unavailability of patient samples, it was not possible to study 
the effect of tobramycin on IL-13R1 expression on CF monocytes differentiated 
macrophages.  
 
 
 
Figure 22: Effect of tobramycin on IL-13R1 expression. Human monocyte-derived 
macrophages (MDMs) were differentiated by 6-day stimulation with GM-CSF in presence or 
absence of CFTRInh-172 alone (n=4), tobramycin (1mg/ml) alone (n=3) or in combination 
(n=3). IL-13 (20ng/ml) was added to induce M2 polarization. Surface expression of IL-13R1 
was analyzed by flow cytometry at 0, 2, 4, 6, 8 and 10 hours after IL-13 treatment. Error bars 
represent the SD. Statistical significance was calculated using non-parametric repetitive 
measure test.  
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5.4 Discussion 
Aminoglycoside antibiotics such as tobramycin and gentamycin were the first drug that 
has been approved to treat patients with CF (263, 314). Expression of functional CFTR and 
restoration of chloride channel on PMNs following IV tobramycin treatment has been 
demonstrated (180). Clinical trials showed successful eradication of P. aeruginosa, significant 
improvement of lung functions and weight gain in patients with moderate to severe CF 
following tobramycin treatment compared to placebo controls (174, 238-242). However, these 
studies did not assess the immunomodulatory effects of tobramycin on host immune cells, 
thereby the mechanism of improved lung function. In this chapter, the effect of tobramycin on 
macrophage polarization was investigated.  
 
After adding tobramycin in the culture media, immediate increase in pH of the medium 
was observed. This might be a mode of action how tobramycin exerts its anti-bacterial activity 
in the tissues. Like in an earlier study (312), cytotoxicity of administered tobramycin on MDMs 
was observed in a dose-dependent manner. Low to medium doses of tobramycin had no effect 
on cell viability, however, macrophages hardly survive at the high dose of tobramycin 
(10mg/ml).  
 
A significant decrease in numbers of circulatory PMNs was observed after IV antibiotic 
treatment including tobramycin among patients with acute exacerbation of CF (180). THP-1 
derived macrophage-like cells showed a considerable reduction in LPS-induced TNF-, IL-
1, IL-8 and CXCL1 release following tobramycin administration (312). Consistent with those 
observations, significant suppressions of both M1 and M2 polarization were when tobramycin 
was added during macrophage differentiation and polarization. Since the abovementioned 
study (312) focused on the pro-inflammatory macrophage responses, modulation of anti-
inflammatory responses of macrophages by tobramycin in CF (CFTR inhibited) got more 
attention in this study. To identify the mechanism of suppressed M2 polarization by 
tobramycin, IL-13R1 expression was analyzed following IL-13 stimulation. No effect of 
tobramycin was observed on IL-131 expression suggesting tobramycin might use different 
signaling pathway to arrest M2 polarization.  
 
Tobramycin with inhibition of CFTR by CFTRInh-172 resulted in a further reduction of 
M1 polarization and a partial restoration of M2 polarization. It was not assessed that whether 
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tobramycin physically or chemically binds to CFTRInh-172 and thereby compete and rule out 
CFTR inhibition. Tobramycin mediated enhanced IL-13R1 expression in CFTR inhibited 
cells correlates with enhanced M2 polarization in synergistic condition of CFTRInh-172 and 
tobramycin. Lowered expression of IL-13R1 during CFTR inhibition and restoration of 
CFTR function by tobramycin suggest that tobramycin in CF (CFTR inhibited cells) restores 
CFTR function which later leads to improved IL-13R1 expression thereby improved M2 
polarization.  
 
Differentiated macrophages from CF monocytes did not show similar restoration of M2 
polarization with no upregulation of IL-13R1 expression following tobramycin treatment.  An 
earlier study showed suppression of two disease-associated stop codon mutations (G542X and 
R553X) (type I mutations) by aminoglycoside antibiotic G-418, thereby resulting in expression 
of full of length CFTR and restoration of Cl channel activity (263). Gentamycin treatment was 
also reported to express full-length CFTR in HeLa cells carrying these mutations (263). 
Expression of full-length CFTR and restoration of chloride channel activity was observed in 
monocytes of patients with CF following intravenous administration of a combination 
antibiotics including tobramycin (180). Effect of tobramycin on macrophages among patients 
carrying F508 mutation is still unknown. CFTRInh-172 were reported to enter into the cells, 
binds to the intracellular portion of CFTR protein and thereby block the channel activity (226, 
227). CFTR inhibition by CFTRInh-172 is therefore supposed to exhibit similar impaired 
channel activity displayed by mutated CFTR protein due to F508 mutation. In this study, 
CFTRInh-172 showed similar repressed M2 polarization with differentiated macrophages from 
CF monocytes. However, tobramycin effect on M2 polarization in CFTR inhibited cells was 
different from macrophages differentiated from CF monocytes. The mechanism by which 
tobramycin modulates macrophage polarization in CFTR inhibited cells and macrophages from 
CF monocytes remained unexplored. However, this data provide some important clues 
regarding the mode of action of tobramycin on host innate immune responses. Furthermore, 
observed restorations of M2 polarization in CFTR inhibited cells as well as in differentiated 
macrophages from CF monocytes validates the CF macrophage model reported in Chapter 4.  
 
Taken together, these data indicates the multifunctional properties of tobramycin. 
Tobramycin is not only able to limit bacterial growth but also able to modulate the host innate 
immune response. Flow cytometry data of this study pointed toward potential effects of 
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tobramycin in damping inflammation and initiating resolution of inflammation in CF. 
However, suppression of M1 genes, induction of M2 genes, cytokine profile as well as 
phagocytosis or endocytosis were not evaluated following tobramycin-treated. The molecular 
mechanism whether tobramycin restores CFTR function and how also remained unexplored. 
Further studies are needed to minimize the knowledge gap.  
 
 
 
 
Chapter 6 Discussion and Future Recommendations 
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6.1 Key Research Findings and Their Clinical Implications 
Historically macrophages are known for their phagocytic activity and responses to 
microbial insults. With recent advancements, macrophages are now recognized as critical 
players not only in the initiation of inflammation but also in the resolution of inflammation. 
These two opposing actions are governed by their two different polarized states: pro-
inflammatory classical or M1 polarization and wound healing alternative or M2 polarization. 
Murine models of inflammatory, autoimmune diseases have elegantly demonstrated that the 
polarized state of macrophages dictates the nature, duration and severity of disease 
pathogenesis. Therefore, understanding the polarized state of macrophages is important in 
studying inflammation. The easiest way to assess their polarized status is by analyzing their 
surface markers and measuring the inflammatory mediators present in the body fluid or in vitro 
culture supernatants. Due to substantial interspecies variability, murine markers are not suitable 
to characterize human macrophages (reviewed in Chapter 1). Therefore a clear phenotypic 
characterization of human M1 and M2 macrophages was needed. Additionally, monocytes and 
differentiated MDMs have been used to study human macrophage biology. Responses to 
stimuli by monocytes and MDMs had never been systemically investigated. Comparative 
transcriptome analysis elegantly demonstrated two different gene expression profiles by 
monocytes and MDMs suggesting that MDMs, not precursor monocytes, should be used while 
studying macrophage biology (72). During this Ph.D. study, an elegant model for in vitro 
differentiation of human M1 and M2 macrophages and their characterization had been 
developed (Chapter 3) (286). This in vitro model systematically demonstrated the phenotypes 
and functions of three states of macrophage: uncommitted M0, classical M1 and alternative 
M2 macrophages. The human macrophage polarization and characterization model described 
in Chapter 3 can be used to investigate potential roles of macrophage in disease pathogenesis 
and facilitate developing therapeutic interventions where restoring the subtle balance of 
macrophage subsets would become beneficial for patients. 
 
Since respiratory linings are rich in GM-CSF, GM-CSF was used to differentiate 
macrophages from monocytes. However, this study as well as Beyer et al (136) showed that 
M-CSF differentiated macrophages showed similar phenotype, gene expression and functions 
to GM-CSF differentiated macrophages. Therefore, this M1-M2 model is not limited only to 
respiratory macrophages. The model can also be used to study roles of macrophages from other 
tissues. Although M2 macrophages were subdivided into three groups: M2a, M2b and M2c 
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(44), no subtype of M1 macrophages had previously been reported. However, the phenotype 
and function of M1 cells were observed to vary with the inducers used to activate the M1 state 
(Chapter 3) (286). M1 cells activated by LPS or IFN- or LPS plus IFN- exhibited three 
distinct phenotypes and functions. LPS induced M1 cells demonstrated surface expression of 
CD80 with a population of CD64+CD80+ cells. M1-LPS cells were highly phagocytic, were 
found to release pro-inflammatory cytokines including TNF-, RANTES, IL-8 with induction 
of Cox-2 gene. M-IFN- cells demonstrated significant expression of CD64, minimal 
phagocytic activity, release of IFN- and IP-10 and induction of CXCLL11 gene. Cells those 
received both LPS and IFN- for M1 polarization displayed similar phenotype with M1-LPS 
cells, however, these M1-LPS plus IFN- cells were not phagocytic. Such subdivisions of M1 
macrophages corresponded with the previously reported pathway analysis study (72) 
suggesting heterogeneity within the M1 macrophages is a real phenomenon. This area needs 
proper attention from experts in this field. Since, many respiratory diseases, such as asthma 
and CF, are dominated by TH2 cytokines, IL-13 conditioned M2a macrophages received the 
most attention in this thesis. However, the term "M2" was used throughout the thesis for the 
sack of simplicity.  
 
Plasticity may not be very important during homeostasis, but becomes more important 
during inflammation. The ability to switch from one polarized state to another had been 
demonstrated in mice (77, 315), however, the fate of once polarized macrophages following 
the withdrawal of inducers had not been studied. Using MDM, I provided an in-depth analysis 
of macrophage behavior following polarization and of the reversibility of phenotype following 
alteration of cytokine stimuli (Chapter 3) (286). Polarized macrophages were observed to 
revert to uncommitted M0 state by 12 days following the removal of the polarizing stimulus. 
Antagonistic effects of M1 and M2 inducers on once polarized macrophages, i.e., 
downregulating M1 phenotype by M2 inducer, thereby polarization toward M2 and vice versa 
was observed. Such a shift from M1 to M2 state or vice versa indicates how the innate immune 
balance could be maintained by macrophage subsets in vivo.  
 
Exaggerated neutrophilic inflammation has been reported to lead to permanent damage 
of lungs in CF. However, the mechanism by which neutrophils get triggered and why they do 
not turn off normally is still unknown. Very few studies showed defective macrophage 
responses and functions in CF (159-161). F508 KO mice demonstrated exaggerated M1 
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induction along with minimal or no induction of M2 genes (257). However, engagement of 
reparative M2 macrophages at the end of pulmonary exacerbation of CF was not thoroughly 
investigated. Due to lack of markers for human M1/M2 macrophages, no comprehensive 
studies have been conducted to analyze subset specific macrophage responses in CF. 
 
Using the in vitro human macrophage polarization and characterization model 
described in Chapter 3, an intrinsic defect of M2 polarization in CF has been identified. 
Percentage of CD209+ cells, a hallmark of M2 polarization has been found to be significantly 
lower among adults and children with CF (Chapter 4). In addition, induction of M1 phenotype 
(CD80+ cells) was observed in both uncommitted M0 and IL-13 treated cells during acute 
pulmonary exacerbation (APE) of CF, but not in clinically stable patients. IL-13 treated CF 
macrophages showed lowered endocytosis as well, however, IL-13 secretion was significantly 
higher in both patient cohorts compared adult healthy controls. Interestingly, in both patient 
cohorts, the levels of IL-13 was observed to be slightly higher at the time of discharge than 
APE. It is possible that during inflammation M1 macrophages take control to initiate 
inflammation and that at the later stage of inflammation macrophages release large amounts of 
IL-13 to initiate the reparative phase.  Together, these data suggest enhanced M1 responses by 
all three macrophage compartments during APE and relentless suppression of M2 polarization 
as underlying contributors to chronic inflammation in CF. These observations were fairly 
similar with CF mouse model data (257) and indicated that CF monocytes are prone to M1 
polarization. Nevertheless, monocyte compartment (classical, intermediate and non-classical) 
of CF was found similar to healthy controls.  
 
To study the mechanism of such aberrant macrophage responses in CF, a CF 
macrophage model had been developed using CFTR inhibitors, CFTRInh-172 and GlyH-101. 
Inhibiting CFTR function in healthy cells recreated the CF phenotype with decreased M2 
polarization and lowered phagocytosis and endocytosis. The model allowed further 
investigation of defective M2 polarization in CF. Wu et al showed the role of IL-13 on CFTR 
expression and Cl- secretion in epithelial cells (316). In agreement with this study, we observed 
decreased surface expression of IL-13 receptor, IL-13Rα1, on CFTR-inhibited macrophages. 
Similarly to CFTR inhibited M0 cells, differentiated M0 cells from CF monocytes showed 
lowered IL-13R1 expression following IL-13 stimulation, indicating a direct regulation on 
the expression of IL-13R1 by functional CFTR. Functional CFTR is therefore essential for 
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M2 polarization. IRF4, the key gene in M2 polarization, was not induced at all in differentiated 
CF M0 macrophages following IL-13 stimulation. These data explained the inability of CF M0 
macrophages to respond to IL-13, a key cytokine that inhibits M1 and promotes M2 
polarization in CFTR-dependent manner. Such CFTR-dependent imbalance in the innate 
immune system might explain the defective resolution of pulmonary inflammation during CF 
which eventually leads to exaggerated neutrophilic responses. Apart from macrophages, IL-13 
induces IgE secretion by B cells and proliferation of TH2 cells. Similar to earlier studies (262), 
IL-13 release was observed to be substantially higher in CF macrophages compared to 
macrophages from healthy controls. It is very likely that IL-13 would induce other immune 
cells, such as, T cells, B cells or structural cells including AECs to initiate pulmonary fibrosis. 
However, this mechanism has to be tested with a systematic study. 
 
 
Figure 23: Proposed signaling pathways of macrophage polarization in CF. The figure 
illustrates several mechanisms underlying macrophage polarization and the feedback 
regulation between M1 and M2 signal pathways in CF (text, dashed lines and signs in red) and 
healthy control. Due to dysfunctional CFTR protein, phagolysosomal acidification fails, 
resulting in less killing and clearance of microbes. Functional CFTR is a negative regulator of 
Cox-2. In presence of defective CFTR, Cox-2 pathway remains activated. Lack of CFTR 
function due to mutation or inhibition (CFTRInh-172) leads to reduced IL-13R1 expression, 
resulting in no or minimal induction of IRF4, the key gene of M2 polarization. IRF4 and IRF5 
are under feedback regulation. Absence of IRF4 results in the continuous induction of IRF5, 
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another key gene of M1 polarization. In summary, lack of anti-inflammatory machinery and 
constant induction of pro-inflammatory Cox-2 and IRF5 pathways might be the underlying 
reason of CF inflammation. The figure was adapted from Liu et al (317). 
 
IL-13 secreted by TH2 and mast cells is the key cytokine that promotes M2 polarization. 
Two different IL-13 receptors, IL-13R1 and IL-13R2 have been reported. IL-13R1 is 
present on monocytes, macrophages, B cells, basophils and endothelial cells. Following IL-13 
stimulation IL-13R1 forms heterodimer with IL-4R and activates JAK1 and JAK3 (30, 318). 
Activation of JAK leads to phosphorylation of STAT6 and translocation to the nucleus. STAT-
6 activation is required for IL-13 production and the development of mucus production and 
AHR in animal models of allergic airway diseases (319). IL-13 also activates IRF4, a crucial 
transcription factor for M2 polarization (135). IRF4 is expressed in macrophages, DCs, 
lymphocytes, downregulates TLR signaling pathway to trigger inflammation and promotes 
differentiation of TH2 (320) and TH17 cells (321). Our data indicates that IL-13R1 induction 
is under CFTR control. Absence of functional CFTR due to either mutation or chemical 
inhibition (CFTRInh-172, GlyH-101) leads to a reduction of IL-13R1 expression resulting in 
reduced induction of IRF4 and ultimately lowered M2 polarization (Figure 23). However, it is 
not clear about the molecular mechanism of substantial IL-13 production in CF. 
Phosphorylation of STAT6 is required for IL-13 production (30, 318). Similar IL-4Ra 
expression was observed in natural (CF) and experimental (CFTR inhibited) cells to controls 
which raised a valid question that whether IL-4Ra alone is enough to activate STAT6 pathway. 
Further study is needed to explore the molecular mechanism of low M2 polarization, but high 
IL-13 production.  
 
Chronic bacterial infection in CF causes non-stop induction of Cox-2 and IRF5 
signaling cascades which later contributes to M1 polarization and thereby relentless production 
of pro-inflammatory cytokines (317). Like earlier studies (301, 305), this study reported that 
suppression of Cox-2 pathway may possibly be beneficial in CF, however, deactivation of Cox-
2 pathway might not be enough to induce the anti-inflammatory machinery in CF macrophages. 
IRF4 and IRF5, activated by LPS maintains a feedback regulation to initiate and resolve 
inflammation (317). Since IRF4 isn’t induced in CF, it is possible that activation of IRF5 stays 
uncontrolled (Figure 23). Taken together our data indicates that lack of anti-inflammatory 
mechanism and constant induction of pro-inflammatory Cox-2 and IRF5 pathways might be 
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the underlying reason of CF inflammation. It is also possible that other pathways are involved 
in the dysregulated inflammation in CF. Further study is needed to explore the molecular 
networks underlying the CF inflammation.  
 
These two novel models described in Chapter 3 and Chapter 4 are likely to be useful 
for biomedical research. The first model that described the phenotypic identification of human 
M0, M1 and M2 macrophages will be able to identify the defective macrophage subset in 
pathogenic conditions. Knowing the pathogenic macrophage subset has a huge impact on 
developing novel therapeutic targets. This model was successfully applied to patients’ samples 
of CF to analyze subset specific macrophage responses in CF and identified a fundamental 
defect in CF macrophages.  The CF macrophage model allowed us to identify a CFTR-
dependent fundamental defect of CF macrophage. This model would also allow CF researchers 
to conduct extensive investigations on macrophage functions without any patient samples.  
 
Lastly, the CF macrophage model was used to gain a better understanding of the 
possible effects of tobramycin, a regular treatment for CF patients, on host innate immune 
systems, especially macrophages (Chapter 5). As an FDA approved bactericidal drug, 
tobramycin is commonly used for patients with CF. Tobramycin had been shown to delay 
colonization of P. aeruginosa in the lungs and significant improvement of lung functions in 
patients with moderate to severe CF (174, 237-242). However, due to lack of appropriate CF 
macrophage model, the mode of action of tobramycin on host immune cells had never been 
studied. Using the CF macrophage model reported in Chapter 4, here I studied the effect of 
tobramycin on healthy macrophages as well as macrophages in CF (CFTR inhibited cells). 
Administration of tobramycin along with CFTR inhibitor exerted superfluous abolition of M1 
polarization. Such synergistic effect of tobramycin and CFTR inhibitor was observed to be 
beneficial toward M2 polarization. These data indicate that tobramycin not only restrained M1 
polarization but also restored M2 polarization in CF. 
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6.2 Limitations 
The limitations of this study need to be acknowledged. Blood donation in Australia is 
an unpaid and volunteer service. Eligibility of the donors is screened by standard protocols by 
ARCBS. Donors of the buffy coats used in this study were assumed to be healthy and not 
carriers of mutated CFTR gene. No data regarding the life-style or smoking habits of the donor 
was accessible. While screening for infections that could be transmitted by blood transfusion, 
not all conditions that could influence macrophage function can be excluded. Only tested and 
infectious agent free buffy coats were supplied by ARCBS and used in these studies. No 
demographic data apart from age, sex and blood group were available for ARCBS blood 
donors. Any clinical information of the donors was inaccessible. However, phenotype or 
functional attributes observed with buffy coat derived macrophages were similar to those 
obtained with macrophages differentiated from freshly isolated monocytes from healthy adult 
donors.  
 
M2 macrophages were subdivided into three groups: M2a, M2b and M2c (44). Since 
elevated IL-13 level had been reported in many respiratory and fibrotic diseases, IL-13 treated 
M2a macrophages received the most attention during this study. Hence, the thesis lacks any 
data on human M2b or M2c macrophages.  
 
Data in Chapter 4 were generated from cohorts of children and adult patients with CF 
and compared with adult healthy controls. Due to lack of ethical permission, it was not possible 
to collect blood samples from healthy children non-CF controls, hence children CF group 
lacked appropriate age-matched control group. Children healthy or patients with non-CF 
respiratory diseases would be the appropriate control for children CF group.  
 
P. aeruginosa is the most commonly found pathogen among patients with CF. 
However, all the experiments in Chapter 4 were conducted with commercially available E. coli 
LPS or E. coli bioparticles which might not reproduce the macrophage responses against P. 
aeruginosa clinical isolates. It is reasonable to surmise that CF macrophage responses would 
be more pronounced with P. aeruginosa clinical isolates. 
 
Although in vitro macrophage models reported in Chapter 3 and Chapter 4 showed 
significant promises, they both lacked the physical influences of lung environment. 
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Macrophages in the BAL and sputum would be the most pertinent macrophages that would 
reflect the real scenario of CF inflammation. Studying the sputum macrophages would give 
some extra weight in this study. However, BAL and sputum from patients with CF mostly 
contained neutrophils, rather than macrophages (189, 322, 323). Earlier studies reported that 
due to chronic inflammation CF PMNs are likely to be exhausted (324). It is also possible that 
macrophages in alveolar spaces are ready exhausted, therefore, might not exhibit the proper 
phenotype. Di et al elegantly showed that engulfment and phagolysosome formation were not 
defective in AMs of CFTR-KO mice, rather phagolysosomes of AMs in CFTR-KO mice were 
less acidic (161). In this study, phagocytosis was monitor by pH-sensitive fluorescence dye 
pHrodo green, engulfment and formation of phagolysosome were not analyzed. Macrophage 
response studied during this Ph.D. study was correlated with any clinical parameters including 
lung function (FEV1), infection status, medication taken by patients before venous blood 
collection.  
 
Although CFTRInh-172 and GlyH-101 treated macrophages displayed similar 
phenotypes with differentiated macrophages from CF monocytes, the detailed mechanism of 
dysfunctional or inhibited CFTR and repressed M2 polarization was not elucidated in the 
thesis. No comparison was conducted among patients those carry F508 homozygous and 
heterozygous mutations or had intermittent and chronic infection with P. aeruginosa. Due to 
insufficient cells numbers, expression of M1 signature gene, Cox-2 was not able to analyze in 
M0 cells from APE patients with CF. Furthermore, monocytes from CF patients were not 
thoroughly studied. It is possible that CFTR-dependent or independent defects may already be 
concealed in monocytes of CF patients.  
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6.3 Future Directions  
There are huge opportunities for conducting further research using the macrophage 
models described in Chapter 3 and Chapter 4. Since polarized status of macrophages dictates 
the nature and duration of inflammation and contributing to disease severity, the human 
macrophage polarization and characterization model described in Chapter 3 can be used as the 
foundation for further investigating the roles of polarized macrophages in fibrotic diseases 
including asthma, atherosclerosis, renal fibrosis as well as obesity and during pregnancy. 
 
A prospective and longitudinal study can be undertaken to study macrophage 
polarization and function during APE prior to treatment, following treatment and at routine 
follow-up and find the association of macrophage responses with clinical outcomes. Such study 
would include the following aims:  
1) Investigating the role of CFTR genotypes (F508 homozygous vs heterozygous vs 
G551D) is an excellent opportunity to study how CFTR genotype effect(s) would 
effect on macrophage functions. 
2) In murine model, the role of MMP28 has been shown to be associated with M2 
polarization (325). Expression of MMP28 on monocytes was analyzed in this study. 
It would be worthy to analyze expression of MMP28 on monocytes from CF 
patients. Such analysis should be performed during APE and clinical stable 
condition of CF. The data might put a light on the underlying mechanism of reduced 
M2 polarization in CF. 
3) Restoration of functional CFTR on macrophages should be tested following 
tobramycin or other antibiotic administration.  
4) With the CF macrophage model, it is possible to investigate the effect of 
potentiators/correctors (Ivacaftor/Lumacaftor) on macrophage responses and 
whether these mutation-specific drugs are able to alter the ability of monocytes to 
differentiate and polarize into M2 macrophages and correlate clinically.  
5) Pathway analysis of next generation sequencing data is an advanced tool in 
biomedical research (326). It would be extremely worthy to use this recently 
developed tool to identify the molecular defects in CF M0, M1 and M2 
macrophages. Such analysis would also explore the underlying mechanism of 
expression of CD80 on M0 and M2 macrophages during APE, but not in clinically 
stable condition of CF. Similar analysis on CFTR inhibited M0, M1 and M2 cells 
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would not only validate the model but also allow researchers to study macrophage-
related CF inflammation without tissue samples from patients with CF.  
6) Macrophage responses should be correlated with lung function of patients with CF.  
7) CF macrophage data reported in Chapter 4 should be validated by the most 
pertinent macrophages, i.e. sputum macrophages. Phenotype of macrophages from 
sputum of HC and CF patients should be studied. Analyzing the sputum 
macrophages from CF and non-CF patients would reveal intriguing information 
regarding their involvement in the lung inflammation during CF. 
 
It is also possible to develop CF AEC model, using CFTR inhibitors, CFTRInh-172 and 
GlyH-101. 
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Appendices  
Following items were attached: 
1. Manuscript version of Chapter 4 which was submitted to the New England Journal of 
Medicine was added here.  
 
